Recommendations on  
the ethical review of hESC 
FP7 research projects

(cid:22)(cid:51)(cid:52)(cid:45)(cid:50)(cid:45)(cid:51)(cid:50)(cid:4)(cid:50)(cid:132)(cid:22)
(cid:22)(cid:51)(cid:52)(cid:45)(cid:50)(cid:45)(cid:51)(cid:50)(cid:4)(cid:50)(cid:132)(cid:22)
(cid:22)(cid:51)(cid:52)(cid:45)(cid:50)(cid:45)(cid:51)(cid:50)(cid:4)(cid:50)(cid:132)(cid:22)

20 June 2007

K
A
-
A
J
-
0
7
-
0
2
2
-
E
N
-
C

ISBN 978-92-79-07137-9

00_2007_5944_cover_EN.indd   1

12-02-2008   13:53:15

 
 
 
How to obtain EU publications

Our priced publications are available from EU Bookshop (http://bookshop.europa.
eu), where you can place an order with the sales agent of your choice.

The Publications Office has a worldwide network of sales agents. You can obtain 
their contact details by sending a fax to (352) 29 29-42758.

00_2007_5944_cover_EN.indd   2

12-02-2008   13:53:15

The European Group on Ethics in Science and New  
Technologies to the European Commission 

Recommendations on the ethical review of 
hESC FP7 research projects 

Opinion No 22 

English original 
Translations in the EU-27 languages available at: 

http://ec.europa.eu/european_group_ethics/activities/docs/opinion_22_final_follow_up_en.pdf 

 20 June 2007 

01_2007_5944_txt_EN.indd   1

12-02-2008   13:58:18

  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Europe Direct is a service to help you find answers  
to your questions about the European Union

Freephone number (*):
00 800 6 7 8 9 10 11

(*)  Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed.

More information on the European Union is available on the Internet (http://europa.eu).

Cataloguing data can be found at the end of this publication.

Luxembourg: Office for Official Publications of the European Communities, 2007

ISBN 978-92-79-07137-9

© European Communities, 2007
Reproduction is authorised provided the source is acknowledged.

Printed in Italy

Printed on white chlorine-free PaPer

01_2007_5944_txt_EN.indd   2

12-02-2008   13:58:18

Contents 

SUMMARY........................................................................................................................ 3 

I. Having regard to............................................................................................................ 5 

II. Whereas ...................................................................................................................... 12 

II.1. Preamble.................................................................................................................. 12 

II.2. The sixth framework programme .................................................................. 13 

II.3. Human embryonic stem cell (hESC) projects financed under FP6 ................ 15 

II.4. The ethics provisions applying to FP6-funded human embryonic  

stem cell projects.................................................................................................... 15 

II.4.1. FP6 ethics review........................................................................................ 15 

II.4.2. Ethics provisions for FP6 hESC projects ................................................ 17 

II.5. The seventh framework programme for research, technological  

development and demonstration (2007–13) (FP7) ........................................... 18 

II.6. Ethics provisions under FP7: hESC research funded  

by the European Union.......................................................................................... 20 

III. Background for the ethical review of hESC projects........................................... 21 

III.1. Existing ethical guidelines: a brief historical overview..................................... 21 

III.2. Research using human embryonic stem cells (hESCs).................................. 23 

III.3. Sources of human embryonic stem cells........................................................... 24 

III.4. Derivation of new hESC lines.............................................................................. 25 

III.5. Alternatives to hESC research ............................................................................ 25 

III.6. European Registry of existing hESC lines ........................................................ 27 

III.7. EU Member States’ regulations on hESC research ........................................ 28 

III.8. Commercialisation and patenting ....................................................................... 32 

1

01_2007_5944_txt_EN.indd   1

12-02-2008   13:58:18

 
 
  
 
 
 
 
 
 
 
 
 
 
IV. Recommendations ................................................................................................... 33 
French translation ..................................................................... 47 
German translation ................................................................... 65 
IV.1. Preamble ................................................................................................................ 33 

IV.2. Recommendations for the ethical review of research projects involving 

hESCs ...................................................................................................................... 34 

IV.2.1. General criteria .......................................................................................... 35 

IV.2.2. Ethical criteria for research projects under FP6 ................................... 39 

IV.2.3. Additional criteria for FP7................................................................................. 40 

IV.2.3.1. Use of alternatives to hESCs ............................................................... 40 

IV.2.3.2. Donors’ rights.......................................................................................... 40 

IV.2.4. The need for continuous promotion of public governance and 

science–society dialogue .................................................................................. 42 

IV.3. The need for further research and continuous public debate ........................ 43 

IV.4. Review of recommendations and communication with the Advisory 

Board of the European Human Embryonic Stem Cell 

Research Registry.................................................................................................. 45 

IV.4.1. The need for review .......................................................................................... 46 

Annexes ........................................................................................................................... 81 

Annex I — The sixth framework programme ............................................................. 85 

Annex II — Ethical review procedures in FP7  .......................................................... 85 

Ethical issues table .................................................................................. 87 

Annex III — List of projects supported within the sixth framework  

programme and within the Health and Consumer Protection DG, 

involving hESCs ....................................................................................... 88 

Annex IV — EU Member States’ regulatory framework for hESC research......... 90 

Appendix : Secretariat of the EGE ............................................................................ 144 

2

01_2007_5944_txt_EN.indd   2

12-02-2008   13:58:18

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV. Recommendations ................................................................................................... 33 

IV.1. Preamble ................................................................................................................ 33 

French translation ..................................................................... 47 

German translation ................................................................... 65 

IV.2. Recommendations for the ethical review of research projects involving 

hESCs ...................................................................................................................... 34 

IV.2.1. General criteria .......................................................................................... 35 

IV.2.2. Ethical criteria for research projects under FP6 ................................... 39 

IV.2.3. Additional criteria for FP7................................................................................. 40 

IV.2.3.1. Use of alternatives to hESCs ............................................................... 40 

IV.2.3.2. Donors’ rights.......................................................................................... 40 

IV.2.4. The need for continuous promotion of public governance and 

science–society dialogue .................................................................................. 42 

IV.3. The need for further research and continuous public debate ........................ 43 

IV.4. Review of recommendations and communication with the Advisory 

Board of the European Human Embryonic Stem Cell 

Research Registry.................................................................................................. 45 

IV.4.1. The need for review .......................................................................................... 46 

Annexes ........................................................................................................................... 81 

Annex I — The sixth framework programme ............................................................. 85 

Annex II — Ethical review procedures in FP7  .......................................................... 85 

Ethical issues table .................................................................................. 87 

Annex III — List of projects supported within the sixth framework  

programme and within the Health and Consumer Protection DG, 

involving hESCs ....................................................................................... 88 

Annex IV — EU Member States’ regulatory framework for hESC research......... 90 

Appendix : Secretariat of the EGE ............................................................................ 144 

SUMMARY 

The  European  Group  on  Ethics  in  Science  and  New  Technologies  (EGE) 
adopted  Opinion  No  22  on  20 June 2007.  The  opinion  indicates  the 
implementing  measures  (guidelines)  to  use  during  the  ethics  review  of 
seventh framework programme for research and development (FP7) research 
projects  on  human  embryonic  stem  cells  (hESCs),  as  requested  by  the 
President  of  the  European  Commission,  Mr  Barroso (1),  and  in  line  with  the 
adoption of the EU’s FP7. 

The  EGE  stressed  that,  as  is  the  case  in  the  European  Union,  there  are 
divergent  views  within  the  group  on  the  moral  legitimacy  of  research  on 
human embryos and hESCs, ranging from objection to research involving the 
destruction of human embryos (which makes the full respect of dignity of the 
human  embryo  impossible)  to  a  position  allowing  hESC  research  under 
certain conditions or on a broader basis.  

The group, however, acknowledged the political decision taken as the starting 
point  for  its  recommendations,  but  emphasised  that  the  ethical  dilemma 
regarding the moral status of the human embryo and its use in research still 
persists both within the EGE members and the EU. Therefore, the group did 
not  elaborate  ethical  arguments  on  hESC  research  as  such,  but  worked  on 
recommendations for FP7 ethics review of hESC projects. 

The  EGE  recognised  the  need  for  promoting  responsible  research  that  is 
transparent,  serves  the  public  interest,  respects  Member  State  autonomy, 
preserves  public  trust,  promotes  international  cooperation  and  requires  the 
embedding  of  ethics  within  research  practice.  The  group  indicated  that,  in 
addition to the FP7 ethics rules already adopted in co-decision, among others 
the following considerations should apply to hESCs funded by the EU: 

(cid:120)  FP7 hESC lines have to result from non-implanted IVF embryos;  
(cid:120) 

if  alternatives  to  hESCs  with  the  same  scientific  potential  as  embryo-
derived  stem  cells  are  found  in  the  future,  their  use  should  be 
maximised; 

(1) 

Letter  sent  by  European  Commission  President  Barroso  to  the  EGE  on  22  November  2006:  ‘I 
would like to invite the European Group on Ethics to provide the Commission with an opinion on 
the  implementing  measures  required  during  the  ethics  review  of  research  projects  on  human 
embryonic stem cells that will assure that the ethical rules and requirements are fully met.’ 

3

01_2007_5944_txt_EN.indd   3

12-02-2008   13:58:19

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
                                                 
(cid:120)  donors’  rights  (in  terms  of  health,  informed  consent,  data  protection 

and free donation) have to be protected and safeguarded.  

The EGE also stressed the following needs: 

(cid:120) 

(cid:120) 

to  maximise  the  use  of  hESCs  banked  in  the  European  Registry  on 
hESC research; 
to  take  concrete  actions  to  stimulate  public  debate  on  this  research 
sector. 

In  addition,  the  EGE  expressed  the  view  that  the  use  of  human  embryos  to 
generate stem cells should be minimised as much as possible in the EU and 
indicated  a  number  of  issues  that  would  deserve  interdisciplinary  research 
and  further  discussion,  such  as,  inter  alia,  the  use  of  the  human  body  for 
modern  medicine,  including  commercialisation  of  products  and  procedures 
stemming  from  the  use  of  human  embryonic  stem  cells;  the  underlying 
anthropology of human embryonic stem cell research, especially in the light of 
hybrids  and  the  chimera  research  connected  to  stem  cell  research;  the 
correlation of human embryonic stem cell research and questions concerning 
regenerative medicine and health-related justice, including the issue of global 
justice;  the  relation  between  science  and  humanities  and  between  science 
and society with respect to the development of new technologies.  

The EGE also indicated two topics that the group may address in the future: 
(1) the patenting of hESC-derived materials, and (2) the tension induced by a 
policy  that  encourages  both  free  donation  and  commercial  use  of  derivates 
from human substances. 

The recommendations were adopted by unanimity and issued to the Commission 
on 11 July 2007.

4

01_2007_5944_txt_EN.indd   4

12-02-2008   13:58:19

 
 
  
 
 
 
 
 
(cid:120)  donors’  rights  (in  terms  of  health,  informed  consent,  data  protection 

and free donation) have to be protected and safeguarded.  

The EGE also stressed the following needs: 

to  maximise  the  use  of  hESCs  banked  in  the  European  Registry  on 

to  take  concrete  actions  to  stimulate  public  debate  on  this  research 

(cid:120) 

(cid:120) 

hESC research; 

sector. 

In  addition,  the  EGE  expressed  the  view  that  the  use  of  human  embryos  to 

generate stem cells should be minimised as much as possible in the EU and 

indicated  a  number  of  issues  that  would  deserve  interdisciplinary  research 

and  further  discussion,  such  as,  inter  alia,  the  use  of  the  human  body  for 

modern  medicine,  including  commercialisation  of  products  and  procedures 

stemming  from  the  use  of  human  embryonic  stem  cells;  the  underlying 

anthropology of human embryonic stem cell research, especially in the light of 

hybrids  and  the  chimera  research  connected  to  stem  cell  research;  the 

correlation of human embryonic stem cell research and questions concerning 

regenerative medicine and health-related justice, including the issue of global 

justice;  the  relation  between  science  and  humanities  and  between  science 

and society with respect to the development of new technologies.  

The EGE also indicated two topics that the group may address in the future: 

(1) the patenting of hESC-derived materials, and (2) the tension induced by a 

policy  that  encourages  both  free  donation  and  commercial  use  of  derivates 

from human substances. 

The recommendations were adopted by unanimity and issued to the Commission 

on 11 July 2007.

RECOMMENDATIONS OF THE EUROPEAN GROUP ON ETHICS  

IN SCIENCE AND NEW TECHNOLOGIES  

TO THE EUROPEAN COMMISSION 

No 22  

      Original in English 

    20 JUNE 2007 

*********************************************************************************************** 

ETHICAL REVIEW OF HESC FP7 PROJECTS 

Reference:  Request by President Barroso 

Rapporteurs: A. Cambon-Thomsen, H. Haker, P. Martinho da Silva  

********************************************************************************************** 

THE EUROPEAN GROUP ON ETHICS IN SCIENCE AND NEW TECHNOLOGIES (EGE), 

I.   HAVING REGARD TO 

Having regard to the Treaty on European Union as amended by the Treaty 

of  Amsterdam,  and  in  particular  Article  6  (formerly  Article  F)  of  the 

common provisions, concerning respect for fundamental rights, Article 152 

(formerly  Article  129)  of  the  EC  Treaty on  public  health,  and  in  particular 

paragraph 4(a) referring to substances of human origin, and Articles 163–

173  (formerly  Articles  130F–130P)  on  research  and 

technological 

development; 

 Having regard to Recommendation (79)5 of the Committee of Ministers of 

the  Council  of  Europe  to  Member  States  concerning  international 

exchange and transportation of human substances, adopted on 14 March 
1979 (2); 

 Having  regard  to  the  resolutions  of  the  European  Parliament  namely  the 

resolution on the ethical and legal problems of genetic engineering, and on 

artificial insemination in vivo and in vitro, both of 16 March 1989; 

(2)  

http://www.coe.int/t/e/social_cohesion/health/recommendations/Rec(79)5.pdf 

5

01_2007_5944_txt_EN.indd   5

12-02-2008   13:58:19

 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
Having  regard  to  Recommendation R(94)1  of  the  Committee of Ministers 

of  the  Council  of  Europe  on  human  tissue  banks  adopted  on  14 March 
1994 (3); 

Having regard to Directive 95/46/EC (4) of the European Parliament and of 

the Council of the European Union of 24 October 1995 on the protection of 

individuals with regard to the processing of personal data and on the free 

movement of such data; 

Having regard to the Council of Europe Convention on Human Rights and 
Biomedicine  signed  on  4  April  1997  in  Oviedo (5),  and  the  additional 

protocols to the convention; 

Having  regards  to  Directive  98/79/EC  of  the  European  Parliament  and  of 
the Council of 27 October 1998 on in vitro diagnostic medical devices (6); 

Having regard to Commission Decision 2002/364/EC (7) on common 

technical specifications for in vitro diagnostic medical devices; 

Having  regard  to  the  Convention  on  the  Grant  of  European  Patents 

(European Patent Convention) of 5 October 1973 (text as amended by the 

act revising Article 63 EPC of 17 December 1991 and by decisions of the 

Administrative  Council  of  the  European  Patent  Organisation  of  21 

December 1978, 13 December 1994, 20 October 1995, 5 December 1996, 

10 December 1998 and 27 October 2005 and comprising the provisionally 

(3)  
(4)  
(5)  
(6)  
(7)  

http://www.coe.int/T/E/Social_Cohesion/Health/Recommendations/Rec(1994)01.asp 
OJ L 281, 23.11.1995, pp. 31–50. 
http://conventions.coe.int/treaty/en/treaties/html/164.htm 
OJ L 331, 7.12.1998, pp. 1–37. 
OJ L 131, 16.5.2002, pp. 17–30. 

6

01_2007_5944_txt_EN.indd   6

12-02-2008   13:58:20

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
Having  regard  to  Recommendation R(94)1  of  the  Committee of Ministers 

of  the  Council  of  Europe  on  human  tissue  banks  adopted  on  14 March 

applicable  provisions  of  the  act  revising  the  EPC  of  29  November 
2000) (8);  

1994 (3); 

Having regard to Directive 95/46/EC (4) of the European Parliament and of 

the Council of the European Union of 24 October 1995 on the protection of 

individuals with regard to the processing of personal data and on the free 

movement of such data; 

Having regard to the Council of Europe Convention on Human Rights and 

Biomedicine  signed  on  4  April  1997  in  Oviedo (5),  and  the  additional 

protocols to the convention; 

Having  regards  to  Directive  98/79/EC  of  the  European  Parliament  and  of 

the Council of 27 October 1998 on in vitro diagnostic medical devices (6); 

Having regard to Commission Decision 2002/364/EC (7) on common 

technical specifications for in vitro diagnostic medical devices; 

Having  regard  to  the  Convention  on  the  Grant  of  European  Patents 

(European Patent Convention) of 5 October 1973 (text as amended by the 

act revising Article 63 EPC of 17 December 1991 and by decisions of the 

Administrative  Council  of  the  European  Patent  Organisation  of  21 

December 1978, 13 December 1994, 20 October 1995, 5 December 1996, 

10 December 1998 and 27 October 2005 and comprising the provisionally 

http://www.coe.int/T/E/Social_Cohesion/Health/Recommendations/Rec(1994)01.asp 

(3)  

(4)  

(5)  

(6)  

(7)  

OJ L 281, 23.11.1995, pp. 31–50. 

http://conventions.coe.int/treaty/en/treaties/html/164.htm 

OJ L 331, 7.12.1998, pp. 1–37. 

OJ L 131, 16.5.2002, pp. 17–30. 

Having regard to Directive 2002/58/EC of the European Parliament and of 

the  Council  of  12 July 2002  concerning  the  processing  of  personal  data 
and the protection of privacy in the electronic communications sector (9); 

Having regard to Directive 2001/20/EC of the European Parliament and of 

the Council of 4 April 2001 on the approximation of the laws, regulations 

and  administrative  provisions  of  the  Member  States  relating  to  the 

implementation of good clinical practice in the conduct of clinical trials on 
medicinal  products  for  human  use (10),  as  amended  in  2003  (Directive 
2003/94/EC) (11) and 2005 (Directive 2005/28/EC);  

Having  regard  to  Directive  98/44/EC  of  the  European  Parliament  and  of 

the  Council  of  6  July  1998  on  the  legal  protection  of  biotechnological 
inventions (12); 

Having  regard  to  Directive  95/46/EC  of  the  European  Parliament  and  of 

the Council of 24 October 1995 on the protection of individuals with regard 

to  the  processing  of  personal  data  and  on  the  free  movement  of  such 
data (13); 

Having  regard  to  the  Universal  Declaration  on  the  Human  Genome  and 
the  Rights  of  Man  adopted  by  Unesco  on  11  November  1997 (14),  the 

Declaration  on  Human  Genetic  Data  adopted  by  Unesco  on  16  October 

(8)  
(9)  
(10)  
(11)  
(12)  
(13)  
(14)   

http://www.european-patent-office.org/legal/epc/e/ma1.html 
OJ L 201, 31.7.2002, pp. 37–47. 
OJ L 121, 1.5.2001, pp. 34–44. 
OJ L 261, 14.10.2003, pp. 22–26.  
OJ L 213, 30.7.1998, pp. 13–21. 
OJ L 281, 23.11.1995, pp. 31–50. 
http://portal.unesco.org/shs/en/ev.php-
URL_ID=2228&URL_DO=DO_TOPIC&URL_SECTION=201.html 

7

01_2007_5944_txt_EN.indd   7

12-02-2008   13:58:20

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
                                                 
2003  and  the  Universal  Declaration  on  Bioethics  and  Human  Rights 

adopted by Unesco on 19 October 2005; 

Having  regard  to  the  Convention  for  the  Protection  of  Individuals  with 

regard to Automatic Processing of Personal Data adopted by the Council 
of Europe on 1 January 1981 (15); 

Having  regard  to  the  United  Nations  Declaration  on  Human  Cloning 

adopted by the UN General Assembly on 8 March 2005;  

Having  regard  to  the  common  position  of  the  Council  of  Ministers  of  23 

March  1998  and  the  second  reading  of  the  European  Parliament  of  17 

June 1998 concerning the fifth framework programme; 

Having  regard  to  Council  Directive  98/44/EC (16)  of  6  July  1998  on  the 

legal  protection  of  biotechnological  inventions,  and  in  particular  Article  6 

concerning ordre public and morality; 

Having  regard  to  the  decision  of  the  European  Parliament  and  of  the 

Council of 22 December 1998 adopting the fifth framework programme of 

the  European  Community  for  research,  technological  development  and 

demonstration  activities 

(1998–2002),  and 

in  particular  Article  7 

concerning compliance with fundamental ethical principles; 

Having regard to the Council decision of 25 January 1999 concerning the 

specific  programme 

for  research,  development  and  demonstration 

activities  on  ‘Quality  of  life  and  management  of  living  resources’,  and  in 

particular the ethical requirements in footnote (1) of Annex II; 

(15)  
(16)  

http://conventions.coe.int/Treaty/en/Treaties/Html/108.htm 
OJ L 213, 6.7.1998, pp. 13–21. 

8

01_2007_5944_txt_EN.indd   8

12-02-2008   13:58:20

 
 
  
 
 
 
 
 
 
 
 
 
 
                                                 
2003  and  the  Universal  Declaration  on  Bioethics  and  Human  Rights 

Having  regard  to  the  Charter  of  Fundamental  Rights  of  the  European 

adopted by Unesco on 19 October 2005; 

Union  of  28 September  2000,  approved  by  the  European  Council  in 
Biarritz  on  14 October 2000  and  proclaimed  solemnly  in  Nice  by  the 

Having  regard  to  the  Convention  for  the  Protection  of  Individuals  with 

European  Parliament,  the  Council  and  the  Commission  on  7  December 

regard to Automatic Processing of Personal Data adopted by the Council 

of Europe on 1 January 1981 (15); 

2000,  and  in  particular  Article  1  (human  dignity),  Article  3  (right  to  the 
integrity of the person) and Article 8 (protection of personal data) (17); 

Having  regard  to  the  United  Nations  Declaration  on  Human  Cloning 

adopted by the UN General Assembly on 8 March 2005;  

Having  regard  to  the  common  position  of  the  Council  of  Ministers  of  23 

March  1998  and  the  second  reading  of  the  European  Parliament  of  17 

June 1998 concerning the fifth framework programme; 

Having  regard  to  Council  Directive  98/44/EC (16)  of  6  July  1998  on  the 

legal  protection  of  biotechnological  inventions,  and  in  particular  Article  6 

concerning ordre public and morality; 

Having  regard  to  the  decision  of  the  European  Parliament  and  of  the 

Council of 22 December 1998 adopting the fifth framework programme of 

the  European  Community  for  research,  technological  development  and 

demonstration  activities 

(1998–2002),  and 

in  particular  Article  7 

concerning compliance with fundamental ethical principles; 

Having regard to the Council decision of 25 January 1999 concerning the 

specific  programme 

for  research,  development  and  demonstration 

activities  on  ‘Quality  of  life  and  management  of  living  resources’,  and  in 

particular the ethical requirements in footnote (1) of Annex II; 

(15)  

(16)  

http://conventions.coe.int/Treaty/en/Treaties/Html/108.htm 

OJ L 213, 6.7.1998, pp. 13–21. 

Having  regard  to  Council  Decision  1513/2002/EC (18)  of  27  June  2002 

concerning  the sixth  framework  programme  of  the  European  Community 

for  research,  technological  development  and  demonstration  activities 

(2002 — 2006), and in particular Article 3; 

Having regard to the programme adopted by the Council on 30 September 

2002  in  implementing  the  sixth  framework  programme  for  research, 

technological  development  and  demonstration: 

‘Integrating  and 

strengthening 
2002/834/EC) (19); 

the  European 

research  area’ 

(2002–06) 

(Decision 

Having regard to the report published by the Commission on 3 April 2003 
(SEC(2003) 441) (20); 

Having regard to the decision of the European Commission on ‘Integrating 

and  strengthening  the  European  research  area’  (2002–06)  (Decision 
2002/834/EC) (21)  and  the  ‘procedural  modalities  for  research  activities 

involving banked or isolated human embryonic stem cells in culture to be 

funded under Council Decision 2002/834/EC’ (COM C(2003) 2952); 

(17) 
(18) 
(19) 
(20)  

OJ C 364, 18.11.2000, pp. 1–22. 
OJ L 138, 21.4.2004, pp. 7–11. 
OJ L 294, 29.10.2002, pp. 1–43. 
http://ec.europa.eu/research/press/2003/pdf/sec2003-441report_en.pdf 

9

01_2007_5944_txt_EN.indd   9

12-02-2008   13:58:20

 
 
  
 
 
 
 
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
 
                                                 
Having regard to Decision No 1982/2006/EC of the European Parliament 

and  of  the  Council  of  18  December  2006  concerning  the  seventh 

framework  programme  of 

the  European  Community 

for  research, 

technological development and demonstration activities (2007–13); 

Having  regard  to  Regulation  (EC)  No  1906/2006 (22)  of  the  European 

Parliament and of the Council of 18 December 2006 laying down the rules 

for  the  participation  of  undertakings,  research  centres  and  universities  in 

actions  under 

the  seventh 

framework  programme  and 

for 

the 

dissemination of research results (2007–13); 

regard 

Having 
and  Regulation 
726/2004/EC (24), currently being amended (25), on medicinal products for 

to  Directive 

2001/83/EC (23) 

human use: advanced therapy medicinal products; 

 Having  regard  to  EGE  Opinion  No  11  ‘Ethical  aspects  of  human  tissue 
banking’ (26), published on 21 July 1998; 

 Having  regard  to  EGE  Opinion  No  12  ‘Ethical  aspects  of  research 

involving  the  use  of  human  embryo  in  the  context  of  the  fifth  framework 
programme’ (27), published on 23 November 1998; 

 Having regard to EGE Opinion No 15 ‘Ethical aspects of human stem cell 
research and use’ (28), published on 14 November 2000; 

(22)  
(23)  
(24)  
(25)  
(26)  
(27)  
(28)   

OJ L 391, 18.12.2006, pp. 1–18. 
OJ L 311, 28.11.2001, pp. 67–128. 
OJ L 136, 30.4.2004, pp. 1–33. 
http://www.europarl.europa.eu/oeil/FindByProcnum.do?lang=2&procnum=COD/2005/0227 
http://www.ec.europa.eu/european_group_ethics/docs/avis11_en.pdf 
http://www.ec.europa.eu/european_group_ethics/docs/avis12_en.pdf 
http://www.ec.europa.eu/european_group_ethics/docs/avis15_en.pdf 

10

01_2007_5944_txt_EN.indd   10

12-02-2008   13:58:21

 
 
  
 
 
 
 
 
 
 
                                                                                                                                                 
 
Having  regard  to  Regulation  (EC)  No  1906/2006 (22)  of  the  European 

for  the  participation  of  undertakings,  research  centres  and  universities  in 

Having 

regard 

to  Directive 

2001/83/EC (23) 

and  Regulation 

726/2004/EC (24), currently being amended (25), on medicinal products for 

human use: advanced therapy medicinal products; 

 Having  regard  to  EGE  Opinion  No  11  ‘Ethical  aspects  of  human  tissue 

banking’ (26), published on 21 July 1998; 

 Having  regard  to  EGE  Opinion  No  12  ‘Ethical  aspects  of  research 

involving  the  use  of  human  embryo  in  the  context  of  the  fifth  framework 

programme’ (27), published on 23 November 1998; 

 Having regard to EGE Opinion No 15 ‘Ethical aspects of human stem cell 

research and use’ (28), published on 14 November 2000; 

OJ L 391, 18.12.2006, pp. 1–18. 

OJ L 311, 28.11.2001, pp. 67–128. 

OJ L 136, 30.4.2004, pp. 1–33. 

(22)  

(23)  

(24)  

(25)  

(26)  

(27)  

(28)   

http://www.europarl.europa.eu/oeil/FindByProcnum.do?lang=2&procnum=COD/2005/0227 

http://www.ec.europa.eu/european_group_ethics/docs/avis11_en.pdf 

http://www.ec.europa.eu/european_group_ethics/docs/avis12_en.pdf 

http://www.ec.europa.eu/european_group_ethics/docs/avis15_en.pdf 

Having regard to Decision No 1982/2006/EC of the European Parliament 

and  of  the  Council  of  18  December  2006  concerning  the  seventh 

 Having  regard  to  EGE  Opinion  No  16  ‘Ethical  aspects  of  patenting 
inventions  involving  human  stem  cells’ (29),  published  on  14  November 

framework  programme  of 

the  European  Community 

for  research, 

2002; 

technological development and demonstration activities (2007–13); 

Having regard the request of November 2006 from the President of the EU 

Commission to the EGE to issue an opinion on the ethics review of human 

Parliament and of the Council of 18 December 2006 laying down the rules 

embryonic stem cell (hESC) projects funded under FP7; 

actions  under 

the  seventh 

framework  programme  and 

for 

the 

Having heard the rapporteurs A. Cambon-Thomsen, H. Haker, P. Martinho 

dissemination of research results (2007–13); 

da Silva, 

(29) 

http://www.ec.europa.eu/european_group_ethics/docs/avis16_en.pdf 

11

01_2007_5944_txt_EN.indd   11

12-02-2008   13:58:21

 
 
  
 
 
 
 
 
 
 
                                                                                                                                                 
 
 
 
  
 
 
 
 
 
                                                 
 
II. WHEREAS 

II.1. Preamble 

It is common knowledge that opinions about the ethical legitimacy of research on 

human  embryos  are  sharply  divided.  The  controversy  is  rooted  in  different 

ethical, philosophical, and/or religious viewpoints, each of which is acknowledged 

to  be  fully  legitimate.  In  this  respect,  some  claim  that  the  divergences  are 

‘intrinsic’  and  therefore  irreconcilable,  while  others  claim  that  common  positions 

are achievable while respecting the pluralism of European societies, as practical 

solutions.  

The  scope  of  these  recommendations,  however,  is  not  to  address  the  ethics  of 

human  embryonic  stem  cell  research  or  research  on  human  embryos.  These 

recommendations  relate  to  the  political  decision  reached  by  the  European 

institutions on the EU’s seventh framework research programme and is intended 

to  contribute  to  the  implementation  of  the  mechanism  established  under  the 

programme  for  an  ethics  review  of  EU-funded  research  activities  involving  the 

use of human embryonic stem cells. 

Because  of  the  particular  scope  of  these  recommendations,  it  is  important  to 

identify  the  main  requirements  regarding  the  ethics  of  human  embryonic  stem 

cells  that  have  been  adopted  in  co-decision  by  the  European  institutions 

involved:  the  Council  and  the  European  Parliament.  In  addition,  as  the  current 

EU  framework  programme  follows  on  from  the  previous  one,  and  since  both 

implement the European research area (the policy strategy of the EU in research 

and development) and are linked to the economic strategy of the EU (the ‘Lisbon 

strategy’),  the  present  document  will  refer  to  the  previous  EU  framework 

programme and its implementation to date by the Commission services. 

12

01_2007_5944_txt_EN.indd   12

12-02-2008   13:58:21

 
 
  
 
 
 
 
 
 
II. WHEREAS 

II.1. Preamble 

It is common knowledge that opinions about the ethical legitimacy of research on 

human  embryos  are  sharply  divided.  The  controversy  is  rooted  in  different 

ethical, philosophical, and/or religious viewpoints, each of which is acknowledged 

to  be  fully  legitimate.  In  this  respect,  some  claim  that  the  divergences  are 

‘intrinsic’  and  therefore  irreconcilable,  while  others  claim  that  common  positions 

are achievable while respecting the pluralism of European societies, as practical 

solutions.  

The  scope  of  these  recommendations,  however,  is  not  to  address  the  ethics  of 

human  embryonic  stem  cell  research  or  research  on  human  embryos.  These 

recommendations  relate  to  the  political  decision  reached  by  the  European 

institutions on the EU’s seventh framework research programme and is intended 

use of human embryonic stem cells. 

Because  of  the  particular  scope  of  these  recommendations,  it  is  important  to 

identify  the  main  requirements  regarding  the  ethics  of  human  embryonic  stem 

cells  that  have  been  adopted  in  co-decision  by  the  European  institutions 

involved:  the  Council  and  the  European  Parliament.  In  addition,  as  the  current 

EU  framework  programme  follows  on  from  the  previous  one,  and  since  both 

implement the European research area (the policy strategy of the EU in research 

and development) and are linked to the economic strategy of the EU (the ‘Lisbon 

strategy’),  the  present  document  will  refer  to  the  previous  EU  framework 

programme and its implementation to date by the Commission services. 

II.2.  The  sixth 

framework  programme 

for 

research, 

technological 

development  and  demonstration: 

‘Integrating  and  strengthening  the 

European research area’ (2002–06) (FP6) 

On  30  September  2002, 

the  Council  adopted 

the  specific  programme 

implementing  the  sixth  framework  programme  for  research,  technological 

development  and  demonstration:  ‘Integrating  and  strengthening  the  European 
research  area’  (2002–06)  (Decision  2002/834/EC (30)  —  hereinafter  referred  to 

as ‘the specific programme’).  

The  specific  programme  allowed  the  funding  of  research  activities  involving  the 

use of human embryos and human embryonic stem cells except in three areas:  

(cid:650) research  activity  aiming  at  human  cloning 

for  reproductive  purposes 

(reproductive cloning); 

to  contribute  to  the  implementation  of  the  mechanism  established  under  the 

(cid:650) research  activity  intended  to  modify  the  genetic  heritage  of  human  beings 

programme  for  an  ethics  review  of  EU-funded  research  activities  involving  the 

which could make such changes heritable (germline gene therapy) (31); 

(cid:650) research activities intended to create human embryos solely for the purpose of 

research  or  for  the  purpose  of  stem  cell  procurement,  including  by  means  of 

somatic cell nuclear transfer (commonly referred to as therapeutic cloning). 

On  adopting  the  programme,  however,  the  Council  indicated  that  ‘detailed 

implementing  provisions  concerning  research  activities  involving  the  use  of 

human  embryos  and  human  embryonic  stem  cells  shall  be  established  by  31 

December  2003’.  It  asked  the  Commission  to:  (1)  prepare  these  provisions;  (2) 

prepare  a  working  paper  on  the  issue;  and  (3)  organise  an  interinstitutional 

seminar on bioethics. 

(30) 
(31)  

OJ L 294, 29.10.2002, p. 1. 
Research into treatment of cancer of the gonads can be financed. 

13

01_2007_5944_txt_EN.indd   13

12-02-2008   13:58:21

 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
                                                 
A moratorium was then implemented by the Commission and no hESC research 

has since been funded with the exception of proposals for projects that involved 

the use of already banked or isolated human embryonic stem cells.  

The  Council  asked  the  Commission  to  publish  a  staff  report  on  scientific 

advances  and  needs  and  on  the  evolution  of  international  and  national 

legislation,  regulations  and ethical rules regarding  research  involving  the  use of 

human  embryonic  stem  cells.  The  report  was  prepared  by  the  Commission, 
published  on  3  April  2003  (SEC(2003)  441 (32)),  and  then  transmitted  to  the 

European  Parliament  and  the  Council  as  a  basis  for  discussion  at  an 
interinstitutional seminar on bioethics organised by the Commission (33).  

On 9 July 2003, the Commission then submitted to the Council a proposal for the 
modification  of  the  specific  programme  (COM(2003)  390 (34)),  on  which  the 
European  Parliament  had  to  express  its  opinion (35).  The  proposal  applied 

specifically to Community funding of research activities involving the procurement 

of  stem  cells  from  human  embryos  created  as  a  result  of  medically  assisted  in 

vitro fertilisation designed to induce pregnancy and no longer to be used for that 

purpose  (non-implanted  human  embryos);  and  it  was  based  on  the  principles 

established  by  the  European  Group  on  Ethics,  in  particular  the  fundamental 

ethical  principles  set  out  in  Opinion  No  15  ‘Ethical  aspects  of  human  stem  cell 
research and use’ (36). This Commission proposal received a favourable opinion 

from  the  European  Parliament  but  did  not  obtain  a  qualified  majority  at  the 

Council of 3 December 2003. 

(32)  
(33)  

(34)  

(35)  
(36)  

http://europa.eu.int/comm/research/conferences/2003/bioethics/index_en.html 
On  24  April  2003,  the  interinstitutional  seminar  on  bioethics  took  place.  The  seminar  addressed 
issues related to human embryonic stem cell research under the sixth  framework programme for 
research  and  provided  an  opportunity  for  discussion  and  exchanging  of  views  between  experts 
(scientific, legal,  and in ethics) and representatives of  the  European Parliament,  the  Council, the 
Commission, the Member States and the accession and candidate countries.  
Proposal  for  a  Council  decision  [COM(2003)  390]  amending  Decision  2002/834/EC  on  the 
specific programme for research, technological development and demonstration: ‘Integrating and 
strengthening the European research area’ (2002–06).  
http://europa.eu.int/comm/research/conferences/2003/bioethics/index_en.html 
http://europa.eu.int/comm/european_group_ethics/index_en.htm 

14

01_2007_5944_txt_EN.indd   14

12-02-2008   13:58:22

 
 
  
 
                                                 
has since been funded with the exception of proposals for projects that involved 

the use of already banked or isolated human embryonic stem cells.  

The  Council  asked  the  Commission  to  publish  a  staff  report  on  scientific 

advances  and  needs  and  on  the  evolution  of  international  and  national 

legislation,  regulations  and ethical rules regarding  research  involving  the  use of 

human  embryonic  stem  cells.  The  report  was  prepared  by  the  Commission, 

published  on  3  April  2003  (SEC(2003)  441 (32)),  and  then  transmitted  to  the 

European  Parliament  and  the  Council  as  a  basis  for  discussion  at  an 

interinstitutional seminar on bioethics organised by the Commission (33).  

modification  of  the  specific  programme  (COM(2003)  390 (34)),  on  which  the 

European  Parliament  had  to  express  its  opinion (35).  The  proposal  applied 

specifically to Community funding of research activities involving the procurement 

of  stem  cells  from  human  embryos  created  as  a  result  of  medically  assisted  in 

vitro fertilisation designed to induce pregnancy and no longer to be used for that 

purpose  (non-implanted  human  embryos);  and  it  was  based  on  the  principles 

established  by  the  European  Group  on  Ethics,  in  particular  the  fundamental 

ethical  principles  set  out  in  Opinion  No  15  ‘Ethical  aspects  of  human  stem  cell 

research and use’ (36). This Commission proposal received a favourable opinion 

from  the  European  Parliament  but  did  not  obtain  a  qualified  majority  at  the 

Council of 3 December 2003. 

(32)  

(33)  

(34)  

(35)  

(36)  

http://europa.eu.int/comm/research/conferences/2003/bioethics/index_en.html 

On  24  April  2003,  the  interinstitutional  seminar  on  bioethics  took  place.  The  seminar  addressed 

issues related to human embryonic stem cell research under the sixth  framework programme for 

research  and  provided  an  opportunity  for  discussion  and  exchanging  of  views  between  experts 

(scientific, legal,  and in ethics) and representatives of  the  European Parliament,  the  Council, the 

Commission, the Member States and the accession and candidate countries.  

Proposal  for  a  Council  decision  [COM(2003)  390]  amending  Decision  2002/834/EC  on  the 

specific programme for research, technological development and demonstration: ‘Integrating and 

strengthening the European research area’ (2002–06).  

http://europa.eu.int/comm/research/conferences/2003/bioethics/index_en.html 

http://europa.eu.int/comm/european_group_ethics/index_en.htm 

A moratorium was then implemented by the Commission and no hESC research 

In  parallel,  the  ‘procedural  modalities  for  research  activities  involving  banked  or 

isolated  human  embryonic  stem  cells  in  culture  to  be  funded  under  Council 
Decision  2002/834/EC’ (37)  were  approved  by 

the  Regulatory  Committee 

(comprising representatives of the Member States) on 25 June 2003 and by the 

Commission on 11 November 2003.  

On 31 December 2003, the moratorium ended and the two legal texts on which 

the  Commission  based  its  research  implementation  were:  (1)  the  specific 

programme 

implementing 

the  sixth 

framework  programme 

for  research, 

technological development and demonstration, ‘Integrating and strengthening the 
European  research  area’  (2002–06)  (Decision  2002/834/EC) (38);  and  (2)  the 

On 9 July 2003, the Commission then submitted to the Council a proposal for the 

‘procedural modalities for research activities involving banked or isolated human 

embryonic stem cells in culture’ (annexed to these recommendations). 

II.3. Human embryonic stem cell (hESC) projects financed under FP6 

In  total,  18  hESC  projects  were  financed  under  FP6  within  the  thematic  priority 

‘Life  sciences,  genomics  and  biotechnology  for  health’.  These  18  projects 

accounted  for  less  than  3 %  of  the  total  number  of  projects  funded  within  this 

thematic priority under FP6. Most FP6 hESC projects also involved research into 

adult stem cells and/or foetal stem cells (comparative approach), but one of the 

18  was  entirely  dedicated  to  human  embryonic  stem  cell  research  (Estools).  A 

detailed  list  of  FP6  projects  involving  the  use  of  hESCs  is  annexed  to  these 

recommendations. 

II.4. The ethics provisions applying to FP6-funded human embryonic stem 
cell projects 

II.4.1. FP6 ethics review 
In order to implement Article 6 of the framework programme and Article 15 of the 

rules  for  participation,  the  FP6  evaluation  procedure  included  a  check  of  the 

ethical  issues  raised  by  the  proposals.  Following  the  scientific  evaluation,  an 

(37)  
(38)  

C(2003) 2952. 
OJ L 294, 29.10.2002, p. 1. 

15

01_2007_5944_txt_EN.indd   15

12-02-2008   13:58:22

 
 
  
 
                                                 
 
 
  
 
 
 
                                                 
ethical review of the successful proposals involving sensitive ethical issues was 

carried out before the final selection by the Commission. 

The objective of the ethical review was to make sure that the European Union did 

not  support  research  contrary  to  fundamental  ethical  principles  and  to  examine 

whether  the  research  complied  with  the  rules  relating  to  ethics  set  out  in  the 

decisions on the sixth framework programme and specific programmes.  

Breakdown of projects subjected to ethical review, by research area 

The ethical review was carried out by external experts with the expertise needed 

for  an  ethical  assessment  of  the  proposals  (interdisciplinary  approach).  The 

experts  were  different  each  time  and  were  selected  by  the  Commission  on  the 

basis of expertise, geographical balance and gender balance.  

The  total  number  of  FP6  proposals  that  underwent  an  ethical  review  was  885 

(11 %  of  FP6  research  projects),  whereby  18  involved  human  embryonic  stem 

cell research (around 2 % of the total number of ethically reviewed proposals).  

16

01_2007_5944_txt_EN.indd   16

12-02-2008   13:58:22

 
 
  
 
 
 
 
 
 
 
 
 
 
ethical review of the successful proposals involving sensitive ethical issues was 

The graph below shows the numbers of FP6 projects subjected to ethical review. 

carried out before the final selection by the Commission. 

The objective of the ethical review was to make sure that the European Union did 

not  support  research  contrary  to  fundamental  ethical  principles  and  to  examine 

whether  the  research  complied  with  the  rules  relating  to  ethics  set  out  in  the 

decisions on the sixth framework programme and specific programmes.  

Breakdown of projects subjected to ethical review, by research area 

The ethical review was carried out by external experts with the expertise needed 

for  an  ethical  assessment  of  the  proposals  (interdisciplinary  approach).  The 

experts  were  different  each  time  and  were  selected  by  the  Commission  on  the 

basis of expertise, geographical balance and gender balance.  

The  total  number  of  FP6  proposals  that  underwent  an  ethical  review  was  885 

(11 %  of  FP6  research  projects),  whereby  18  involved  human  embryonic  stem 

cell research (around 2 % of the total number of ethically reviewed proposals).  

FP6 Proposals undergoing Ethical Reviews

Other

hESC Proposals

s
l
a
s
o
p
o
r
P

f
o
r
e
b
m
u
N

450

400

350

300

250

200

150

100

50

0

1

2

3

4

FP6 Years (2003-2006)

II.4.2. Ethics provisions for FP6 hESC projects 

For  human  embryonic  stem  cell  projects  funded  under  FP6,  the  following 

provisions applied. 

(a)  During  the  scientific  evaluation,  independent  experts  assessed  the  need  to 
use hESCs to achieve the scientific objectives set forth in the proposal (39). 

(b) An ethical review was organised by the Commission with independent experts 

on  a  case-by-case  basis.  It  was  based  on  the  ethical  rules  embodied  in  the 

European  Charter  of  Fundamental  Rights  and  in  the  different  national,  EU 

and  international  regulations  or  conventions,  also  taking  into  account  the 
opinions  of  the  European  Group  on  Ethics (40).  In  particular,  four  different 

criteria were assessed: 

(cid:120)  whether  the  applicants  took  into  account  the  legislation,  regulations, 

ethical  rules  and/or  codes  of  conduct  in  place  in  the  country  where  the 

(39)  

(40)  

The  type  of  stem  cells  to  be  used  is  chosen  by  the  scientists  in  view  of  the  objectives  of  the 
proposal,  which  should  relate  to  fundamental  research  questions  or  medical  applications.  Then, 
independent experts evaluate the proposal to assess the appropriateness of the approach chosen by 
the scientists. 
Council Decision 2002/834/EC, OJ L 294, 29.10.2002; see pp. 7–8 for details. 

17

01_2007_5944_txt_EN.indd   17

12-02-2008   13:58:23

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 
 
research  using  banked  or  isolated  hESCs  in  culture  was  to  take  place, 
including the procedures for obtaining informed consent (41); 

the source of the banked or isolated hESCs in culture;  

the measures taken to protect personal data, including  genetic data, and 

privacy; 

the nature of financial inducements, if any. 

(cid:120) 

(cid:120) 

(cid:120) 

(c) A  positive  opinion  from  a  regulatory  committee  comprising  Member  State 

representatives was required.  

(d) Finally,  the  Commission  checked  that  the  participants  in  research  projects 

had received the approval of the relevant national or local ethics committees 

prior to the start of research activities. 

All these conditions were cumulative. 

In conclusion, each hESC research proposal supported under FP6 was assessed 

by at least two independent ethical reviews: one at national level (in the country 
where the research was to be carried out) (42) and one at EU level.  

II.5.  The  seventh  framework  programme  for  research,  technological 
development and demonstration (2007–13) (FP7) 

As with FP6, ethics and hESCs played a major role in the interinstitutional debate 

on  the  seventh  framework  programme;  this  was  intended  to  contribute  to  the 

(41)  

(42)  

The EU has never required a uniform regulatory system for all fields of science and technology. 
The  Treaty  itself  guarantees  the  autonomy  of  the  Member  States.  As  a  consequence,  diverse 
regulatory  frameworks  coexist  (e.g.  for  research  on  non-human  primates,  nuclear  research, 
security and prevention of terrorism, bio-banking, etc.). The principle of subsidiarity is respected 
in full, assuming respect of fundamental ethical principles. 
If the research raising ethical issues is performed in more than one country (i.e. n countries), this 
implies that more than two ethical reviews will be performed (i.e. in fact n + 1 ethical reviews). 

18

01_2007_5944_txt_EN.indd   18

12-02-2008   13:58:23

 
 
  
 
 
 
 
                                                 
the source of the banked or isolated hESCs in culture;  

the measures taken to protect personal data, including  genetic data, and 

(cid:120) 

(cid:120) 

(cid:120) 

privacy; 

the nature of financial inducements, if any. 

(c) A  positive  opinion  from  a  regulatory  committee  comprising  Member  State 

representatives was required.  

(d) Finally,  the  Commission  checked  that  the  participants  in  research  projects 

had received the approval of the relevant national or local ethics committees 

prior to the start of research activities. 

All these conditions were cumulative. 

In conclusion, each hESC research proposal supported under FP6 was assessed 

where the research was to be carried out) (42) and one at EU level.  

II.5.  The  seventh  framework  programme  for  research,  technological 

development and demonstration (2007–13) (FP7) 

As with FP6, ethics and hESCs played a major role in the interinstitutional debate 

on  the  seventh  framework  programme;  this  was  intended  to  contribute  to  the 

(41)  

(42)  

The EU has never required a uniform regulatory system for all fields of science and technology. 

The  Treaty  itself  guarantees  the  autonomy  of  the  Member  States.  As  a  consequence,  diverse 

regulatory  frameworks  coexist  (e.g.  for  research  on  non-human  primates,  nuclear  research, 

security and prevention of terrorism, bio-banking, etc.). The principle of subsidiarity is respected 

in full, assuming respect of fundamental ethical principles. 

If the research raising ethical issues is performed in more than one country (i.e. n countries), this 

implies that more than two ethical reviews will be performed (i.e. in fact n + 1 ethical reviews). 

research  using  banked  or  isolated  hESCs  in  culture  was  to  take  place, 

including the procedures for obtaining informed consent (41); 

implementation  of  the  Lisbon  strategy  and  benefited  from  a  budget  of 
EUR 53 billion for the time frame 2007–13 (43). 

The Commission proposal for FP7 was adopted on 6 April 2005. As for FP6, the 

proposal had a specific article (Article 6) stating that ‘All the research activities … 

shall  be  carried  out  in  compliance  with  fundamental  ethical  principles’.  The 

specific programme for FP7 was adopted by the Commission on 21 September 

2005. The Commission proposal was then transmitted to the relevant institutions 

(the European Parliament and the Council) for their approval by co-decision.  

The  Parliament  adopted  (first  reading)  the  proposed  programme  on  15  June 

2006  after  a  preceding  vote  and  a  request  for  amendments  by  the  relevant 

Parliamentary  commission  (ITRE)  on  30  May  2005.  The  Commission  accepted 

Parliament’s request to have the ethics framework incorporated in the framework 

programme  text,  which  required  a  co-decision  by  the  European  Parliament  and 

the  Council  on  this  issue.  This  was  not  the  case  for  FP6,  where  the  ethical 

framework was included in the specific programme adopted by the Council alone. 

by at least two independent ethical reviews: one at national level (in the country 

After intense discussions, the programme was adopted by the Council on 24 July 

2006  (qualified  majority).  The  Council  agreement  was  based  on  a  Commission 

declaration stating that ‘The European Commission will continue with the current 

practice and  will not  submit  to  the  Regulatory  Committee  proposals  for  projects 

which include research activities which destroy human embryos, including for the 

procurement of stem cells. The exclusion of funding of this step of research will 

not prevent Community funding of subsequent steps involving human embryonic 

stem cells’. 

(43)  

A  detailed  description  of  the  interinstitutional  adoption  of  the  programme  can  be  found  at 
http://ec.europa.eu/prelex/detail_dossier_real.cfm?CL=en&DosId=192725 

19

01_2007_5944_txt_EN.indd   19

12-02-2008   13:58:23

 
 
  
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
                                                 
The  programme,  including  the  Commission  declaration,  was  then  approved  at 

the  European  Parliament  plenary  session  (second  reading)  on  30  November 

2006 and adopted in co-decision on 18 December 2006. 

II.6.  Ethics  provisions  under  FP7:  hESC  research  funded  by  the  European 
Union 

The  Council  agreement  made  the  eligibility  of  hESC  research  for  EU  funding 

subject to the same specific restrictions and conditions as with FP6. 

To  ensure  an  optimal  ethics  review  system,  the  President  of  the  European 

Commission asked the EGE on November 2006 to issue an opinion on the ethics 

review of hESC projects funded under FP7: 

I  would  like  to  invite  the  European  Group  on  Ethics  to  provide  the  Commission 

with an opinion on the implementing measures required during the ethics review 

of  research  projects  on  human  embryonic  stem  cells  that  will  assure  that  the 

ethical  rules  and  requirements  are  fully  met.  Such  an  opinion  would  provide 

guidance (in relation to the values and principles to apply) for the Ethics Review 

within  the  frame  of  the  Programme  approved  by  the  Council  and  the  European 

Parliament. It would be important that this opinion is available for use when the 
first FP7 projects involving human embryonic stem cells are evaluated (44).  

(44)  

Letter by Commission President J. M. Barroso addressed to the EGE on 22 November 2006. 

20

01_2007_5944_txt_EN.indd   20

12-02-2008   13:58:23

 
 
  
 
 
 
 
 
 
                                                 
The  programme,  including  the  Commission  declaration,  was  then  approved  at 

the  European  Parliament  plenary  session  (second  reading)  on  30  November 

2006 and adopted in co-decision on 18 December 2006. 

Union 

The  Council  agreement  made  the  eligibility  of  hESC  research  for  EU  funding 

subject to the same specific restrictions and conditions as with FP6. 

To  ensure  an  optimal  ethics  review  system,  the  President  of  the  European 

Commission asked the EGE on November 2006 to issue an opinion on the ethics 

review of hESC projects funded under FP7: 

I  would  like  to  invite  the  European  Group  on  Ethics  to  provide  the  Commission 

with an opinion on the implementing measures required during the ethics review 

of  research  projects  on  human  embryonic  stem  cells  that  will  assure  that  the 

ethical  rules  and  requirements  are  fully  met.  Such  an  opinion  would  provide 

guidance (in relation to the values and principles to apply) for the Ethics Review 

within  the  frame  of  the  Programme  approved  by  the  Council  and  the  European 

Parliament. It would be important that this opinion is available for use when the 

first FP7 projects involving human embryonic stem cells are evaluated (44).  

(44)  

Letter by Commission President J. M. Barroso addressed to the EGE on 22 November 2006. 

II.6.  Ethics  provisions  under  FP7:  hESC  research  funded  by  the  European 

scientific and ethical).  

III. 

BACKGROUND FOR THE ETHICAL REVIEW OF HESC PROJECTS 

III.1. Existing ethical guidelines: a brief historical overview 

In  a  fast-developing  area  such  as  stem  cell  research,  ethical  requirements  are 

assuming increasing importance in project assessment. The process of research 

approval  includes  a  review  of  projects  by  a  panel  of  independent  experts  (both 

Up  to  the  present,  no  clinical  research  making  use  of  human  embryonic  stem 

cells has been carried out. In view of the long-term perspective of FP7, however, 

all ethical guidelines and regulations must be applied to FP7  projects whenever 

they involve research on human subjects.  

Guidelines  and  regulations  governing  the  participation  of  human  subjects  in 

biomedical  research  have  been  established  at  international  level  for  many 

decades.  These  principles  are  laid  down  in  internationally  recognised  research 

ethics  guidelines  and  other  instruments,  including  (to  cite  only  the  most 
important):  the  Nuremburg  Code  of  1947 (45),  the  Declaration  of  Helsinki  of 
1964 (46) (plus amendments), the Belmont Report of 1979 (47), the Convention for 

the  Protection  of  Human  Rights  and  Dignity  of  the  Human  Being  with  regard  to 
the  Application  of  Biology  and  Medicine  of  1997  (the  ‘Oviedo  Convention’) (48) 
and  the  additional  protocols  to  the  convention (49),  the  Unesco  Universal 
Declaration  on  the  Human  Genome  and  Human  Rights (50)  of  1997  and  the 
International  Declaration  on  Human  Genetic  Data (51)  of  2003,  the  Council  for 

International  Organisations  of  Medical  Sciences  (CIOMS)  International  Ethical 

(45) 
(46) 
(47) 
(48) 
(49) 
(50) 

(51) 

http://www.ushmm.org/research/doctors/Nuremberg_Code.htm 
http://www.wma.net/e/ethicsunit/helsinki.htm 
http://ohsr.od.nih.gov/guidelines/belmont.html 
http://conventions.coe.int/treaty/en/treaties/html/164.htm 
http://conventions.coe.int/Treaty/EN/Treaties/Html/168.htm 
http://portal.unesco.org/fr/ev.php-
URL_ID=13177&URL_DO=DO_TOPIC&URL_SECTION=201.html 
http://portal.unesco.org/en/ev.php-
URL_ID=17720&URL_DO=DO_TOPIC&URL_SECTION=201.html 

21

01_2007_5944_txt_EN.indd   21

12-02-2008   13:58:24

 
 
  
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
                                                 
Guidelines for Biomedical Research Involving Human Subjects of 2002 (52), and 
the Unesco Universal Declaration on Bioethics and Human Rights of 2005 (53).  

Over  the  last  few  years,  several  international  bodies  have  been  established 

across the world, which give information and guidance in the process of research 

proposal preparation, application, and definition of standards, both scientific and 

ethically sound.  

As  noted  before,  the  volume  of  documents  addressing  the  ethics  of  hESCs  is 

vast and diverse. Additional information on relevant initiatives in this area may be 

found,  for  example,  on  the  following  websites:  the  BioCentre  for  Bioethics  and 
Public  Policy  (CBPP) (54),  CARE  for  Europe (55),  the  International  Society  for 
Stem  Cell  Research (56),  and  the  Nuffield  Council  on  Bioethics (57),  along  with 

those 
of 
organisations (60)(61). 

various 

national 

institutions (58)(59) 

and 

international 

In  addition  to  the  abovementioned  ethics  guidelines  produced  by  relevant 

international  organisations,  in  2006  the  International  Society  for  Stem  Cell 

Research  (ISSCR)  published  specific  guidelines  on  hESCs  (Guidelines  for  the 

conduct of human embryonic stem cell research). 

The  guidelines  address  the  procurement,  derivation,  banking,  distribution,  and 

use  of  cells  and  tissues  taken  from  pre-implantation  stages  of  human 

(52) 
(53) 

(54) 
(55) 
(56) 
(57) 
(58) 
(59) 

(60) 

(61) 

http://www.cioms.ch/ 
http://portal.unesco.org/shs/en/ev.php-
URL_ID=1883&URL_DO=DO_TOPIC&URL_SECTION=201.html 
http://www.bioethics.ac.uk/ 
http://www.careforeurope.org/ 
http://www.isscr.org/guidelines/ 
http://www.nuffieldbioethics.org/go/ourwork/stemcells/introduction 
http://www.dfg.de/en/news/press_releases/2006/press_release_2006_60.html 
UK HFEA, UK Department of Health, UK Stem Cell Initiative: 
http://www.hfea.gov.uk/cps/rde/xchg/SID-3F57D79B-370119F4/hfea/hs.xsl/295.html, 
http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/StemCell/fs/en, 
http://www.advisorybodies.doh.gov.uk/uksci/uksci-reportnov05.pdf 
EMBO: 
http://www.vr.se/download/18.2aebc6b810f3c933b158000194/EMBO+document+nov+2006.pdf#
search='stem+cell' 
European Science Foundation: http://www.esf.org/publication/142/ESPB18.pdf 

22

01_2007_5944_txt_EN.indd   22

12-02-2008   13:58:24

 
 
  
 
                                                 
development;  procurements  of  gametes  and  somatic  tissues  for  stem  cell 
research; and the use of human stem cell lines (62).  

proposal preparation, application, and definition of standards, both scientific and 

III.2. Research using human embryonic stem cells (hESCs) 

As  noted  before,  the  volume  of  documents  addressing  the  ethics  of  hESCs  is 

Human  embryonic  stem  cells  are  used  in  a  variety  of  research  projects  with 

vast and diverse. Additional information on relevant initiatives in this area may be 

different  scientific  goals.  Some  research  protocols  focus  completely  on  hESCs, 

found,  for  example,  on  the  following  websites:  the  BioCentre  for  Bioethics  and 

but  sometimes  they  may  use  human  embryonic  and  adult  stem  cells  for 

comparative  purposes  or  may  use  hESCs  as  a  tool  to  obtain  other  scientific 

outcomes (for example, to make in vitro tests of a given experimental drug or a 

new chemical).  

The relevance and use of hESCs therefore varies considerably according to the 

expected  scientific  outcomes  of  the  research  trials.  The  scientific  community  is 

interested in investigating the  basic physiology of stem cells, their potential and 

characteristics.  One  important  aspect  of  such  research  is  the  comparative 

analysis of hESCs and other types of stem cells, such as umbilical-cord and adult 

tissue-specific  stem  cells,  in  order  to  address  specific  questions  concerning  the 

suitability  of  these  types  of  cells.  Stem  cell  research  is  also  done  to  explore  its 

potential use for regenerative medicine (degenerative diseases such as diabetes 

and  Parkinson’s  disease)  and  gene  therapy  (e.g.  for  cystic  fibrosis  and 

Huntington’s disease). At present, there are no indications that clinical trials will 

be carried out in the near future.  

In addition, researchers are exploring the potential use of hESCs in toxicological 

studies  in  order  to  replace  animal  models  with  in  vitro  models.  Other  uses  of 

hESCs,  with  the  exception  of  the  ESTOOL  project  (see  annex  to  this  opinion), 

are  in  large  multidisciplinary  studies,  such  as  those  involving  genomics  and 

Guidelines for Biomedical Research Involving Human Subjects of 2002 (52), and 

the Unesco Universal Declaration on Bioethics and Human Rights of 2005 (53).  

Over  the  last  few  years,  several  international  bodies  have  been  established 

across the world, which give information and guidance in the process of research 

ethically sound.  

Public  Policy  (CBPP) (54),  CARE  for  Europe (55),  the  International  Society  for 

Stem  Cell  Research (56),  and  the  Nuffield  Council  on  Bioethics (57),  along  with 

those 

of 

various 

national 

institutions (58)(59) 

and 

international 

organisations (60)(61). 

In  addition  to  the  abovementioned  ethics  guidelines  produced  by  relevant 

international  organisations,  in  2006  the  International  Society  for  Stem  Cell 

Research  (ISSCR)  published  specific  guidelines  on  hESCs  (Guidelines  for  the 

conduct of human embryonic stem cell research). 

The  guidelines  address  the  procurement,  derivation,  banking,  distribution,  and 

use  of  cells  and  tissues  taken  from  pre-implantation  stages  of  human 

(52) 

(53) 

(54) 

(55) 

(56) 

(57) 

(58) 

(59) 

URL_ID=1883&URL_DO=DO_TOPIC&URL_SECTION=201.html 

http://www.cioms.ch/ 

http://portal.unesco.org/shs/en/ev.php-

http://www.bioethics.ac.uk/ 

http://www.careforeurope.org/ 

http://www.isscr.org/guidelines/ 

http://www.nuffieldbioethics.org/go/ourwork/stemcells/introduction 

http://www.dfg.de/en/news/press_releases/2006/press_release_2006_60.html 

UK HFEA, UK Department of Health, UK Stem Cell Initiative: 

http://www.hfea.gov.uk/cps/rde/xchg/SID-3F57D79B-370119F4/hfea/hs.xsl/295.html, 

http://www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/StemCell/fs/en, 

http://www.advisorybodies.doh.gov.uk/uksci/uksci-reportnov05.pdf 

(60) 

EMBO: 

search='stem+cell' 

http://www.vr.se/download/18.2aebc6b810f3c933b158000194/EMBO+document+nov+2006.pdf#

(61) 

European Science Foundation: http://www.esf.org/publication/142/ESPB18.pdf 

(62) 

http://www.isscr.org/guidelines/ISSCRhESCguidelines2006.pdf 

23

01_2007_5944_txt_EN.indd   23

12-02-2008   13:58:24

 
 
  
 
                                                 
 
 
  
 
 
 
 
 
 
                                                 
proteomics  approaches,  which  focus  on  broader  contexts  with  only  a  subset  of 

experiments specifically dealing with hESCs. 

Examples of EU-funded projects that make different uses of hESCs: 

(1)  EUROSTEMCELL:  project  aiming  to  compare  adult,  foetal,  embryonic  and 
tissue-specific stem cells (see http://www.eurostemcell.org/); 

(2)  BETACELL  THERAPY:  project  aiming  to  study  the  generation  of  insulin-
producing  pancreatic  beta  cells 
(see 
for 
http://www.betacelltherapy.org); 

treatment  of  diabetes 

the 

(3)  CARCINOGENOMICS:  project  aiming  to  carry  out  in  vitro  testing  to  assess 
the  genotoxic  and  carcinogenomic  properties  of  chemical  compounds  (in  silico 
models  to  evaluate  the  carcinogenic  potential  of  a  compound  in  vivo)  (see 
http://www.ecopa.eu/doc/CarcinogenomicsPressRelease-201106.pdf). 

III.3. Sources of human embryonic stem cells  

The  most  common  source  of  tissue  for  human  embryonic  stem  cell  isolation  is 

the  inner  cell  mass  (ICM)  of  embryos  created  using  assisted  reproduction 

technologies  (ART),  but  not  transferred  to  the  woman’s  uterus,  either  because 

the number of embryos exceeds the number allowed to be transferred under the 

law  (usually  two  or  three)  or  because  of  genetic  defects  detected  by  pre-
implantation  genetic  diagnostics  (PGD) (63).  In  the  same  way,  embryos  as  a 

source  of  stem  cells  can  be  created  solely  for  research  purposes  via  in  vitro 
fertilisation (IVF), but outside the ART context (64). 

Another  source  of  human  embryonic  stem  cells,  which  is  allowed  in  only  a  few 
countries (65), is their creation by means of somatic nuclear cell transfer (SCNT), 

where  a  somatic  cell  is  taken  from  an  adult  patient  and  its  nucleus  transferred 

(63) 
(64) 
(65) 

This practice is not permitted in all EU Member States.  
This practice is not permitted in most EU Member States. See Table 1, p. 29. 
In the EU, therapeutic cloning is allowed only in the following countries: Belgium, Spain, Sweden 
and the UK.  

24

01_2007_5944_txt_EN.indd   24

12-02-2008   13:58:25

 
 
  
 
 
 
 
 
 
 
 
 
                                                 
proteomics  approaches,  which  focus  on  broader  contexts  with  only  a  subset  of 

into  a  donated  enucleated  oocyte.  Unlike  hESCs  derived  from  a  donated  IVF 

experiments specifically dealing with hESCs. 

embryo, the resulting cell line using SCNT is genetically identical to the donor of 

Examples of EU-funded projects that make different uses of hESCs: 

(1)  EUROSTEMCELL:  project  aiming  to  compare  adult,  foetal,  embryonic  and 

tissue-specific stem cells (see http://www.eurostemcell.org/); 

(2)  BETACELL  THERAPY:  project  aiming  to  study  the  generation  of  insulin-

producing  pancreatic  beta  cells 

for 

the 

treatment  of  diabetes 

(see 

http://www.betacelltherapy.org); 

(3)  CARCINOGENOMICS:  project  aiming  to  carry  out  in  vitro  testing  to  assess 

the  genotoxic  and  carcinogenomic  properties  of  chemical  compounds  (in  silico 

models  to  evaluate  the  carcinogenic  potential  of  a  compound  in  vivo)  (see 

http://www.ecopa.eu/doc/CarcinogenomicsPressRelease-201106.pdf). 

III.3. Sources of human embryonic stem cells  

The  most  common  source  of  tissue  for  human  embryonic  stem  cell  isolation  is 

the  inner  cell  mass  (ICM)  of  embryos  created  using  assisted  reproduction 

technologies  (ART),  but  not  transferred  to  the  woman’s  uterus,  either  because 

the number of embryos exceeds the number allowed to be transferred under the 

law  (usually  two  or  three)  or  because  of  genetic  defects  detected  by  pre-

implantation  genetic  diagnostics  (PGD) (63).  In  the  same  way,  embryos  as  a 

source  of  stem  cells  can  be  created  solely  for  research  purposes  via  in  vitro 

fertilisation (IVF), but outside the ART context (64). 

Another  source  of  human  embryonic  stem  cells,  which  is  allowed  in  only  a  few 

countries (65), is their creation by means of somatic nuclear cell transfer (SCNT), 

where  a  somatic  cell  is  taken  from  an  adult  patient  and  its  nucleus  transferred 

the nucleus. 

Another possible way of creating stem cells by means of SCNT, but not leading 

to therapeutic cloning, is to create human/animal hybrids by mixing a human cell 
with  an  animal  egg  in  order  to  obtain  ‘humanised’  stem  cells (66).  There  is 

currently  debate  on  the  ethics  of  human/animal  hybrids  in  several  EU  and  non-

EU countries. The EC is at present financing a  project on the ethical, legal and 
social implications of human/animal hybrids (67).  

III.4. Derivation of new hESC lines 

As  indicated  in  Section  II.2,  the  derivation  of  new  totipotent  cells  or  pluripotent 

stem cell lines from donated pre-implantation human embryos or embryonic cells, 

or via nuclear reprogramming, is not funded by the EU research programme. The 

derivation  of  new  hESCs  necessarily  involves  the  procurement  of  biological 

material from human subjects, which then (when allowed) needs to be approved 

by  institutional  oversight  bodies  with  specific  responsibility  for  the  protection  of 

human subjects.  

III.5. Alternatives to hESC research  

As  stated  in  Section  II.2,  the  justification  for  the  use  of  human  embryonic  stem 

cells  under  FP7  is  to  be  assessed  during  the  scientific  evaluation  of  research 

proposals.  EU  projects  can  be  funded  only  if  no  suitable  alternatives  to  human 

embryonic  stem  cells  can  be  found  and  the  absolute  necessity  of  using  hESCs 

has  been  scientifically 

justified  and  evaluated.  With  regard 

to  possible 

(63) 

(64) 

(65) 

This practice is not permitted in all EU Member States.  

This practice is not permitted in most EU Member States. See Table 1, p. 29. 

In the EU, therapeutic cloning is allowed only in the following countries: Belgium, Spain, Sweden 

and the UK.  

(66) 

(67) 

Recently, British scientists have been seeking HFEA approval to create rabbit–human stem cells 
by  using  rabbits’  oocytes,  in  order  to  overcome  the  shortage  of  egg  donors  in  the  UK,  in  a 
collaboration between King’s College in London and Edinburgh University.  
See www.chimbrids.org 

25

01_2007_5944_txt_EN.indd   25

12-02-2008   13:58:25

 
 
  
 
 
 
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
 
                                                 
alternatives  to  hESCs,  the  first  factor  to  consider  is  the  possible  use  of  adult 

human stem cells. 

Adult  stem  cells  are  multipotent  stem  cells,  suitable  for  the  treatment  of  human 

diseases  such  as  leukaemia,  lymphomas  and  other  blood  diseases.  Such 

therapies 

rely  on 

the  very  well-established  practice  of 

transplanting 

haematopoietic  stem  cells  (blood-forming  stem  cells)  present  in  bone  marrow, 

placenta  or  umbilical  cord  blood  cells.  Other  diseases  that may  be  cured  in  the 

near future by using adult stem cells are, for example, diabetes and some forms 

of  cancer  (e.g.  kidney),  for  which  the  clinical  potential  of  adult  stem  cells  looks 

very promising.  

Given  the  nature  of  embryonic  stem  cells  and  the  moral  dilemma  regarding  the 

destruction of human embryos to obtain embryonic stem cells, research has also 

been  focusing  on  alternative  sources  of  human  embryonic  stem  cells,  an 

endeavour which received criticisms, both scientific and ethical, as in the case of 
altered nuclear transfer (68), which was developed by scientists as a technological 

to 

the  related  ethical 
solution 
issues (69)(70), but implies an epigenetic alteration of the egg to preclude natural 

the  destruction  of  human  embryos  and 

embryogenesis. 

Nevertheless, some recent promising research into alternatives to hESCs has 

been carried out, such as for:  

(cid:120) 

 pluripotent stem cells derived from ‘arrested’ embryos (71); 

(69)  

(68)   Melton, D. A., Daley, G. D. and Jennings, C. G. ‘Altered nuclear transfer in stem-cell research — 
A flawed proposal’, The New England Journal of Medicine, Vol. 351: 2791–2792 (30 December 
2004). 
Solter,  D.  ‘Politically  correct  human  embryonic  stem  cells?’,  The  New  England  Journal  of 
Medicine, Vol. 353: 2321–2323 (1 December 2005). 
Green,  R.  M.  ‘Can  we  develop  ethically  universal  embryonic  stem-cell  lines?’.  Nature  Reviews 
Genetics 8: 480–485 (2007). 
Zhang,  X.  et  al.  ‘Derivation  of  human  embryonic  stem  cells  from  developing  and  arrested 
embryos’, Stem Cells 24: 2660–76 (2006). 

(71)  

(70)  

26

01_2007_5944_txt_EN.indd   26

12-02-2008   13:58:25

 
 
  
 
 
 
 
                                                 
alternatives  to  hESCs,  the  first  factor  to  consider  is  the  possible  use  of  adult 

(cid:120)  pluripotent stem cells via blastomere extraction from developing 

human stem cells. 

Adult  stem  cells  are  multipotent  stem  cells,  suitable  for  the  treatment  of  human 

diseases  such  as  leukaemia,  lymphomas  and  other  blood  diseases.  Such 

therapies 

rely  on 

the  very  well-established  practice  of 

transplanting 

haematopoietic  stem  cells  (blood-forming  stem  cells)  present  in  bone  marrow, 

placenta  or  umbilical  cord  blood  cells.  Other  diseases  that may  be  cured  in  the 

near future by using adult stem cells are, for example, diabetes and some forms 

of  cancer  (e.g.  kidney),  for  which  the  clinical  potential  of  adult  stem  cells  looks 

very promising.  

Given  the  nature  of  embryonic  stem  cells  and  the  moral  dilemma  regarding  the 

destruction of human embryos to obtain embryonic stem cells, research has also 

been  focusing  on  alternative  sources  of  human  embryonic  stem  cells,  an 

endeavour which received criticisms, both scientific and ethical, as in the case of 

altered nuclear transfer (68), which was developed by scientists as a technological 

solution 

to 

the  destruction  of  human  embryos  and 

the  related  ethical 

issues (69)(70), but implies an epigenetic alteration of the egg to preclude natural 

embryogenesis. 

Nevertheless, some recent promising research into alternatives to hESCs has 

been carried out, such as for:  

(cid:120) 

 pluripotent stem cells derived from ‘arrested’ embryos (71); 

(68)   Melton, D. A., Daley, G. D. and Jennings, C. G. ‘Altered nuclear transfer in stem-cell research — 

A flawed proposal’, The New England Journal of Medicine, Vol. 351: 2791–2792 (30 December 

2004). 

(69)  

(70)  

(71)  

Solter,  D.  ‘Politically  correct  human  embryonic  stem  cells?’,  The  New  England  Journal  of 

Medicine, Vol. 353: 2321–2323 (1 December 2005). 

Green,  R.  M.  ‘Can  we  develop  ethically  universal  embryonic  stem-cell  lines?’.  Nature  Reviews 

Genetics 8: 480–485 (2007). 

embryos’, Stem Cells 24: 2660–76 (2006). 

Zhang,  X.  et  al.  ‘Derivation  of  human  embryonic  stem  cells  from  developing  and  arrested 

embryos (72); 

(cid:120)  pluripotent stem cells via somatic cell dedifferentiation (73); 
(cid:120)  human materials using cell fusion rather than genetic factors (74); 

(cid:120)  non-embryonal sources of ‘embryonic like’, multipotent human stem cells 
(from human umbilical cord blood (75) or from human amniotic fluid (76)).  

III.6. European Registry of existing hESC lines 

According  to  the  available  data,  81  different  hESC  lines  have  at  present  been 

established and are used in EU-funded projects. Since there is certain variability 

from cell line to cell line, the Commission has felt it important to: (1) gather in a 

centralised  manner  all  information  available  on  each  single  cell  line  for 

comparative purposes; and (2) render such information available at international 

level. 

The  European  Commission  has  therefore  decided  to  establish  and  fund  a 
European  Registry  for  human  embryonic  stem  cell  lines (77)  in  order  to  help 

researchers  to  optimise  the  hESC  resources  available  and  avoid  duplication  of 

work and/or the creation of new cell lines where possible. This registry is expected 

to  boost  the  coordination  and  rationalisation  of  human  embryonic  stem  cell 

(72) 

(73) 

(74) 

(75) 

(76) 

(77) 

 Klimanskya, I. et al. ‘Human embryonic stem cell lines derived from single blastomeres’, Nature 
444: 481–485 (2006). 
Takahashi, K. and Yamanaka, S. ‘Induction of pluripotent stem cells from mouse embryonic and 
adult fibroblast cultures by defined factors’, Cell 126: 1–14 (2006).  
Wernig,  M.  et  al.  ‘In  vitro  reprogramming  of  fibroblasts  into  a  pluripotent  ES-cell-like  state’, 
Nature, AOP doi:10.1038/nature05944 (2007). 
Cowan, C. A. et al. ‘Nuclear reprogramming of somatic cells after fusion with human embryonic 
stem cells’, Science, 309: 1369–1373 (2005).  
Zhao, Y. et al. ‘Identification of stem cells from human umbilical cord blood with embryonic and 
hematopoietic characteristics’, Experimental Cell Research, 312: 2454–2464 (2006). 
De  Coppi,  P.  et  al.  ‘Isolation  of  amniotic  stem  cell  lines  with  potential  for  therapy’,  Nature 
Biotechnology 25: 100–106 (2007). 
The  project will  be  funded  for three years with  grants  for a total  of EUR 1 million.  The  registry 
will be mainly coordinated by two institutions: the Centre of Regenerative Medicine (CRMB) in 
Barcelona,  Spain,  and  the  Berlin-Brandenburg  Centre  for  Regenerative  Therapies  (BCRT)  in 
Berlin, Germany. 

27

01_2007_5944_txt_EN.indd   27

12-02-2008   13:58:26

 
 
  
 
 
 
 
                                                 
 
 
  
 
 
 
 
                                                 
    
research  in  Europe.  It  will  provide  a  platform  to  maximise  reproducibility, 
comparability and transparency in the field (78). 

The main objective of this initiative is to provide comprehensive information about 

all human embryonic stem cell lines available in Europe. The information will be 

gathered  together  on  a  publicly  accessible  Internet  site  containing  data  on  the 

cell lines (e.g. cell characteristics) and their use (e.g. research project outcomes, 

clinical  trials,  etc.).  The  registry  will  provide  information  on  the  sources  of  the 

stem  cell  lines  and  include  comprehensive  information  on  human  embryonic 

stem  cell  lines  obtained  from  ongoing  and  future  EU-funded  projects.  The  data 

will be regularly updated and made accessible to the public.  

A Steering Committee comprising representatives of the leading European public 

institutions  involved  in  human  embryonic  stem  cell  research  has  also  been 

established. The committee will be assisted by an Advisory Board, comprising 17 

top  scientists  from  Europe  and  outside  Europe  in  the  field  of  human  embryonic 

stem  cell  research,  and  an  independent  Ethics  Advisory  Board  to  ensure 

compliance with ethical requirements and ethical guidance.  

III.7. EU Member States’ regulations on hESC research 

Among the 27 EU Member States (EU-27), several clusters of countries can be 

identified according to how they regulate hESC research. However, all countries 

apply at least some regulations and/or procedural rules to specific projects 

involving hESCs. Where hESC research is allowed, project proposals have to 

undergo strict evaluation criteria, both scientific and ethical, decided upon by the 
competent national bodies (79).  

(78)  

(79) 

  For more information see: www.cmrb.eu; www.cellnet.org; 

www.ec.europa.eu/research/fp6/index_en.cfm?p=1_stem_projects 
See annex (pp. 52–102) for further details in single Member States. 

28

01_2007_5944_txt_EN.indd   28

12-02-2008   13:58:26

 
 
  
 
 
 
 
 
 
                                                 
gathered  together  on  a  publicly  accessible  Internet  site  containing  data  on  the 

cell lines (e.g. cell characteristics) and their use (e.g. research project outcomes, 

clinical  trials,  etc.).  The  registry  will  provide  information  on  the  sources  of  the 

stem  cell  lines  and  include  comprehensive  information  on  human  embryonic 

stem  cell  lines  obtained  from  ongoing  and  future  EU-funded  projects.  The  data 

will be regularly updated and made accessible to the public.  

A Steering Committee comprising representatives of the leading European public 

institutions  involved  in  human  embryonic  stem  cell  research  has  also  been 

established. The committee will be assisted by an Advisory Board, comprising 17 

top  scientists  from  Europe  and  outside  Europe  in  the  field  of  human  embryonic 

stem  cell  research,  and  an  independent  Ethics  Advisory  Board  to  ensure 

compliance with ethical requirements and ethical guidance.  

III.7. EU Member States’ regulations on hESC research 

Among the 27 EU Member States (EU-27), several clusters of countries can be 

identified according to how they regulate hESC research. However, all countries 

apply at least some regulations and/or procedural rules to specific projects 

involving hESCs. Where hESC research is allowed, project proposals have to 

competent national bodies (79).  

research  in  Europe.  It  will  provide  a  platform  to  maximise  reproducibility, 

Permissive position 

comparability and transparency in the field (78). 

A few EU Member States have specific legislation for hESC research, covering 
the procurement of stem cells and their use for research. In Belgium, Spain (80), 

The main objective of this initiative is to provide comprehensive information about 

Sweden and the UK, for example, embryo creation is allowed for research 

all human embryonic stem cell lines available in Europe. The information will be 

purposes.  

Permissive position with restrictions 

In  other  EU  Member  States  such  as  the  Czech  Republic,  Denmark,  Greece, 
France, the Netherlands, Portugal and Finland (81), regulations allow the derivation 

of  new  hESCs  from  embryos  created  as  a  result  of  assisted  reproduction 

technology (ART) and in vitro fertilisation to induce pregnancy, but only when they 

can no longer be used for that purpose.  

Restrictive position 

Germany  and  Italy  have  stricter  hESC  research  regulations.  Scientists  in  these 

countries  cannot  derive  new  hES  cell  lines,  but  can  import  them.  In  Germany,  a 

new  discussion  has  arisen  as  to  whether  the  2002  Stem  Cell  Act  regulating  the 

importation  of  hESC  lines  should  be  revised,  but  no  legal  proposal  has  been 

forthcoming  by  the  date  of  these  recommendations.  Italian  legislation  covers 

artificial  reproduction  technology  and  the  production  of  new  hESCs  (research 

involving  the  destruction  of  embryos  is  not  allowed).  Italy  therefore  has  no  legal 

provision as regards the use of imported hESCs or existing hESCs. 

undergo strict evaluation criteria, both scientific and ethical, decided upon by the 

No specific legislation or indirect legislation only 

In many Member States, hESC research still has no specific legislation (Bulgaria, 

Estonia, Ireland, Cyprus, Latvia, Luxembourg  and Romania). Ireland, for instance, 

(78)  

(79) 

  For more information see: www.cmrb.eu; www.cellnet.org; 

www.ec.europa.eu/research/fp6/index_en.cfm?p=1_stem_projects 

See annex (pp. 52–102) for further details in single Member States. 

(80) 
(81) 

A new law in Spain has just been voted for. 
A new regulation is under way in Portugal. 

29

01_2007_5944_txt_EN.indd   29

12-02-2008   13:58:26

 
 
  
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
 
 
                                                 
currently  has  no  specific  legislation  dealing  with  embryonic  stem  cell  research 

and furthermore does not have a legislative basis for the practice of IVF. 

Some  other  EU  Member  States  have  no  ‘specific’  regulation  on  hESC  research, 

but  explicitly  indicated  that  they  are  against  it  (Lithuania,  Malta,  Austria,  Poland 

and  Slovakia)  by  voting  against  hESC  research  during  the  Council  decision  for 

FP7. 

Lastly, in some countries hESC is at present regulated only by indirect legislation 

for embryo research (Hungary, Slovenia), but without specific reference to hESCs. 

The  table  below  summarises  the  current  regulatory  systems  in  the  EU-27,  but 

specific  information  on  the  position  of  each  Member  State  can  be  found  in  the 

annex to these recommendations (regulatory issues). 

30

01_2007_5944_txt_EN.indd   30

12-02-2008   13:58:26

 
 
  
 
 
 
 
 
currently  has  no  specific  legislation  dealing  with  embryonic  stem  cell  research 

and furthermore does not have a legislative basis for the practice of IVF. 

Table 1. Regulations in EU Member States regarding hESC research  
(updated June 2007) 

Some  other  EU  Member  States  have  no  ‘specific’  regulation  on  hESC  research, 

but  explicitly  indicated  that  they  are  against  it  (Lithuania,  Malta,  Austria,  Poland 

and  Slovakia)  by  voting  against  hESC  research  during  the  Council  decision  for 

FP7. 

Lastly, in some countries hESC is at present regulated only by indirect legislation 

for embryo research (Hungary, Slovenia), but without specific reference to hESCs. 

The  table  below  summarises  the  current  regulatory  systems  in  the  EU-27,  but 

specific  information  on  the  position  of  each  Member  State  can  be  found  in  the 

annex to these recommendations (regulatory issues). 

Allowing 
procurement of 
hESCs from 
supernumerary 
embryos by law 

Specific 
legislation for 
embryo research 
including 
supernumerary 
embryos but 
without specific 
reference to 
hESCs 

Prohibiting 
procurement 
of hESCs from 
human 
embryos but 
allowing 
importation of 
hESC lines  

AT 
BE 
BG 
CY 
CZ 
DE 
DK 
EE 
EL 
ES 
FI 
FR 
HU 
IE 
IT 
LT 
LU 
LV 
MT 
NL 
PL 
PT 
RO 
SE 
SI 
SK 
UK 

X 

X 

X 

X 
X 
X 
X 

X 

X 

X 

X 

X (a) 

X (b) 

X 

X 

No specific 
regulation on 
hESC 
research  

Allowing 
creation of 
human 
embryos for 
procurement 
of hESCs by 
law 

Countries which signed 
and ratified the Oviedo 
Convention of 4.4.1997 
(against the creation of 
human embryos for 
research purposes) 

X (d) 

X 
X 

X 

X 

X (d) 
X 
X 
X (d) 

X (d) 

X 

X (d) 

X 

X (c) 

X 

X 

X 
X 
X 

X 
X 
X 
X 

X 

X 

X 
X 

X 
X 

Italy has no law regarding importation. 

(a)  Germany has a law and hESC lines have to be derived before 1 January 2002. 
(b) 
(c)  Spain allows techniques such as SCNT to obtain hESCs. 
(d)   Countries which voted against hESC research during Council decision for FP7. 

Country code key: 
AT: Austria  
BE: Belgium 
CY: Cyprus 
CZ: Czech Republic 
DE: Germany 

DK: Denmark  FR: France 
EE: Estonia 
EL: Greece 
ES: Spain 
FI: Finland 

HU: Hungary   LV: Latvia 
MT: Malta 
IE: Ireland  
NL: Netherlands 
IT: Italy  
LT: Lithuania  PL: Poland 

LU: Luxembourg 

PT: Portugal 
SE: Sweden 
SI: Slovenia 
SK: Slovakia 
UK: United Kingdom 

31

01_2007_5944_txt_EN.indd   31

12-02-2008   13:58:27

 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III.8. Commercialisation and patenting 

inventions 
The  directive  on 
 (98/44/EC) (82)  regulates  patentability  of  biological  material,  including  hESCs. 

legal  protection  of  biotechnological 

the 

The debate on patenting hESCs is ongoing at both institutional (European Patent 
Office,  the  European  Commission (83))  and  academic  level.  At  present,  there  is 

no  EU  consensus  on  the  moral  status  of  the  embryo  and  its  products  and, 

reflecting  this  wide  diversity  of  moral  cultures,  there  are  different  policies  for 

patenting  among  national  patent  offices.  The  European  Group  on  Ethics  (EGE) 

has evaluated the ethical aspects of patenting inventions involving human stem 
cells (84). 

(82)  
(83)  
(84)  

OJ L 213, 30.7.1998, pp. 13–21. 
See COM(2005) 312 
EGE Opinion No 16, ‘Ethical aspects involving the patenting of human stem cells’. 

32

01_2007_5944_txt_EN.indd   32

12-02-2008   13:58:27

 
 
  
 
 
 
                                                 
III.8. Commercialisation and patenting 

The  directive  on 

the 

legal  protection  of  biotechnological 

inventions 

 (98/44/EC) (82)  regulates  patentability  of  biological  material,  including  hESCs. 

The debate on patenting hESCs is ongoing at both institutional (European Patent 

Office,  the  European  Commission (83))  and  academic  level.  At  present,  there  is 

no  EU  consensus  on  the  moral  status  of  the  embryo  and  its  products  and, 

reflecting  this  wide  diversity  of  moral  cultures,  there  are  different  policies  for 

patenting  among  national  patent  offices.  The  European  Group  on  Ethics  (EGE) 

has evaluated the ethical aspects of patenting inventions involving human stem 

cells (84). 

IV. RECOMMENDATIONS  

IV.1 Preamble 

These  recommendations  constitute  the  reply  to  the  request  from  the 
President of the European Commission, Mr Barroso (85), after the adoption of 
the  EU’s  seventh  framework  programme  for  research  and  development 
(FP7), to elaborate an opinion on the implementing measures required during 
the  ethics  review  of  research  projects  on  human  embryonic  stem  cells 
(hESCs).  

As  is  the  case  in  the  European  Union,  there  are  divergent  views  within  the 
European  Group  on  Ethics  (EGE)  on  the  moral  legitimacy  of  research  on 
human embryos and hESCs, ranging from objection to research involving the 
destruction of human embryos (which makes the full respect of dignity of the 
human  embryo  impossible),  to  a  position  allowing  hESC  research  under 
certain conditions or on a broader basis.  

The group acknowledges the political decision taken as the starting point for 
its recommendations, but emphasises that the ethical dilemma regarding the 
moral status of the human embryo and its use in research still persists. The 
EGE  therefore  stresses  that  the  ethical  differences  of  opinion  concerning 
hESC research have not been resolved. 

However,  these  recommendations  do  not  elaborate  ethical  arguments  on 
hESC  research  as  such;  this  is  because  this  was  not  the  task  given  to  the 
group by the European Commission.  

(82)  

(83)  

(84)  

OJ L 213, 30.7.1998, pp. 13–21. 

See COM(2005) 312 

EGE Opinion No 16, ‘Ethical aspects involving the patenting of human stem cells’. 

(85) 

Letter sent by Commission President Barroso to the EGE on 22 November 2006. ‘I would like to 
invite  the  European  Group  on  Ethics  to  provide  the  Commission  with  an  opinion  on  the 
implementing  measures  required  during  the  ethics  review  of  research  projects  on  human 
embryonic stem cells that will assure that the ethical rules and requirements are fully met’. 

33

01_2007_5944_txt_EN.indd   33

12-02-2008   13:58:27

 
 
  
 
 
 
                                                 
 
 
  
 
 
 
 
 
 
 
 
 
                                                 
IV.2.  Recommendations  for  the  ethical  review  of  research 
projects involving hESCs 

FP7 research projects involving the use of hESCs are subject to stringent rules 

for  selection,  are  scrutinised  at  both  national  and  EU  level,  and  undergo  both 

scientific and ethical reviews. 

Under FP7, research proposals must include information about ethical aspects of 

the  proposed  research,  explain  in  detail  the  project  design,  and  show  that  the 

proposal meets the national legal and ethical requirements of the country where 

the research is performed. 

After successfully passing the scientific evaluation, the selected hESC proposals 

undergo  a  specific  ethics  review  organised  by  the  Commission  on  a  case-by-

case  basis.  The  objective  of  the  review  is  to  ensure  that  the  European  Union 

does  not  support  research  that  would  not  comply  with  fundamental  ethical 
principles (86) and to examine whether the ethics rules set out in FP7 are met.  

The  ethics  review  panel  is  a  transnational  body  composed  of  experts  from 

different disciplines. The panel produces an ethical review report, which lists the 

different  ethical  issues,  describes  the  way  these  issues  were  handled  by 

applicants, and gives the recommendations of the panel.  

After having successfully passed both the scientific and ethics review, proposals 

for hESC projects are then handed over to a Regulatory Committee composed of 

EU  Member  State  representatives,  which  decides  upon  the  projects  on  a  case-

by-case basis.  

(86)  

Seventh  framework  programme  (Decision  No  1982/2006/EC),  Article  6(1):  ‘All  the  research 
activities carried out under the Seventh Framework Programme shall be carried out in compliance 
with fundamental ethical principles.’; Rules for Participation, Article 10: ‘A proposal […] which 
contravenes  fundamental  ethical  principles  […]  shall  not  be  selected.  Such  a  proposal  may  be 
excluded from the evaluation and selection procedures at any time.’  

34

01_2007_5944_txt_EN.indd   34

12-02-2008   13:58:28

 
 
  
 
 
 
 
 
 
 
                                                 
IV.2.  Recommendations  for  the  ethical  review  of  research 

projects involving hESCs 

FP7 research projects involving the use of hESCs are subject to stringent rules 

for  selection,  are  scrutinised  at  both  national  and  EU  level,  and  undergo  both 

scientific and ethical reviews. 

Under FP7, research proposals must include information about ethical aspects of 

the  proposed  research,  explain  in  detail  the  project  design,  and  show  that  the 

After successfully passing the scientific evaluation, the selected hESC proposals 

undergo  a  specific  ethics  review  organised  by  the  Commission  on  a  case-by-

case  basis.  The  objective  of  the  review  is  to  ensure  that  the  European  Union 

does  not  support  research  that  would  not  comply  with  fundamental  ethical 

principles (86) and to examine whether the ethics rules set out in FP7 are met.  

The  ethics  review  panel  is  a  transnational  body  composed  of  experts  from 

different disciplines. The panel produces an ethical review report, which lists the 

different  ethical  issues,  describes  the  way  these  issues  were  handled  by 

applicants, and gives the recommendations of the panel.  

After having successfully passed both the scientific and ethics review, proposals 

for hESC projects are then handed over to a Regulatory Committee composed of 

EU  Member  State  representatives,  which  decides  upon  the  projects  on  a  case-

by-case basis.  

(86)  

Seventh  framework  programme  (Decision  No  1982/2006/EC),  Article  6(1):  ‘All  the  research 

activities carried out under the Seventh Framework Programme shall be carried out in compliance 

with fundamental ethical principles.’; Rules for Participation, Article 10: ‘A proposal […] which 

contravenes  fundamental  ethical  principles  […]  shall  not  be  selected.  Such  a  proposal  may  be 

excluded from the evaluation and selection procedures at any time.’  

In  order  to  provide  guidance  to  the  members  of  the  FP7  hESC  ethics  review 

panels who will be asked to review the research projects using hESC lines, and 

under the specific remit and conditions laid down by the political decision of the 

European Parliament and of the Council on FP7, and also by the specific request 

of the President of the European Commission, Mr J. M. Barroso (see above), the 

EGE elaborated the following guidelines and points to consider when conducting 
such ethics review of FP7 projects (87).  

proposal meets the national legal and ethical requirements of the country where 

IV.2.1. General criteria 

the research is performed. 

The European Commission has stated that it ‘will support actions and initiatives 

that  contribute  to  coordination  and  rationalisation  of  hESC  research  within  a 
responsible ethical approach’ (88). In line with this statement, the EGE recognises 

the  need  to  promote  responsible  research  that  is  transparent,  serves  the  public 

interest,  respects  Member  States’  autonomy,  preserves  public  trust,  promotes 

international  cooperation,  and  requires  the  embedding  of  ethics  within  research 
practice (89). 

Ethically  responsible  research  involving  human  embryonic  stem  cells  must 

comply  with  fundamental  ethical  principles  and  human  rights  in  the  European 
Union (90), from the  procurement  of  stem  cells (91)  to  clinical research  based  on 

hESCs.  

(87)  

(88)  

(89)  
(90)  

(91)  

According  to  FP7  rules,  evaluators  sign  a  conflict  of  interest  declaration  and  EC  staff  verify 
conflicts with each proposal they evaluate. Evaluation panels of ethics and scientific reviews are 
anonymous. 
Declaration  of  the  European  Commission  on  24 July 2006 during  the  meeting of the  Council  of 
Ministers regarding FP7. See OJ  L 412, 30.12.2006. 
For example, the Council of Europe Oviedo Convention (Article 2).  
For  details,  see  Section  I  of  this  opinion  referring  to  the  pertinent  documents  relevant  to  the 
context of medical research. 
FP7  excludes  the  procurement  of  hESCs  from  Community  funding  (see  paragraph  II.2).  See 
Decision No 1982/2006/EC of the European Parliament and of the Council of 18 December 2006 
concerning  the  seventh  framework  programme  of  the  European  Community  for  research, 
technological development and demonstration activities (2007–13), OJ L 412, 30.12.2006, pp. 1–
41. 

35

01_2007_5944_txt_EN.indd   35

12-02-2008   13:58:28

 
 
  
 
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
                                                 
The  fundamental  rights  include:  protection  rights  such  as  protection  of  human 

life, respect of its integrity, protection of health and freedom, political rights such 

as freedom from undue state intervention or participatory rights in political affairs, 

and  positive  rights  such  as  basic  social  and  economic  rights  insofar  as  these 

contribute  to  health  and  a  threshold  of  development,  resulting  in  health-related 
governance (92).  

The balancing of these three groups of fundamental rights is by no means easy 

or  pre-determined.  Rather,  it  involves  ongoing  efforts  to  ensure  their  protection, 

granting and promotion of human dignity and human rights and, more concretely, 

it involves priority setting with respect to health-related research.  

General  criteria  for  research  incentives  in  specific  areas  incorporate  this 

balancing. They can be summarised as follows:  

(cid:120)  scientific necessity and high-ranking status of the research (93); 
(cid:120)  urgency (94);  
(cid:120)  social desirability; 

(cid:120)  primacy of the interest and welfare of the human being over the sole 

interest of society or science. 

Social  desirability  is  open  to  political  and  societal  discourse  on  the  goals  and 

perspectives of the European Union in the 21st century, in particular the relation 

between economic growth and social goals, such as the promotion of healthcare 

standards  and  their  sustainable  application  at  national,  international  and  global 

level.  

(92)  

(93)  
(94)  

See  the  United  Nations’  millennium  goals,  which  the  European  Union  has  committed  itself  to 
achieving. 
http://ec.europa.eu/research/fp7/index_en.cfm?pg=documents 
http://www.who.int/rpc/en/HealthResearchinPolicyMaking.pdf 

36

01_2007_5944_txt_EN.indd   36

12-02-2008   13:58:28

 
 
  
 
 
 
 
 
 
                                                 
The  fundamental  rights  include:  protection  rights  such  as  protection  of  human 

As  far  as  hESC  research  is  concerned,  there  is  no  consensus  on  its  social 

life, respect of its integrity, protection of health and freedom, political rights such 

acceptability  in  the  European  Union,  and  divergent  views  coexist.  A  debate  on 

as freedom from undue state intervention or participatory rights in political affairs, 

the  best  model  (e.g.  ‘minimal  consensus’  or  ‘subsidiarity’  model)  to  regulate 

and  positive  rights  such  as  basic  social  and  economic  rights  insofar  as  these 

hESC research at EU level is therefore taking place within and across several EU 

contribute  to  health  and  a  threshold  of  development,  resulting  in  health-related 

Member States. 

governance (92).  

The balancing of these three groups of fundamental rights is by no means easy 

as in the case of human embryonic stem cells –— where not the goal of therapy-

or  pre-determined.  Rather,  it  involves  ongoing  efforts  to  ensure  their  protection, 

oriented  research  is  questioned  but  the  means  to  accomplish  it,  the  EGE  holds 

granting and promotion of human dignity and human rights and, more concretely, 

that additional criteria apply concerning the  necessity of the research: (1) non-

Where morally sensitive means are to be used to achieve well-accepted goals — 

it involves priority setting with respect to health-related research.  

General  criteria  for  research  incentives  in  specific  areas  incorporate  this 

balancing. They can be summarised as follows:  

(cid:120)  scientific necessity and high-ranking status of the research (93); 

(cid:120)  urgency (94);  

(cid:120)  social desirability; 

(cid:120)  primacy of the interest and welfare of the human being over the sole 

interest of society or science. 

Social  desirability  is  open  to  political  and  societal  discourse  on  the  goals  and 

perspectives of the European Union in the 21st century, in particular the relation 

between economic growth and social goals, such as the promotion of healthcare 

standards  and  their  sustainable  application  at  national,  international  and  global 

level.  

See  the  United  Nations’  millennium  goals,  which  the  European  Union  has  committed  itself  to 

(92)  

(93)  

(94)  

achieving. 

http://ec.europa.eu/research/fp7/index_en.cfm?pg=documents 

http://www.who.int/rpc/en/HealthResearchinPolicyMaking.pdf 

availability  of  validated  alternatives,  and  (2)  the  non-redundancy  of  FP7 
projects (95). 

However,  all  the  above  criteria,  which  constitute  the  key  scientific  evaluation 

criteria, need to be assessed from an ethical perspective during the ethics review 

process.  It  is  clear  that  the  ethics  review  cannot  and  should  not  duplicate  the 

scientific evaluation, which remains the main assessment of the scientific quality 

of  the  project  proposals.  Nevertheless,  the  two  reviews  are  complementary.  As 

far as FP7 hESC projects are concerned, the Commission should ensure that the 

scientific evaluation report is available to the ethics review panel and that there is 

effective communication between the two panels if needed. 

To  ensure  the  complementarity  of  the  two  reviews,  the  scientific  review  report 

should address at least the points below. 

(cid:120)  Applicants  must  have  shown  that  research  with  human  stem  cells 

derived  from  alternative  sources,  such  as  adult  stem  cells,  amniotic 

fluid,  umbilical  cord  blood  or  other  relevant  ones,  cannot  achieve  the 

expected  goals  of  the  project.  This  does  not  apply  to  research 

(95)  

However,  repetitions  are  sometimes  necessary  to  provide  evidence  of  success;  these  are  not 
redundant exercises in the sense used here. 

37

01_2007_5944_txt_EN.indd   37

12-02-2008   13:58:29

 
 
  
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
                                                 
comparing  hESCs  with  human  stem  cells  derived  from  alternative 

sources. 

(cid:120)  Applicants must have documented the fact that, in accordance with the 

basic  ethical  principles  of  medical  research,  relevant  research  on 

animals and on cell lines of other origin (animal and human) has been 

adequately carried out before hESC research is performed. 

(cid:120)  Applicants  must  show  that  their  research  is  aimed  at  future  human 

health  benefit  or  biomedical  knowledge,  and  cannot  be  achieved  by 

alternatives.  This  includes  basic  research  using  hESCs,  which  is 

allowed in FP7. 

(cid:120)  Applicants  must  have  demonstrated  that  no  alternatives  can  achieve 

the goals of the project. Although the group is aware of the importance 

of  respecting  animal  welfare,  it  is  concerned  that  respect  for  human 

dignity may not be maintained when hESCs are used in toxicity testing 

of  industrial  or  other  commercially  produced  chemicals  not  related  to 

drugs,  such  as  cosmetics,  or  for  replacement  of  animal  testing. 

Therefore, particular attention is to be drawn to this issue (see below, 

paragraph IV.3, point 2). 

(cid:120)  Applicants  must  provide  extensive  scientific  justification  when  their 

projects involve toxicity drug testing; this justification should make clear 

what sort of additional information is expected from the use of hESCs 

as compared with the established tests.  

The  scientific  panel  should  ensure  that  researchers  of  hESC  FP7  projects 

collaborate  nationally  and  internationally  in  order  to  minimise  the  use  of  hESCs 

within  FP7-funded  projects  and  to  achieve  complementary  synergy  rather  than 

competition. 

38

01_2007_5944_txt_EN.indd   38

12-02-2008   13:58:29

 
 
  
 
 
 
 
 
 
comparing  hESCs  with  human  stem  cells  derived  from  alternative 

IV.2.2. Ethical criteria for research projects under FP6 

sources. 

(cid:120)  Applicants must have documented the fact that, in accordance with the 

A few conditions have already been laid down under FP6 to ensure that ethical 

requirements are met, and these can be taken over under FP7. 

basic  ethical  principles  of  medical  research,  relevant  research  on 

1.  Applicants  must  explicitly  prove  that  the  regulatory  criteria  are  met  for  the 

animals and on cell lines of other origin (animal and human) has been 

given  project  and  must  indicate  the  relevant  national  legal  and/or  regulatory 

adequately carried out before hESC research is performed. 

(cid:120)  Applicants  must  show  that  their  research  is  aimed  at  future  human 

health  benefit  or  biomedical  knowledge,  and  cannot  be  achieved  by 

alternatives.  This  includes  basic  research  using  hESCs,  which  is 

requirements  of  the  country/countries  where  the  research  takes  place, 
according to FP7, Article 6(3) (96). For further information, see Annex 1. 

2.  Applicants must provide information that the hESCs used in the given project 

result  from  non-implanted  IVF  embryos  (see  following  paragraph  on  donors’ 

allowed in FP7. 

rights). 

(cid:120)  Applicants  must  have  demonstrated  that  no  alternatives  can  achieve 

3.  Applicants  must  provide  information  on  the  protection  of  personal  data  and 

the goals of the project. Although the group is aware of the importance 

of  respecting  animal  welfare,  it  is  concerned  that  respect  for  human 

dignity may not be maintained when hESCs are used in toxicity testing 

of  industrial  or  other  commercially  produced  chemicals  not  related  to 

drugs,  such  as  cosmetics,  or  for  replacement  of  animal  testing. 

Therefore, particular attention is to be drawn to this issue (see below, 

paragraph IV.3, point 2). 

(cid:120)  Applicants  must  provide  extensive  scientific  justification  when  their 

projects involve toxicity drug testing; this justification should make clear 

what sort of additional information is expected from the use of hESCs 

as compared with the established tests.  

The  scientific  panel  should  ensure  that  researchers  of  hESC  FP7  projects 

collaborate  nationally  and  internationally  in  order  to  minimise  the  use  of  hESCs 

within  FP7-funded  projects  and  to  achieve  complementary  synergy  rather  than 

competition. 

privacy of the donors of embryos for the creation of stem cell lines. 

4.  Applicants  must  provide  information  on  the  conditions  of  donation  of  the 

embryos  (e.g.  no  financial  inducement,  number  of  eggs  retrieved,  etc.).  In 

order to guarantee the non-commercialisation of the human body and in line 

with Article 12 of Directive 2004/23/EC, the EGE holds the view that, in order 

to  protect  the  freedom  of  donation,  human  embryo  donation  should  not 

involve financial inducement, other than the reimbursement of costs incurred.  

In  addition  to  these  conditions,  the  EGE  recommends  that  the  ethics  review 

panel  should  ensure  that  applicants  provide  information  on  the  points  listed 

below. 

(96)  

Article 6(3), http://cordis.europa.eu/fp7/ethics-ict_en.html 

39

01_2007_5944_txt_EN.indd   39

12-02-2008   13:58:29

 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
                                                 
IV.2.3. Additional criteria for FP7 

IV.2.3.1. Use of alternatives to hESCs 

Should  alternatives  to  hESCs  with  the  same  potential  as  embryo-derived  stem 

cells  be  found  in  the  future,  the  implications  of  such  developments  for  both 

scientific  and  ethical  aspects  of  the  hESC-based  research  projects  ought  to  be 

taken into account as soon as possible.  

IV.2.3.2. Donors’ rights 

The  donation  of  human  embryos  for  the  production  of  hESCs  for  research 

purposes poses a moral dilemma. This arises from the fact that human embryos 

are  not  ‘neutral  objects’.  Informed  consent  should  address  explicitly  this  moral 

dilemma, leaving the decision to the donors. 

The protection rights of donors need particular attention, in a very concrete way, 

meaning  that  those  countries  allowing  the  procurement  of  hESCs  must  provide 

information  on  the  procurement  process  for  the  stem  cell  lines  used  by  the 

applicant. The information should state that the measures of this process are in 

accordance with the fundamental ethical principles and human rights in force in 

the European Union, national legislation applicable at the time of the donation in 

the  country  where  the  donation  was  carried  out  and  other  relevant  EU 
regulations (97).  Applicants  must  provide 

information 

institutes 

from 

the 

generating  the  stem  cell  lines  that  the  following  criteria  have  been  met  for  the 

procurement of hESCs:  

(cid:120)  no pressure has been put on the donors at any stage (98);  

(97)  
(98)  

See EC/2004/23. 
See  ISSCR  guidelines  (http://www.isscr.org/guidelines/,  p.  9,  ‘Procurement  of  materials:  For 
donating  embryos  or  gametes  generated  in  the  course  of  clinical  treatment.  Except  when 
specifically authorized by the SCRO (relevant ethics board) process, no reimbursement of direct 
expenses  or  financial  considerations  of  any  kind  may  be  provided  for  donating  embryos  or 
gametes that have been generated in the course of clinical treatment and are in excess of clinical 

40

01_2007_5944_txt_EN.indd   40

12-02-2008   13:58:29

 
 
  
 
 
 
 
 
                                                 
IV.2.3. Additional criteria for FP7 

IV.2.3.1. Use of alternatives to hESCs 

Should  alternatives  to  hESCs  with  the  same  potential  as  embryo-derived  stem 

cells  be  found  in  the  future,  the  implications  of  such  developments  for  both 

scientific  and  ethical  aspects  of  the  hESC-based  research  projects  ought  to  be 

taken into account as soon as possible.  

IV.2.3.2. Donors’ rights 

The  donation  of  human  embryos  for  the  production  of  hESCs  for  research 

purposes poses a moral dilemma. This arises from the fact that human embryos 

are  not  ‘neutral  objects’.  Informed  consent  should  address  explicitly  this  moral 

dilemma, leaving the decision to the donors. 

The protection rights of donors need particular attention, in a very concrete way, 

meaning  that  those  countries  allowing  the  procurement  of  hESCs  must  provide 

information  on  the  procurement  process  for  the  stem  cell  lines  used  by  the 

applicant. The information should state that the measures of this process are in 

accordance with the fundamental ethical principles and human rights in force in 

the European Union, national legislation applicable at the time of the donation in 

the  country  where  the  donation  was  carried  out  and  other  relevant  EU 

regulations (97).  Applicants  must  provide 

information 

from 

the 

institutes 

generating  the  stem  cell  lines  that  the  following  criteria  have  been  met  for  the 

procurement of hESCs:  

(cid:120)  no pressure has been put on the donors at any stage (98);  

(97)  

(98)  

See EC/2004/23. 

See  ISSCR  guidelines  (http://www.isscr.org/guidelines/,  p.  9,  ‘Procurement  of  materials:  For 

donating  embryos  or  gametes  generated  in  the  course  of  clinical  treatment.  Except  when 

specifically authorized by the SCRO (relevant ethics board) process, no reimbursement of direct 

expenses  or  financial  considerations  of  any  kind  may  be  provided  for  donating  embryos  or 

gametes that have been generated in the course of clinical treatment and are in excess of clinical 

(cid:120) 

the donor’s health has not been put at risk by excessive ovarian stimulation;  

(cid:120)  as far as new hESC lines are concerned, informed consent to the donation for 

research  of  an  embryo,  originally  planned  for  reproduction,  is  given  in 
knowledge  of  the  kind  of  research  intended (99),  its  implications  (including 

commercial)  and  in  respect  of  the  conditions  foreseen  by  law  at  the  time  of 

the donation in the country where the donation was carried out; 

information was given that consent could be withdrawn up to the stage of the 
creation of stem cells (100); 

infertility treatment and research was appropriately separated; 

(cid:120) 

(cid:120) 

(cid:120)  no financial incentives have  been offered to donate embryos for research  at 
any stage, in line with Article 12 of Directive 2004/23/EC (101). However, some 

members  of  the  EGE  hold  the  view  that  the  reduction  of  IVF  costs  is 

acceptable. 

If any of these criteria cannot be met because of the former conditions in which 

cell  lines  were  generated,  the  applicants  must  explain  why.  The  ethics  review 

board must then decide how to deal with this matter on a case-by-case basis; for 

new  hESC  lines  the  above  criteria  are  strongly  recommended  (see  following 

paragraph, IV.2.4). 

need or deemed of insufficient quality for clinical use. Researchers may not request that members 
of the infertility treatment team generate more embryos or harvest more oocytes than necessary for 
the  optimal  chance  of  reproductive  success.  People  who  elect  to  donate  stored  materials  for 
research  should  not  be  reimbursed  for  the  costs  of  storage  prior  to  the  decision  to  donate. 
Reimbursement  for  direct  expenses  incurred  by  donors  as  a  consequence  of  the  consent  process 
may be determined during the SCRO process.) 
ISSCR guidelines, 11.3–11.3a (http://www.isscr.org/guidelines/). 
Informed consent must take into account the fact that the materials will be used in the derivation 
of cells for research: ‘Consent for donation of materials for research should be obtained at the time 
of proposed transfer of materials to the research team. Only after a rigorous review by a SCRO 
mechanism or body can permission be granted to use materials for which prior consent exists but 
for which re-consent is prohibitively difficult.’ (ISSCR, http://www.isscr.org/guidelines/). 
Article 12, Directive 2004/23/EC: ‘Member States shall endeavour to ensure voluntary and unpaid 
donations of tissues and cells’. 

(99)  
(100)  

(101)  

41

01_2007_5944_txt_EN.indd   41

12-02-2008   13:58:30

 
 
  
 
 
 
 
 
                                                 
 
 
  
 
 
 
                                                                                                                                                 
Researchers must present all the data referred to donors in an anonymous way. 

The  process  used  to  encode  the  data  must  be  explained  and  referenced 
according to relevant provisions (102)(103).  

IV.2.4.  The  need  for  continuous  promotion  of  public  governance  and 

science–society dialogue  

Apart  from  consent  and  respect  of  donors’  rights,  hESC  research  needs 

appropriate  measures  to  be  put  in  place  to  promote  the  public  governance  and 

science–society  dialogue  with  regard  to  its  aims,  achievements  and  failures. 

Adequate  means  should  be  established  for  public  access  to  relevant  and 

comprehensible  information  on  FP7  hESC  research  to  ensure  these  goals  are 

being continuously fostered and achieved.  

As  the  Council  has  stated,  the  Commission  is  supporting  the  creation  of  a 

European Registry for human embryonic stem cell lines. This registry is intended 

to  allow  the  monitoring  of  existing  hESCs  in  Europe  and  to  help  maximise  their 

use by avoiding unnecessary derivations of new hESC lines.  

In  due  time,  the  registry  should  ask  applicants  to  provide  relevant  data  on 

hESCs.  The  registry  will  store  the  data  according  to  scientific  and  ethical 

standards  to  be  defined  by  its  newly  established  Scientific  and  Ethics  Advisory 

Boards.  

With  regard  to  the  use  of  the  hESC  lines  banked  in  the  registry,  the  EGE 

recommends:  

(cid:120)  once the registry is operational, after a necessary transitional period, the use 

of  the  hESC  lines  banked  in  the  registry  should  be  in  line  with  the  criteria 

(102) 
(103)  

Directive on the protection of personal data (95/46/EC). 
Council of Europe Bioethics Conventions and additional protocols, Council of Europe Convention 
for  the  Protection  of  Individuals  with  regard  to  the  Automatic  Processing  of  Personal  Data  (No 
108). 

42

01_2007_5944_txt_EN.indd   42

12-02-2008   13:58:30

 
 
  
 
 
 
 
 
 
                                                 
according to relevant provisions (102)(103).  

science–society dialogue  

Apart  from  consent  and  respect  of  donors’  rights,  hESC  research  needs 

appropriate  measures  to  be  put  in  place  to  promote  the  public  governance  and 

science–society  dialogue  with  regard  to  its  aims,  achievements  and  failures. 

Adequate  means  should  be  established  for  public  access  to  relevant  and 

comprehensible  information  on  FP7  hESC  research  to  ensure  these  goals  are 

being continuously fostered and achieved.  

As  the  Council  has  stated,  the  Commission  is  supporting  the  creation  of  a 

European Registry for human embryonic stem cell lines. This registry is intended 

to  allow  the  monitoring  of  existing  hESCs  in  Europe  and  to  help  maximise  their 

use by avoiding unnecessary derivations of new hESC lines.  

In  due  time,  the  registry  should  ask  applicants  to  provide  relevant  data  on 

hESCs.  The  registry  will  store  the  data  according  to  scientific  and  ethical 

standards  to  be  defined  by  its  newly  established  Scientific  and  Ethics  Advisory 

Boards.  

recommends:  

(cid:120)  once the registry is operational, after a necessary transitional period, the use 

of  the  hESC  lines  banked  in  the  registry  should  be  in  line  with  the  criteria 

(102) 

(103)  

108). 

Directive on the protection of personal data (95/46/EC). 

Council of Europe Bioethics Conventions and additional protocols, Council of Europe Convention 

for  the  Protection  of  Individuals  with  regard  to  the  Automatic  Processing  of  Personal  Data  (No 

Researchers must present all the data referred to donors in an anonymous way. 

indicated in IV.2.3. The Commission should develop and actively maintain the 

The  process  used  to  encode  the  data  must  be  explained  and  referenced 

necessary means to ensure this requirement is fulfilled; 

(cid:120)  applicants  should  use  hESCs  banked  in  the  EU  registry.  The  need  to  use 

other  hESC  lines  in  FP7  proposals  must  therefore  be  justified  on  both 

IV.2.4.  The  need  for  continuous  promotion  of  public  governance  and 

scientific and ethical grounds; 

(cid:120) 

the  registry  should  prepare  and  publish  (on  its  website)  information  on  the 

hESCs  banked  and  on  the  positive  and  negative  results  of  the  research 

performed  with/on  the  hESC  lines  provided  to  the  researchers.  At  the 

project’s  conclusion,  in  addition  to  the  scientific  data,  particularly  health-

related  information,  the  publication  of  user-friendly  information  on  hESC 

research, freely accessible to EU citizens, is also highly recommended. The 

portal should include interactive elements if possible. 

Researchers working in the field have a responsibility to inform the public about 

their work, but also to engage with the social, political and ethical debates. With 

regard  to  open  questions  such  as  how  to  balance  different  rights  and  how  to 

prioritise  conflicting  interests,  researchers  should  participate  in  public  discourse 

and  respect  the  democratic  decision-making  process  with  regard  to  common 

societal goals. Applicants should therefore commit time, money and activities to 

advance  the  dialogue  of  science  and  society  in  the  field  of  human  embryonic 

stem  cell  research.  Applicants  for  hESC  research  under  FP7  are  therefore 

strongly encouraged to include the science and humanities dialogue, i.e. social, 

cultural/religious,  philosophical  and  ethical  reflection  on  hESC  research,  in  their 

projects  and  to  collaborate  for  this  purpose  with  other  disciplines  from  the 

With  regard  to  the  use  of  the  hESC  lines  banked  in  the  registry,  the  EGE 

humanities.  

IV.3. The need for further research and continuous public debate 

As  the  ethical  conflicts  concerning  hESCs  have  not  been  resolved  either 

academically or politically, the EGE recommends that, under FP7, funding should 

43

01_2007_5944_txt_EN.indd   43

12-02-2008   13:58:31

 
 
  
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
 
be  provided  in  order  to  foster  further  collaborative  and  multidisciplinary 

international  research  on  the  ethical  implications  of  hESC  research  and  the 

pertinent surrounding issues, as well as to encourage informed public debate.  

The EGE believes the following topics may be of particular immediate interest in 
such research and discourse: 

(cid:120) 

the potentially conflicting goals of economic competitiveness and compliance 

with ethical standards;  

(cid:120) 

the use of the human body for modern medicine, including commercialisation 

of products and procedures stemming from the use of human embryonic stem 

cells;  

(cid:120) 

the  underlying  anthropology  of  human  embryonic  stem  cell  research, 

especially in the light of hybrids and the chimera research connected to stem 

cell research;  

(cid:120)  optimisation  of  clinical  and  therapeutic  needs  of  patients  suffering  from  the 

most common diseases addressed in hESC research on treatment and/or for 

specific diseases; 

(cid:120) 

 policy  regarding  numbers  and  production  process  of  stem  cell  lines 

necessary in the case of successful therapies;  

(cid:120) 

the  correlation  of  human  embryonic  stem  cell  research  and  questions 

concerning  regenerative  medicine  and  health-related  justice,  including  the 

issue of global justice; 

(cid:120) 

the  relation  between  science  and  humanities  and  between  science  and 

society with respect to the development of new technologies;  

(cid:120) 

the  ongoing  efforts  of  scientific  alternatives  and  their  anthropological  and 

ethical interpretations. 

The  EGE  also  acknowledges  that  a  number  of  issues  will  need  further 

clarification,  interdisciplinary  research,  thorough  ethical  evaluation  and,  if  found 

necessary  in  the  future,  also  appropriate  legal  action.  At  present,  the  EGE 

believes, the following issues require particular attention.  

44

01_2007_5944_txt_EN.indd   44

12-02-2008   13:58:31

 
 
  
 
 
 
be  provided  in  order  to  foster  further  collaborative  and  multidisciplinary 

1.  The  current  provisions  for  patenting  hESC-derived  materials  need  to  be 

international  research  on  the  ethical  implications  of  hESC  research  and  the 

addressed.  Given  new  developments 

in 

research  and 

taking 

into 

pertinent surrounding issues, as well as to encourage informed public debate.  

consideration  the  ongoing  debate  on  the  limits  of  patenting  of  biological 

The EGE believes the following topics may be of particular immediate interest in 

such research and discourse: 

(cid:120) 

the potentially conflicting goals of economic competitiveness and compliance 

with ethical standards;  

(cid:120) 

the use of the human body for modern medicine, including commercialisation 

of products and procedures stemming from the use of human embryonic stem 

(cid:120) 

the  underlying  anthropology  of  human  embryonic  stem  cell  research, 

especially in the light of hybrids and the chimera research connected to stem 

(cid:120)  optimisation  of  clinical  and  therapeutic  needs  of  patients  suffering  from  the 

most common diseases addressed in hESC research on treatment and/or for 

cells;  

cell research;  

specific diseases; 

(cid:120) 

 policy  regarding  numbers  and  production  process  of  stem  cell  lines 

necessary in the case of successful therapies;  

(cid:120) 

the  correlation  of  human  embryonic  stem  cell  research  and  questions 

concerning  regenerative  medicine  and  health-related  justice,  including  the 

issue of global justice; 

(cid:120) 

the  relation  between  science  and  humanities  and  between  science  and 

society with respect to the development of new technologies;  

(cid:120) 

the  ongoing  efforts  of  scientific  alternatives  and  their  anthropological  and 

ethical interpretations. 

The  EGE  also  acknowledges  that  a  number  of  issues  will  need  further 

clarification,  interdisciplinary  research,  thorough  ethical  evaluation  and,  if  found 

necessary  in  the  future,  also  appropriate  legal  action.  At  present,  the  EGE 

believes, the following issues require particular attention.  

materials,  the  EGE  would  like  to  deal  with  this  issue  at  a  later  point  in 
time (104).  

2.  The tension induced by a policy that encourages both free donation (105) and 

commercial use of derivates from human substances needs to be addressed. 

The EGE emphasises its view that the use of human embryos to generate stem 

cells should be minimised as much as possible. The EGE calls on the European 

Union to develop appropriate systems to minimise the use of human embryos to 

cases for which no alternatives exist. 

IV.4.  Review  of  recommendations  and  communication  with  the  Advisory 
Board of the European Registry on Human Embryonic Stem Cell Research 

The  EGE  would  also  welcome  interaction  with  the  Advisory  Board  of  the 

European Registry on Human Embryonic Stem Cell Research, in particular with 

the  registry’s  Ethics  Advisory  Board,  in  order  to  address  the  ethical  concerns 

regarding the procurement of stem cells and the storing of data in the light of the 

ongoing progress in this area.  

The  concrete  form  and  means  of  this  collaboration  should  be  specified  and  put 

into  place,  and  should  be  appropriately  supported  and 

funded  by 

the 

Commission. 

(104)  

(105)  

The EGE has issued an opinion on ‘Ethical aspects of patenting inventions involving human stem 
cells’ (http://www.ec.europa.eu/european_group_ethics/docs/avis16_en.pdf). 
Article 12, Directive 2004/23/EC: ‘The EC encourages Member States  to promote the voluntary 
and unpaid donation of tissue and cells’. 

45

01_2007_5944_txt_EN.indd   45

12-02-2008   13:58:31

 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
                                                 
01_2007_5944_txt_EN.indd   46

12-02-2008   13:58:31

IV. TRANSLATIONS OF THE RECOMMENDATIONS IN FRENCH AND GERMAN (106) 

IV.I.  French translation 

RECOMMANDATIONS CONCERNANT L'EXAMEN ÉTHIQUE DES PROJETS DE RECHERCHE 
DU 7E PC DANS LE DOMAINE DES CSEH — Avis n° 22 

IV. RECOMMANDATIONS  

IV.1. Préambule 

Les  présentes  recommandations  constituent  la  réponse  à  la  demande  du 
président de la Commission européenne, M. Barroso (107), après l'adoption du 
septième  programme-cadre  de  l'Union  européenne  pour  la  recherche  et  le 
développement  (7e PC),  de  formuler  un  avis  sur  les  mesures  d'exécution 
requises  lors  de  l'examen  éthique  des  projets  de  recherche  sur  les  cellules 
souches embryonnaires humaines (CSEH).  

Tout comme au sein de l'Union européenne, il existe des vues divergentes au 
sein du Groupe européen d'éthique (GEE) quant à la légitimité morale de la 
recherche  sur  les  embryons  humains  et  les  CSEH,  qui  vont  du  refus  de  la 
recherche comportant la destruction d'embryons humains (rendant impossible 
le respect total de la dignité de l'embryon humain) à une position permettant 
la  recherche  sur  les  CSEH  sous  certaines  conditions  ou  sur  une  base  plus 
générale.  

Le groupe prend acte de la décision politique servant de point de départ à ses 
recommandations,  mais  souligne  que  le  dilemme  éthique  subsiste  à  propos 
du statut moral de l'embryon humain et de son utilisation dans le cadre de la 
recherche.  Le  GEE  insiste  donc  sur  le  fait  que  les  divergences  de  vues 
d'ordre éthique relatives à la recherche sur les CSEH n'ont pas été résolues. 

Cependant, ces recommandations ne formulent pas d'arguments éthiques sur 
la  recherche  sur  les  CSEH  en  tant  que  telle,  car  telle  n'était  pas  la  mission 
confiée au Groupe par la Commission européenne.  

47

01_2007_5944_txt_EN.indd   47

12-02-2008   13:58:32

 
 
  
 
 
 
 
 
 
 
 
 
 
 
106107    

(106) 

  Lettre  envoyée  au  GEE  le  22 novembre  2006  par  M.  Barroso,  président  de  la  Commission 
européenne: «Je souhaiterais inviter le Groupe européen d'éthique à remettre à la Commission un 
avis sur les mesures d'exécution requises lors de l'examen éthique des projets de recherche sur les 
cellules souches embryonnaires humaines pour assurer le respect intégral des règles et exigences 
éthiques». 

(107) 

  Translations from the English original — only the English text is authentic. Translations in the 

EU-27 languages are available at: 
http://ec.europa.eu/european_group_ethics/activities/docs/opinion_22_final_follow_up_en.pdf, or 
upon request to the EGE Secretariat mailbox (bepa-ethics-group@ec.europa.eu) 

48

01_2007_5944_txt_EN.indd   48

12-02-2008   13:58:32

 
 
  
 
                                                 
 
106107    

(106) 

  Lettre  envoyée  au  GEE  le  22 novembre  2006  par  M.  Barroso,  président  de  la  Commission 

européenne: «Je souhaiterais inviter le Groupe européen d'éthique à remettre à la Commission un 

avis sur les mesures d'exécution requises lors de l'examen éthique des projets de recherche sur les 

cellules souches embryonnaires humaines pour assurer le respect intégral des règles et exigences 

(107) 

  Translations from the English original — only the English text is authentic. Translations in the 

éthiques». 

EU-27 languages are available at: 

http://ec.europa.eu/european_group_ethics/activities/docs/opinion_22_final_follow_up_en.pdf, or 

upon request to the EGE Secretariat mailbox (bepa-ethics-group@ec.europa.eu) 

IV.2.  Recommandations  pour  l'examen  éthique  des  projets  de 
recherche impliquant des CSEH 

Les projets de recherche du 7e PC comportant l'utilisation de CSEH sont soumis 

à  des  règles  de  sélection  rigoureuses,  sont  contrôlés  aux  niveaux  national  et 

communautaire, et font l'objet d'examens scientifiques et éthiques. 

Dans le cadre du 7e PC, les propositions de recherche doivent comprendre des 

informations  sur  les  aspects  éthiques  de  la  recherche  proposée,  expliquer  en 

détail  la  conception  du  projet  et  démontrer  que  la  proposition  répond  aux 

exigences juridiques et éthiques du pays dans lequel la recherche est menée. 

Après  avoir  passé  avec  succès 

l'étape  de 

l'évaluation  scientifique, 

les 

propositions  CSEH  retenues  subissent  un  examen  éthique  spécifique  organisé 

par la Commission au cas par cas. L'objectif de cet examen est de garantir que 

l'Union  européenne  ne  soutient  pas  des  recherches  qui  ne  seraient  pas 
conformes aux principes éthiques fondamentaux (108) et de contrôler si les règles 
d'éthique définies dans le 7e PC sont respectées.  

Le  comité  d'examen  éthique  est  un  organisme  transnational  composé  d'experts 

de  différentes  disciplines.  Le  comité  produit  un  rapport  d'examen  éthique,  qui 

énumère les différentes questions éthiques, décrit la manière dont ces questions 

ont été traitées par les demandeurs et énonce les recommandations du comité.  

Après avoir passé avec succès l'examen scientifique et éthique, les propositions 

de  projets  CSEH  sont  ensuite  transmises  à  un  comité  de  réglementation 

composé de représentants des États membres de l'UE, qui statue sur les projets 

au cas par cas. 

(108) 

Septième  programme-cadre  (décision  n° 1982/2006/CE),  article 6,  paragraphe 1:  «Toutes  les 
actions de recherche menées au titre du septième programme-cadre sont réalisées dans le respect 
des  principes  éthiques  fondamentaux.»;  règles  de  participation,  article 10:  «une  proposition  […] 
allant  à  l’encontre  des  principes  éthiques  fondamentaux  […]  n’est  pas  sélectionnée.  Une  telle 
proposition peut être exclue à tout moment des procédures d’évaluation et de sélection.» 

49

01_2007_5944_txt_EN.indd   49

12-02-2008   13:58:32

 
 
  
 
                                                 
 
 
 
  
 
 
 
 
 
 
                                                 
Afin de fournir des lignes directrices aux membres des comités d'examen éthique 
du  7e PC  en  matière  de  CSEH,  qui  seront  invités  à  examiner  les  projets  de 

recherche  utilisant  des  lignées  de  CSEH,  et  dans  le  cadre  du  mandat  et  des 

conditions spécifiques établis par la décision politique du Parlement européen et 
du Conseil relative au 7e PC, ainsi que par  la demande spécifique du président 

de  la  Commission  européenne,  M. J.  M.  Barroso  (voir  ci-dessus),  le  GEE  a 

élaboré  les  lignes  directrices  et  points  suivants  à  prendre  en  compte  lors  de 
l'examen éthique de projets dans le cadre du 7e PC (109). 

IV.2.1. Critères généraux 

La  Commission  européenne  a  déclaré  qu'elle  «soutiendra  les  actions  et 

initiatives  qui  contribuent  à  coordonner  et  rationaliser  les activités de  recherche 

sur 
les  cellules  souches  embryonnaires  humaines  selon  une  approche 
déontologique  responsable» (110).  En  conformité  avec  cette  déclaration,  le  GEE 

reconnaît 

la  nécessité  de  promouvoir  une 

recherche 

responsable  et 

transparente,  qui  sert  l'intérêt  public,  respecte  l'autonomie  des  États  membres, 

préserve la confiance du public, encourage la coopération internationale et exige 
l'adoption d'une démarche déontologique dans les activités de recherche (111). 

La  recherche  sur  les  cellules  souches  embryonnaires  humaines,  menée  selon 

une  approche  déontologique  responsable,  doit  être  conforme  aux  principes 
éthiques fondamentaux et aux droits de l'homme dans l'Union européenne (112), 

(109) 

(110) 

(111) 
(112) 

Selon les règles du 7e PC, les évaluateurs signent une déclaration d'absence de conflit d'intérêts, et 
le personnel de la Commission européenne vérifie les conflits avec chacune des propositions qu'ils 
évaluent. Les comités d'évaluation des examens éthiques et scientifiques sont anonymes.  
Déclaration  de  la  Commission  européenne  du  24  juillet  2006,  lors  de  la  réunion  du  Conseil  de 
ministres, à propos du 7e PC. Voir JO L 412 du 30.12.2006, p. 43. 
Par exemple la convention d'Oviedo du Conseil de l'Europe (article 2). 
Pour  plus  de  détails,  voir  la  section I  du  présent  avis  relative  aux  documents  pertinents  dans  le 
cadre de la recherche médicale.  

50

01_2007_5944_txt_EN.indd   50

12-02-2008   13:58:32

 
 
  
 
 
 
 
 
                                                 
Afin de fournir des lignes directrices aux membres des comités d'examen éthique 

du  7e PC  en  matière  de  CSEH,  qui  seront  invités  à  examiner  les  projets  de 

recherche  utilisant  des  lignées  de  CSEH,  et  dans  le  cadre  du  mandat  et  des 

depuis  la  fourniture  des  cellules  souches (113)  jusqu'aux  activités  de  recherche 

cliniques portant sur les CSEH. 

conditions spécifiques établis par la décision politique du Parlement européen et 

Les  droits  fondamentaux  comprennent:  les  droits  de  protection  tels  que  la 

du Conseil relative au 7e PC, ainsi que par  la demande spécifique du président 

protection de la vie humaine, le respect de son intégrité, la protection de la santé 

de  la  Commission  européenne,  M. J.  M.  Barroso  (voir  ci-dessus),  le  GEE  a 

et de la liberté, les droits politiques tels que l'absence d'intervention injustifiée de 

élaboré  les  lignes  directrices  et  points  suivants  à  prendre  en  compte  lors  de 

l'État  ou  les  droits  participatifs  dans  le  domaine  politique,  ainsi  que  les  droits 

l'examen éthique de projets dans le cadre du 7e PC (109). 

IV.2.1. Critères généraux 

La  Commission  européenne  a  déclaré  qu'elle  «soutiendra  les  actions  et 

initiatives  qui  contribuent  à  coordonner  et  rationaliser  les activités de  recherche 

sur 

les  cellules  souches  embryonnaires  humaines  selon  une  approche 

déontologique  responsable» (110).  En  conformité  avec  cette  déclaration,  le  GEE 

reconnaît 

la  nécessité  de  promouvoir  une 

recherche 

responsable  et 

transparente,  qui  sert  l'intérêt  public,  respecte  l'autonomie  des  États  membres, 

préserve la confiance du public, encourage la coopération internationale et exige 

l'adoption d'une démarche déontologique dans les activités de recherche (111). 

La  recherche  sur  les  cellules  souches  embryonnaires  humaines,  menée  selon 

une  approche  déontologique  responsable,  doit  être  conforme  aux  principes 

éthiques fondamentaux et aux droits de l'homme dans l'Union européenne (112), 

(109) 

Selon les règles du 7e PC, les évaluateurs signent une déclaration d'absence de conflit d'intérêts, et 

le personnel de la Commission européenne vérifie les conflits avec chacune des propositions qu'ils 

évaluent. Les comités d'évaluation des examens éthiques et scientifiques sont anonymes.  

Déclaration  de  la  Commission  européenne  du  24  juillet  2006,  lors  de  la  réunion  du  Conseil  de 

ministres, à propos du 7e PC. Voir JO L 412 du 30.12.2006, p. 43. 

Par exemple la convention d'Oviedo du Conseil de l'Europe (article 2). 

Pour  plus  de  détails,  voir  la  section I  du  présent  avis  relative  aux  documents  pertinents  dans  le 

(110) 

(111) 

(112) 

cadre de la recherche médicale.  

positifs tels que les droits sociaux et économiques de base dans la mesure où ils 

contribuent  à  la  santé  et  à  un  seuil  de  développement,  avec  pour  résultat  une 
gouvernance de la santé (114). 

L'équilibre  entre  ces  trois  catégories  de  droits  fondamentaux  n'est  nullement 

facile  ni  prédéterminé,  mais  implique  des  efforts  continus  pour  assurer  leur 

protection, la reconnaissance et la promotion de la dignité humaine et des droits 

de l'homme et, plus concrètement, implique de définir des priorités en matière de 

recherche médicale.  

Les  critères  généraux  des  éléments  d'incitation  de  la  recherche  dans  des 

domaines spécifiques intègrent cet équilibre. Ils peuvent être récapitulés comme 

suit:  

(cid:120) 

(cid:120) 

(cid:120) 

(cid:120) 

la nécessité scientifique et le haut statut de la recherche (115), 
l'urgence (116) et  

la désirabilité sociale,  

la primauté de l'intérêt et du bien-être de l'être humain sur l'intérêt 

exclusif de la société ou de la science. 

(113) 

(114) 
(115) 
(116) 

Le  7e PC  exclut 
l'approvisionnement  en  CSEH  du  financement  communautaire  (voir 
paragraphe II.2).  Voir  décision  n° 1982/2006/CE  du  Parlement  européen  et  du  Conseil  du 
18 décembre 2006 relative au septième programme-cadre de la Communauté européenne pour des 
actions de recherche, de développement technologique et de démonstration (2007-2013), JO L 412 
du 30.12.2006, p. 1-41. 
Cf. les objectifs du millénaire des Nations Unies, que l'Union européenne s'est engagée à réaliser. 
http://ec.europa.eu/research/7PC/index_en.cfm?pg=documents.  
http://www.who.int/rpc/en/HealthResearchinPolicyMaking.pdf.  

51

01_2007_5944_txt_EN.indd   51

12-02-2008   13:58:33

 
 
  
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
                                                 
La  désirabilité  sociale  donne  lieu  à  un  discours  politique  et  sociétal  sur  les 
objectifs et perspectives de l'Union européenne au XXIe siècle, en particulier sur 

la  relation  entre  la  croissance  économique  et  les  objectifs  sociaux,  tels  que  la 

promotion des normes de santé et leur application durable aux niveaux national, 

international et mondial.  

En ce qui concerne la recherche sur les CSEH, il n'y a aucun consensus sur son 

acceptabilité  sociale  au  sein  de  l'Union  européenne,  et  des  vues  divergentes 

coexistent.  Un  débat  sur  le  meilleur  modèle  (par  exemple  un  «consensus 

minimal»  ou  la  «subsidiarité»)  pour  réglementer  la  recherche  sur  les  CSEH  au 

niveau de l'UE a donc lieu dans plusieurs États membres de l'UE. 

Lorsque  des  moyens  sensibles  sur  le  plan  éthique  doivent  être  utilisés  pour 

atteindre  des  objectifs  unanimement  acceptés —  comme  dans  le  cas  des 

cellules souches embryonnaires humaines —, lorsque la finalité de la recherche 

thérapeutique n'est pas remise en cause mais les moyens  d'y parvenir, le GEE 

soutient  que  des  critères  additionnels  s'appliquent  en  ce  qui  concerne  la 

nécessité de la recherche: 1) la non-disponibilité d'alternatives validées et 2) 
la non-redondance des projets du 7e PC (117). 

Cependant,  tous  les  critères  indiqués  ci-dessus,  qui  constituent  les  principaux 

critères d'évaluation scientifique, doivent être évalués d'un point de vue éthique 

au  cours  du  processus  d'examen  éthique.  Il  est  clair  que  l'examen  éthique  ne 

peut  pas  et  ne  doit  pas  faire  double  emploi  avec  l'évaluation  scientifique,  qui 

demeure  la  principale  évaluation  de  la  qualité  scientifique  des  propositions  de 

projets.  Néanmoins,  les  deux  examens  sont  complémentaires.  En  ce  qui 
concerne  les  projets  CSEH  du  7e PC,  la  Commission  doit  veiller  à  ce  que  le 

(117) 

Des  répétitions  sont  cependant  parfois  nécessaires  pour  apporter  la  preuve  de  la  réussite;  il  ne 
s'agit pas d'exercices redondants au sens où on l'entend ici.  

52

01_2007_5944_txt_EN.indd   52

12-02-2008   13:58:33

 
 
  
 
 
 
 
 
                                                 
La  désirabilité  sociale  donne  lieu  à  un  discours  politique  et  sociétal  sur  les 

rapport d'évaluation scientifique soit à la disposition du comité d'examen éthique 

objectifs et perspectives de l'Union européenne au XXIe siècle, en particulier sur 

la  relation  entre  la  croissance  économique  et  les  objectifs  sociaux,  tels  que  la 

et qu'il existe une communication efficace entre les deux comités si nécessaire. 

promotion des normes de santé et leur application durable aux niveaux national, 

Pour  assurer  la  complémentarité  des  deux  examens,  le  rapport  d'examen 

international et mondial.  

scientifique doit porter au moins sur les points suivants: 

En ce qui concerne la recherche sur les CSEH, il n'y a aucun consensus sur son 

(cid:120) 

les demandeurs doivent avoir démontré que la recherche pratiquée sur 

acceptabilité  sociale  au  sein  de  l'Union  européenne,  et  des  vues  divergentes 

des cellules souches humaines dérivées de sources alternatives, telles 

coexistent.  Un  débat  sur  le  meilleur  modèle  (par  exemple  un  «consensus 

que  des  cellules  souches  adultes,  du  liquide  amniotique,  du  sang 

minimal»  ou  la  «subsidiarité»)  pour  réglementer  la  recherche  sur  les  CSEH  au 

provenant  du  cordon  ombilical  ou  d'autres  sources  appropriées,  ne 

niveau de l'UE a donc lieu dans plusieurs États membres de l'UE. 

permet  pas  de  réaliser  les  objectifs  prévus  du  projet.  Cela  ne 

s'applique pas aux activités de recherche comparant des CSEH à des 

Lorsque  des  moyens  sensibles  sur  le  plan  éthique  doivent  être  utilisés  pour 

cellules souches humaines dérivées de sources alternatives; 

cellules souches embryonnaires humaines —, lorsque la finalité de la recherche 

(cid:120) 

les  demandeurs  doivent  avoir  documenté  le  fait  que,  conformément 

aux principes éthiques de base de la recherche médicale, des activités 

de recherche pertinentes sur des animaux et sur des lignées cellulaires 

d'une  autre  origine  (animale  et  humaine)  ont  été  menées  de  façon 

suffisante avant d'entreprendre des recherches sur les CSEH;  

(cid:120) 

les demandeurs doivent démontrer que leurs activités de recherche ont 

pour  but  des  bénéfices  futurs  en  termes  de  santé  humaine  ou  des 

connaissances biomédicales, et qu'elles ne peuvent être réalisées par 

des moyens alternatifs. Cela comprend la recherche fondamentale sur 
les CSEH, qui est autorisée dans le 7e PC; 

(cid:120) 

les  demandeurs  doivent  avoir  démontré  qu'aucune  autre  solution  ne 

permet  de  réaliser  les  objectifs  du  projet.  Bien  que  le  groupe  soit 

conscient  de  l'importance  de  respecter  le  bien-être  des  animaux,  il 

s'inquiète  que  le  respect  de  la  dignité  humaine  puisse  ne  pas  être 

assuré  lorsque  des  CSEH  sont  utilisées  dans  le  cadre  d'essais  de 

53

01_2007_5944_txt_EN.indd   53

12-02-2008   13:58:33

atteindre  des  objectifs  unanimement  acceptés —  comme  dans  le  cas  des 

thérapeutique n'est pas remise en cause mais les moyens  d'y parvenir, le GEE 

soutient  que  des  critères  additionnels  s'appliquent  en  ce  qui  concerne  la 

nécessité de la recherche: 1) la non-disponibilité d'alternatives validées et 2) 

la non-redondance des projets du 7e PC (117). 

Cependant,  tous  les  critères  indiqués  ci-dessus,  qui  constituent  les  principaux 

critères d'évaluation scientifique, doivent être évalués d'un point de vue éthique 

au  cours  du  processus  d'examen  éthique.  Il  est  clair  que  l'examen  éthique  ne 

peut  pas  et  ne  doit  pas  faire  double  emploi  avec  l'évaluation  scientifique,  qui 

demeure  la  principale  évaluation  de  la  qualité  scientifique  des  propositions  de 

projets.  Néanmoins,  les  deux  examens  sont  complémentaires.  En  ce  qui 

concerne  les  projets  CSEH  du  7e PC,  la  Commission  doit  veiller  à  ce  que  le 

(117) 

Des  répétitions  sont  cependant  parfois  nécessaires  pour  apporter  la  preuve  de  la  réussite;  il  ne 

s'agit pas d'exercices redondants au sens où on l'entend ici.  

 
 
  
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
 
toxicité portant sur des produits chimiques industriels ou du commerce 

sans  rapport  avec  les  médicaments,  tels  que  les  cosmétiques,  ou  en 

remplacement d'essais sur les animaux. Il convient par conséquent de 

porter  une  attention  particulière  à  cette  question  (voir  ci-après  le 

point IV.3.2); 

(cid:120) 

les  demandeurs  doivent  fournir  une  justification  scientifique  complète 

lorsque 

leurs  projets  comportent  des  essais  de 

toxicité  de 

médicaments;  cette  justification  devra  établir  clairement  le  type 

d'informations  additionnelles  que  l'on  peut  attendre  de  l'utilisation  de 

CSEH par rapport aux essais établis.  

Le  comité  scientifique  doit  veiller  à  ce  que  les  chercheurs  participant  à  des 
projets  CSEH  du  7e PC  collaborent  sur  le  plan  national  et  international  afin  de 

limiter au minimum l'utilisation de CSEH dans le cadre de projets financés par le 
7e PC  et  pour  mettre  en  place  une  synergie  de  complémentarité  plutôt  qu'une 

situation de compétition. 

IV.2.2. Critères éthiques des projets de recherche dans le cadre du 6e PC 
Certaines conditions ont déjà été définies dans le cadre du 6e PC pour assurer le 

respect  des  exigences  éthiques,  et  celles-ci  peuvent  être  reprises  au  titre  du 
7e PC:  

(cid:120)  les  demandeurs  doivent  prouver  de  façon  explicite  que  le  projet  en 

question  répond  aux  critères  réglementaires  et  doivent  indiquer  les 

exigences juridiques et/ou réglementaires applicables du/des pays où 
la recherche a lieu, conformément à l'article 6, paragraphe 3 (118), du 
7e PC. Pour de plus amples informations, voir l'annexe 1; 

(118)  Article 6, paragraphe 3, http://cordis.europa.eu/7PC/ethics-ict_en.html  

54

01_2007_5944_txt_EN.indd   54

12-02-2008   13:58:34

 
 
  
 
 
 
 
 
                                                 
 
toxicité portant sur des produits chimiques industriels ou du commerce 

(cid:120)  les demandeurs doivent indiquer que les CSEH utilisées dans le cadre 

sans  rapport  avec  les  médicaments,  tels  que  les  cosmétiques,  ou  en 

du  projet  sont  issues  d'embryons  de  FIV  non  implantés  (voir 

remplacement d'essais sur les animaux. Il convient par conséquent de 

paragraphe suivant sur les droits des donneurs); 

porter  une  attention  particulière  à  cette  question  (voir  ci-après  le 

(cid:120)  les demandeurs doivent fournir des informations sur la protection des 

point IV.3.2); 

données  personnelles  et  de  l'anonymat  des  donneurs  d'embryons 

pour la production de lignées de cellules souches; 

(cid:120) 

les  demandeurs  doivent  fournir  une  justification  scientifique  complète 

(cid:120)  les demandeurs doivent fournir des informations sur les conditions de 

don des embryons (par exemple: aucune incitation financière, nombre 

d'ovules  prélevés,  etc.).  Afin  de  garantir  la  non-commercialisation  du 

corps humain et en accord avec l'article 12 de la directive 2004/23/CE, 

le GEE estime que pour protéger la liberté de don, le don d'embryons 

humains  ne  doit  pas  comporter  d'incitation  financière  autre  que  le 

remboursement des frais encourus.  

Outre ces conditions, le GEE recommande que le comité d'examen éthique veille 

à ce  que  les demandeurs fournissent des  informations sur les points énumérés 

situation de compétition. 

ci-après. 

lorsque 

leurs  projets  comportent  des  essais  de 

toxicité  de 

médicaments;  cette  justification  devra  établir  clairement  le  type 

d'informations  additionnelles  que  l'on  peut  attendre  de  l'utilisation  de 

CSEH par rapport aux essais établis.  

Le  comité  scientifique  doit  veiller  à  ce  que  les  chercheurs  participant  à  des 

projets  CSEH  du  7e PC  collaborent  sur  le  plan  national  et  international  afin  de 

limiter au minimum l'utilisation de CSEH dans le cadre de projets financés par le 

7e PC  et  pour  mettre  en  place  une  synergie  de  complémentarité  plutôt  qu'une 

IV.2.2. Critères éthiques des projets de recherche dans le cadre du 6e PC 

Certaines conditions ont déjà été définies dans le cadre du 6e PC pour assurer le 

respect  des  exigences  éthiques,  et  celles-ci  peuvent  être  reprises  au  titre  du 

7e PC:  

(cid:120)  les  demandeurs  doivent  prouver  de  façon  explicite  que  le  projet  en 

question  répond  aux  critères  réglementaires  et  doivent  indiquer  les 

exigences juridiques et/ou réglementaires applicables du/des pays où 

la recherche a lieu, conformément à l'article 6, paragraphe 3 (118), du 

7e PC. Pour de plus amples informations, voir l'annexe 1; 

(118)  Article 6, paragraphe 3, http://cordis.europa.eu/7PC/ethics-ict_en.html  

55

01_2007_5944_txt_EN.indd   55

12-02-2008   13:58:34

 
 
  
 
 
 
 
 
                                                 
 
 
 
  
 
 
IV.2.3. Critères additionnels pour le 7e PC 

IV.2.3.1. Utilisation de solutions alternatives aux CSEH 

En  cas  de  découverte  future  de  solutions  alternatives  aux  CSEH  présentant  le 

même  potentiel  que  les  cellules  souches  embryonnaires,  il  conviendra  de 

prendre  en  compte  au  plus  vite  les  implications  de  ces  avancées,  pour  les 

aspects  tant  scientifiques  qu'éthiques  des  projets  de  recherche  basés  sur  les 

CSEH.  

IV.2.3.2. Droits des donneurs 

Le don d'embryons humains pour la production de CSEH à des fins de recherche 

pose  un  dilemme  moral,  qui  résulte  du  fait  que  les  embryons  humains  ne  sont 

pas des «objets neutres». Ce dilemme moral doit faire l'objet d'un consentement 

éclairé explicite, laissant la décision aux donneurs.  

Les droits de protection des donneurs requièrent une attention particulière, sous 

une 

forme 

très  concrète,  ce  qui  signifie  que 

les  pays  autorisant 

l'approvisionnement  en  CSEH doivent  fournir  des  informations  sur  le  processus 

d'obtention  des  lignées  de  cellules  souches  utilisées  par  le  demandeur.  Ces 

informations doivent préciser que les mesures de ce processus sont conformes 

aux principes éthiques fondamentaux et aux droits de l'homme en vigueur dans 

l'Union européenne, à la législation nationale applicable au moment du don dans 

le  pays  où  le  don  est  effectué  et  aux  autres  règlements  communautaires 
applicables (119).  Les  demandeurs  doivent 

informations  en 

fournir  des 

provenance  des  instituts  produisant  les  lignées  de  cellules  souches  selon 

lesquelles  les  critères  énoncés  ci-après ont  été  respectés  lors  de  l'obtention  de 

CSEH:  

(cid:120)  aucune pression n'a été exercée à aucun moment sur les donneurs (120); 

(119) 
(120) 

Voir la directive 2004/23/CE. 
Voir les lignes directrices de l'ISSCR (société internationale de recherche sur les cellules souches) 
[http://www.isscr.org/guidelines/,  p. 9,  «Approvisionnement  en  matériels:  pour 
les  dons 
d'embryons  ou de gamètes produits au cours d'un traitement clinique. Sauf en cas d'autorisation 

56

01_2007_5944_txt_EN.indd   56

12-02-2008   13:58:34

 
 
  
 
 
 
 
                                                 
IV.2.3. Critères additionnels pour le 7e PC 

(cid:120) 

la  santé  du  donneur  n'a  pas  été  mise  en  danger  par  une  stimulation 

ovarienne excessive;  

IV.2.3.1. Utilisation de solutions alternatives aux CSEH 

(cid:120)  pour les nouvelles lignées de CSEH, un consentement éclairé concernant le 

En  cas  de  découverte  future  de  solutions  alternatives  aux  CSEH  présentant  le 

même  potentiel  que  les  cellules  souches  embryonnaires,  il  conviendra  de 

prendre  en  compte  au  plus  vite  les  implications  de  ces  avancées,  pour  les 

aspects  tant  scientifiques  qu'éthiques  des  projets  de  recherche  basés  sur  les 

CSEH.  

IV.2.3.2. Droits des donneurs 

Le don d'embryons humains pour la production de CSEH à des fins de recherche 

pose  un  dilemme  moral,  qui  résulte  du  fait  que  les  embryons  humains  ne  sont 

pas des «objets neutres». Ce dilemme moral doit faire l'objet d'un consentement 

éclairé explicite, laissant la décision aux donneurs.  

Les droits de protection des donneurs requièrent une attention particulière, sous 

une 

forme 

très  concrète,  ce  qui  signifie  que 

les  pays  autorisant 

l'approvisionnement  en  CSEH doivent  fournir  des  informations  sur  le  processus 

d'obtention  des  lignées  de  cellules  souches  utilisées  par  le  demandeur.  Ces 

informations doivent préciser que les mesures de ce processus sont conformes 

aux principes éthiques fondamentaux et aux droits de l'homme en vigueur dans 

l'Union européenne, à la législation nationale applicable au moment du don dans 

le  pays  où  le  don  est  effectué  et  aux  autres  règlements  communautaires 

applicables (119).  Les  demandeurs  doivent 

fournir  des 

informations  en 

provenance  des  instituts  produisant  les  lignées  de  cellules  souches  selon 

lesquelles  les  critères  énoncés  ci-après ont  été  respectés  lors  de  l'obtention  de 

CSEH:  

(cid:120)  aucune pression n'a été exercée à aucun moment sur les donneurs (120); 

(119) 

(120) 

Voir la directive 2004/23/CE. 

Voir les lignes directrices de l'ISSCR (société internationale de recherche sur les cellules souches) 

[http://www.isscr.org/guidelines/,  p. 9,  «Approvisionnement  en  matériels:  pour 

les  dons 

d'embryons  ou de gamètes produits au cours d'un traitement clinique. Sauf en cas d'autorisation 

don pour la recherche d'un embryon initialement destiné à la reproduction est 

donné  en  connaissant 

la  nature  des  recherches  prévues (121), 

leurs 

implications  (y  compris  commerciales)  et  dans  le  respect  des  conditions 

prévues par la loi au moment du don dans le pays où celui-ci a été effectué; 

le  donneur  a  été  informé  qu'il  pourrait  retirer  son  consentement  jusqu'au 
stade de la création des cellules souches (122); 

le traitement de l'infertilité et la recherche sont correctement séparés; 

(cid:120) 

(cid:120) 

(cid:120)  aucune  incitation  financière  n'a  été  proposée  à  aucun  moment  pour  donner 

des  embryons  pour  la  recherche,  conformément  à  l'article 12  de  la  directive 
2004/23/CE (123). Cependant, certains membres du GEE estiment acceptable 

la réduction des coûts de FIV. 

Si  l'un  ou  plusieurs  de  ces  critères  ne  peuvent  être  respectés  en  raison  des 

conditions préalables dans lesquelles les lignées cellulaires ont été produites, les 

demandeurs  doivent  expliquer  pourquoi.  Le  comité  d'examen  éthique  doit  alors 

statuer au cas par cas sur la manière de traiter cette question; pour les nouvelles 

expresse  par  le  processus  du  SCRO  (comité  d'éthique  compétent),  aucun  remboursement  de 
dépenses directes ni rémunération financière d'aucune sorte ne peuvent être accordés pour le don 
d'embryons ou de gamètes produits au cours d'un traitement clinique et qui excèdent les besoins 
cliniques  ou  sont  considérés  de  qualité  insuffisante  pour  un  usage  clinique.  Les  chercheurs  ne 
doivent pas demander à ce que les membres de l'équipe de traitement de la stérilité produisent plus 
d'embryons ou recueillent plus d'ovocytes que nécessaire pour garantir des chances optimales de 
succès  reproductif.  Les  personnes  qui  choisissent  de  faire  don  de  matériels  stockés  pour  la 
recherche  ne  doivent  pas  être  remboursées  des  frais  de  stockage  correspondant  à  la  période 
précédant la décision du don. Le remboursement des frais directs encourus par des donneurs à la 
suite du consentement peut être déterminé pendant le processus de surveillance de la recherche sur 
les cellules souches (SCRO)»].  
Lignes directrices de l'ISSCR, 11.3-11.3.a (http://www.isscr.org/guidelines/). 
Le consentement éclairé doit tenir compte du fait que les matériels seront utilisés afin de produire 
des cellules pour la recherche: «Le consentement du don de matériels pour la recherche doit être 
obtenu au moment de la proposition de cession de matériels à l'équipe de recherche. Ce n'est 
qu'après un examen rigoureux par un mécanisme ou organisme de surveillance de la recherche sur 
les cellules souches que l'autorisation peut être accordée d'utiliser des matériels pour lesquels il 
existe un consentement préalable dont le renouvellement s'avère extrêmement difficile» (ISSCR, 
http://www.isscr.org/guidelines/). 

(121) 
(122) 

57

01_2007_5944_txt_EN.indd   57

12-02-2008   13:58:35

 
 
  
 
 
 
 
                                                 
 
 
  
 
 
                                                                                                                                                 
lignées  de  CSEH,  les  critères  ci-dessus  sont  vivement  recommandés  (voir  le 

point IV.2.4). 

Les chercheurs doivent présenter de façon anonyme toutes les données faisant 

référence  aux  donneurs.  Le  procédé  utilisé  pour  coder  les  données  doit  être 
expliqué et référencé selon les dispositions applicables (124) (125). 

IV.2.4. Nécessité d'encourager en permanence la gouvernance publique et 

le dialogue science-société 

Indépendamment  du  consentement  et  du  respect  des  droits  des  donneurs,  la 

recherche sur les CSEH nécessite la mise en place de mesures pour favoriser la 

gouvernance  publique  et  le  dialogue  science-société  en  ce  qui  concerne  ses 

objectifs,  réussites  et  échecs.  Des  moyens  suffisants  doivent  être  établis  pour 

permettre  l'accès  du  public  à  des  informations  pertinentes  et  compréhensibles 
sur  la  recherche  sur  les  CSEH  dans  le  cadre  du  7e PC,  afin  de  promouvoir  et 

d'atteindre en permanence ces objectifs.  

Comme  l'a  indiqué  le  Conseil  de  ministres,  la  Commission  soutient  la  création 

d'un  registre  européen  des 

lignées  de  cellules  souches  embryonnaires 

humaines. Ce registre permettra une surveillance des CSEH existant en Europe 

et favorisera leur utilisation optimale en évitant d'inutiles dérivations de nouvelles 

lignées de CSEH.  

Le  moment  venu,  le  registre  invitera  les  demandeurs  à  fournir  des  données 

appropriées  sur  les  CSEH.  Le  registre  stockera  les  données  selon  des  normes 

scientifiques  et  éthiques  à  définir  par  ses  comités  consultatifs  scientifiques  et 

éthiques récemment formés.  

(123) 

(124) 

(125) 

Article 12  de  la  directive  2004/23/CE:  «Les  États  membres  s'efforcent  de  garantir  les  dons 
volontaires et non rémunérés de tissus et cellules.» 

  Directive  95/46/CE  du  Parlement  européen  et  du  Conseil  du  24 octobre  1995  relative  à  la 
protection des personnes physiques à l'égard du traitement des données à caractère personnel et à 
la libre circulation de ces données. 

  Conventions  de  bioéthique  du  Conseil  de  l'Europe  et  protocoles  additionnels,  convention  du 
Conseil  de  l'Europe  pour  la  protection  des  personnes  à  l'égard  du  traitement  automatisé  des 
données à caractère personnel (n° 108). 

58

01_2007_5944_txt_EN.indd   58

12-02-2008   13:58:35

 
 
  
 
 
 
 
                                                                                                                                                 
lignées  de  CSEH,  les  critères  ci-dessus  sont  vivement  recommandés  (voir  le 

point IV.2.4). 

En ce qui concerne l'utilisation des lignées de CSEH stockées dans le registre, le 

GEE formule les recommandations suivantes:  

Les chercheurs doivent présenter de façon anonyme toutes les données faisant 

(cid:120)  une fois le registre opérationnel, après une période de transition nécessaire, 

référence  aux  donneurs.  Le  procédé  utilisé  pour  coder  les  données  doit  être 

l'utilisation  des  lignées  de  CSEH  stockées  dans  le  registre  devra  être 

expliqué et référencé selon les dispositions applicables (124) (125). 

conforme  aux  critères  énoncés  au  point  IV.2.3.  La  Commission  devra 

développer et maintenir activement les moyens nécessaires pour assurer le 

IV.2.4. Nécessité d'encourager en permanence la gouvernance publique et 

respect de cette exigence; 

le dialogue science-société 

Indépendamment  du  consentement  et  du  respect  des  droits  des  donneurs,  la 

recherche sur les CSEH nécessite la mise en place de mesures pour favoriser la 

gouvernance  publique  et  le  dialogue  science-société  en  ce  qui  concerne  ses 

objectifs,  réussites  et  échecs.  Des  moyens  suffisants  doivent  être  établis  pour 

permettre  l'accès  du  public  à  des  informations  pertinentes  et  compréhensibles 

sur  la  recherche  sur  les  CSEH  dans  le  cadre  du  7e PC,  afin  de  promouvoir  et 

d'atteindre en permanence ces objectifs.  

Comme  l'a  indiqué  le  Conseil  de  ministres,  la  Commission  soutient  la  création 

d'un  registre  européen  des 

lignées  de  cellules  souches  embryonnaires 

humaines. Ce registre permettra une surveillance des CSEH existant en Europe 

et favorisera leur utilisation optimale en évitant d'inutiles dérivations de nouvelles 

lignées de CSEH.  

Le  moment  venu,  le  registre  invitera  les  demandeurs  à  fournir  des  données 

appropriées  sur  les  CSEH.  Le  registre  stockera  les  données  selon  des  normes 

scientifiques  et  éthiques  à  définir  par  ses  comités  consultatifs  scientifiques  et 

éthiques récemment formés.  

(123) 

(124) 

(125) 

Article 12  de  la  directive  2004/23/CE:  «Les  États  membres  s'efforcent  de  garantir  les  dons 

volontaires et non rémunérés de tissus et cellules.» 

  Directive  95/46/CE  du  Parlement  européen  et  du  Conseil  du  24 octobre  1995  relative  à  la 

protection des personnes physiques à l'égard du traitement des données à caractère personnel et à 

la libre circulation de ces données. 

  Conventions  de  bioéthique  du  Conseil  de  l'Europe  et  protocoles  additionnels,  convention  du 

Conseil  de  l'Europe  pour  la  protection  des  personnes  à  l'égard  du  traitement  automatisé  des 

données à caractère personnel (n° 108). 

(cid:120) 

(cid:120) 

les  demandeurs  devront  utiliser  des  CSEH  stockées  dans  le  registre 

communautaire.  La  nécessité  d'utiliser  d'autres  lignées  de  CSEH  dans  les 
propositions  du  7e PC  devra  par  conséquent  être  justifiée  sur  le  plan 

scientifique et éthique; 

le  registre  devra  préparer  et  publier  (sur  son  site  internet)  des  informations 

sur les CSEH stockées en banque et sur les résultats positifs et négatifs des 

recherches effectuées sur les lignées de CSEH fournies aux chercheurs. En 

fin  de  projet,  en  plus  des  données  scientifiques,  en  particulier  des 

informations relatives à la santé, il est également fortement recommandé de 

publier des informations conviviales et librement accessibles aux citoyens de 

l'UE  sur  les  activités  de  recherche  en  matière  de  CSEH.  Le  portail  devra  si 

possible intégrer des éléments interactifs. 

Il  incombe  aux  chercheurs  opérant  sur  le  terrain  d'informer  le  public  de  leurs 

travaux, mais également de participer aux débats sociaux, politiques et éthiques. 

Concernant des questions ouvertes telles que «comment trouver l'équilibre entre 

des droits divergents» et «comment classer des intérêts conflictuels par ordre de 

priorité»,  les  chercheurs  doivent  prendre  part  au  débat  public  et  respecter  le 

processus  décisionnel  démocratique  en  ce  qui  concerne  les  objectifs  sociétaux 

communs.  Les  demandeurs  doivent  par  conséquent  consacrer  du  temps,  de 

l'argent  et  des  activités  pour  faire  progresser  le  dialogue  de  la  science  et  de  la 

société dans le domaine de la recherche sur les cellules souches embryonnaires 

humaines.  Les  demandeurs  [déposant  un  dossier]  de  recherche  sur  les  CSEH 

59

01_2007_5944_txt_EN.indd   59

12-02-2008   13:58:35

 
 
  
 
 
 
 
                                                                                                                                                 
 
 
  
 
 
 
dans  le  cadre  du  7e PC  sont  donc  fortement  encouragés  à  inclure  dans  leurs 

projets  le  dialogue  science  et  sciences  humaines,  c'est-à-dire  une  réflexion 

sociale,  culturelle/religieuse,  philosophique  et  éthique  sur  la  recherche  sur  les 

CSEH,  et  à  collaborer  à  cet  effet  avec  d'autres  disciplines  des  sciences 

humaines.  

IV.3.  Nécessité  de  recherches  complémentaires  et  d'un  débat  public 

permanent 

Étant donné que les conflits éthiques concernant les CSEH n'ont pas été résolus 

au niveau universitaire ou politique, le GEE recommande qu'un financement soit 
octroyé dans le cadre du 7e PC afin de permettre des recherches internationales 

complémentaires de nature collaborative et multidisciplinaire sur les implications 

éthiques de la recherche sur les CSEH et les questions connexes, ainsi que pour 

encourager un débat public éclairé.  

Le GEE estime que les thèmes suivants peuvent présenter un intérêt particulier 

immédiat dans le cadre de ces recherches et débats: 

(cid:120) 

les  objectifs  potentiellement  contradictoires  de  la  compétitivité  et  du  respect 

des normes éthiques;  

(cid:120) 

l'utilisation  du  corps  humain  pour  la  médecine  moderne,  y  compris  la 

commercialisation  de  produits  et  procédures  provenant  de  l'utilisation  de 

cellules souches embryonnaires humaines;  

(cid:120) 

l'anthropologie  sous-jacente  de  la  recherche  sur  les  cellules  souches 

embryonnaires  humaines,  en  particulier  à  la  lumière  des  hybrides  et  de  la 

recherche sur les chimères liée à la recherche sur les cellules souches;  

(cid:120) 

l'optimisation  des  besoins  cliniques  et  thérapeutiques  des  patients  souffrant 

des maladies les plus communes visées par la recherche CSEH en matière 

de traitement et/ou de maladies spécifiques; 

(cid:120) 

 la politique relative au nombre et au processus de production des lignées de 

cellules souches nécessaires dans le cas de thérapies réussies;  

60

01_2007_5944_txt_EN.indd   60

12-02-2008   13:58:36

 
 
  
 
 
 
 
 
humaines.  

permanent 

IV.3.  Nécessité  de  recherches  complémentaires  et  d'un  débat  public 

Étant donné que les conflits éthiques concernant les CSEH n'ont pas été résolus 

au niveau universitaire ou politique, le GEE recommande qu'un financement soit 

octroyé dans le cadre du 7e PC afin de permettre des recherches internationales 

complémentaires de nature collaborative et multidisciplinaire sur les implications 

éthiques de la recherche sur les CSEH et les questions connexes, ainsi que pour 

encourager un débat public éclairé.  

Le GEE estime que les thèmes suivants peuvent présenter un intérêt particulier 

immédiat dans le cadre de ces recherches et débats: 

(cid:120) 

les  objectifs  potentiellement  contradictoires  de  la  compétitivité  et  du  respect 

des normes éthiques;  

(cid:120) 

l'utilisation  du  corps  humain  pour  la  médecine  moderne,  y  compris  la 

commercialisation  de  produits  et  procédures  provenant  de  l'utilisation  de 

des maladies les plus communes visées par la recherche CSEH en matière 

de traitement et/ou de maladies spécifiques; 

(cid:120) 

 la politique relative au nombre et au processus de production des lignées de 

cellules souches nécessaires dans le cas de thérapies réussies;  

dans  le  cadre  du  7e PC  sont  donc  fortement  encouragés  à  inclure  dans  leurs 

(cid:120) 

la  corrélation  entre  la  recherche  sur  les  cellules  souches  embryonnaires 

projets  le  dialogue  science  et  sciences  humaines,  c'est-à-dire  une  réflexion 

humaines et les questions concernant la médecine régénérative, la justice en 

sociale,  culturelle/religieuse,  philosophique  et  éthique  sur  la  recherche  sur  les 

matière de santé, y compris la question de la justice globale; 

CSEH,  et  à  collaborer  à  cet  effet  avec  d'autres  disciplines  des  sciences 

(cid:120) 

la relation entre la science et les sciences humaines et entre la science et la 

société en ce qui concerne le développement de nouvelles technologies;  

(cid:120) 

les  efforts  continus  des  solutions  alternatives  scientifiques  et 

leurs 

interprétations anthropologiques et éthiques. 

Le  GEE  reconnaît  également  qu'un  certain  nombre  de  questions  devront  faire 

l'objet  de  précisions  supplémentaires,  d'une  recherche  interdisciplinaire,  d'une 

évaluation  éthique  complète  et  également,  si  cela  s'avère  nécessaire  dans  le 

futur,  d'une  action  en  justice  appropriée.  Le  GEE  estime  actuellement  que  les 

questions suivantes exigent une attention particulière:  

(cid:120) 

les  dispositions  courantes  de  brevetabilité  des  matériels  issus  de  CSEH 

doivent  être  abordées.  Étant  donné  les  nouvelles  avancées  de  la 

recherche  et  compte  tenu  du  débat  en  cours  sur  les  limites  de 

brevetabilité  des  matériels  biologiques,  le  GEE  voudrait  traiter  cette 
question ultérieurement (126); 

(cid:120) 

la  tension  induite  par  une  politique  qui  encourage  à  la  fois  le  don 
gratuit (127) et l'utilisation commerciale de dérivés de substances humaines 

cellules souches embryonnaires humaines;  

doit être abordée. 

(cid:120) 

l'anthropologie  sous-jacente  de  la  recherche  sur  les  cellules  souches 

embryonnaires  humaines,  en  particulier  à  la  lumière  des  hybrides  et  de  la 

Le GEE souligne avec insistance le fait que l'utilisation d'embryons humains pour 

recherche sur les chimères liée à la recherche sur les cellules souches;  

produire  des  cellules  souches  doit  être  limitée  au  minimum  possible.  Le  GEE 

(cid:120) 

l'optimisation  des  besoins  cliniques  et  thérapeutiques  des  patients  souffrant 

invite  l'Union  européenne  à  développer  des  systèmes  appropriés  pour  limiter 

(126) 

(127) 

Le GEE a émis un avis sur les aspects éthiques de la brevetabilité des inventions impliquant des 
cellules souches humaines, http://www.ec.europa.eu/european_group_ethics/docs/avis16_fr.pdf. 
Article 12  de  la  directive  2004/23/CE:  «Les  États  membres  s'efforcent  de  garantir  les  dons 
volontaires et non rémunérés de tissus et cellules.» 

61

01_2007_5944_txt_EN.indd   61

12-02-2008   13:58:36

 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
                                                 
l'utilisation d'embryons humains aux cas pour lesquels il n'existe aucune solution 

de rechange. 

IV.4.  Examen  des  recommandations  et  communication  avec  le 
comité  consultatif  du  registre  européen  des  lignées  de  cellules 
souches embryonnaires humaines 
Le  GEE  serait  également  favorable  à  une  interaction  avec  le  comité  consultatif 

du registre européen des lignées de cellules souches embryonnaires humaines, 

en  particulier  avec  le  comité  consultatif  du  registre  en  matière  d'éthique,  afin 

d'aborder les questions éthiques relatives à l'obtention de cellules souches et au 

stockage des données à la lumière des progrès continus dans ce domaine.  

La forme et les moyens concrets de cette collaboration devraient être précisés et 

mis  en  place,  et  devraient  être  convenablement  soutenus  et  financés  par  la 

Commission.

62

01_2007_5944_txt_EN.indd   62

12-02-2008   13:58:36

 
 
  
 
 
l'utilisation d'embryons humains aux cas pour lesquels il n'existe aucune solution 

IV.4.1. Nécessité d'une révision 

de rechange. 

IV.4.  Examen  des  recommandations  et  communication  avec  le 

comité  consultatif  du  registre  européen  des  lignées  de  cellules 

souches embryonnaires humaines 

Le  GEE  serait  également  favorable  à  une  interaction  avec  le  comité  consultatif 

du registre européen des lignées de cellules souches embryonnaires humaines, 

en  particulier  avec  le  comité  consultatif  du  registre  en  matière  d'éthique,  afin 

d'aborder les questions éthiques relatives à l'obtention de cellules souches et au 

stockage des données à la lumière des progrès continus dans ce domaine.  

La forme et les moyens concrets de cette collaboration devraient être précisés et 

mis  en  place,  et  devraient  être  convenablement  soutenus  et  financés  par  la 

Commission.

Le GEE propose de réviser les lignes directrices éthiques adoptées à la lumière 

des avancées scientifiques, juridiques et sociales.  

Groupe européen d'éthique des sciences et des nouvelles technologies  

Président: Göran Hermerén 

Membres: 

Emmanuel Agius 

Diana Banati 

Anne Cambon-Thomsen 

Rafael Capurro 

Inez de Beaufort 

Jozef Glasa 

Hille Haker 

Julian Kinderlerer 

Krzysztof Marczewski 

Paula Martinho Da Silva 

Linda Nielsen 

Pere Puigdomenech-Rosell 

Günter Virt 

63

01_2007_5944_txt_EN.indd   63

12-02-2008   13:58:37

 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IV.I.  GERMAN TRANSLATION128 

DEUTSCHE ÜBERSETZUNG DER : EMPFEHLUNGEN ZUR ETHISCHEN PRÜFUNG VON FP7-

FORSCHUNGSPROJEKTEN MIT HUMANEN EMBRYONALEN STAMMZELLEN - 

STELLUNGNAHME NR. 22 - 

IV. EMPFEHLUNGEN  

IV.1 Einleitung 

die  Gruppe 

Nach  Verabschiedung  des  Siebten  Rahmenprogramms  für  Forschung  und 
Entwicklung (FP7) forderte der Präsident der Europäischen Kommission, Herr 
Barroso129, 
den 
Durchführungsmaßnahmen auszuarbeiten, die bei der ethischen Prüfung von 
Forschungsprojekten  mit  humanen  embryonalen  Stammzellen  (hES-Zellen) 
erforderlich  sind.  Die  vorliegenden  Empfehlungen  sind  das  Ergebnis  dieser 
Arbeit.  

Stellungnahme 

eine 

auf, 

zu 

Wie  in  der  Europäischen  Union  generell,  so  gehen  auch  innerhalb  der  EGE 
die  Ansichten  über  die  moralische  Legitimität  der  Forschung  an  humanen 
Embryonen  und  humanen  embryonalen  Stammzellen  auseinander;  sie 
reichen  von  der  Ablehnung  der  verbrauchenden  Embryonenforschung  (da 
diese es unmöglich macht, die Würde des menschlichen Embryos zu wahren) 
bis  zur  Position,  die  Forschung  mit  hES-Zellen  unter  bestimmten 
Bedingungen oder auf breiterer Basis zu erlauben.  

Die  Gruppe  erkennt  den  politischen  Beschluss  als  Ausgangspunkt  dieser 
Empfehlungen  an,  betont  aber  gleichzeitig,  dass  das  ethische  Dilemma 
hinsichtlich  des  Status  des  humanen  Embryos  und  seiner  Verwendung  für 
Forschungszwecke nach wie vor besteht. Die EGE unterstreicht daher, dass 
die  Meinungsunterschiede  in  ethischen  Fragen  im  Zusammenhang  mit  der 
Forschung an humanen embryonalen Stammzellen nicht ausgeräumt wurden. 

In diesen Empfehlungen werden jedoch keine ethischen Argumente über die 
Forschung  an  humanen  embryonalen  Stammzellen  als  solche  erarbeitet,  da 
dies  nicht  dem  von  der  Europäischen  Kommission  der  Gruppe  erteilten 
Auftrag entsprach.  

64

01_2007_5944_txt_EN.indd   64

12-02-2008   13:58:37

 
 
  
 
 
 
 
 
 
 
 
DEUTSCHE ÜBERSETZUNG DER : EMPFEHLUNGEN ZUR ETHISCHEN PRÜFUNG VON FP7-

FORSCHUNGSPROJEKTEN MIT HUMANEN EMBRYONALEN STAMMZELLEN - 

128129

IV.I.  GERMAN TRANSLATION128 

STELLUNGNAHME NR. 22 - 

IV. EMPFEHLUNGEN  

IV.1 Einleitung 

Nach  Verabschiedung  des  Siebten  Rahmenprogramms  für  Forschung  und 

Entwicklung (FP7) forderte der Präsident der Europäischen Kommission, Herr 

Barroso129, 

die  Gruppe 

auf, 

eine 

Stellungnahme 

zu 

den 

Durchführungsmaßnahmen auszuarbeiten, die bei der ethischen Prüfung von 

Forschungsprojekten  mit  humanen  embryonalen  Stammzellen  (hES-Zellen) 

erforderlich  sind.  Die  vorliegenden  Empfehlungen  sind  das  Ergebnis  dieser 

Arbeit.  

Wie  in  der  Europäischen  Union  generell,  so  gehen  auch  innerhalb  der  EGE 

die  Ansichten  über  die  moralische  Legitimität  der  Forschung  an  humanen 

Embryonen  und  humanen  embryonalen  Stammzellen  auseinander;  sie 

reichen  von  der  Ablehnung  der  verbrauchenden  Embryonenforschung  (da 

diese es unmöglich macht, die Würde des menschlichen Embryos zu wahren) 

bis  zur  Position,  die  Forschung  mit  hES-Zellen  unter  bestimmten 

Bedingungen oder auf breiterer Basis zu erlauben.  

Die  Gruppe  erkennt  den  politischen  Beschluss  als  Ausgangspunkt  dieser 

Empfehlungen  an,  betont  aber  gleichzeitig,  dass  das  ethische  Dilemma 

hinsichtlich  des  Status  des  humanen  Embryos  und  seiner  Verwendung  für 

Forschungszwecke nach wie vor besteht. Die EGE unterstreicht daher, dass 

die  Meinungsunterschiede  in  ethischen  Fragen  im  Zusammenhang  mit  der 

Forschung an humanen embryonalen Stammzellen nicht ausgeräumt wurden. 

In diesen Empfehlungen werden jedoch keine ethischen Argumente über die 

Forschung  an  humanen  embryonalen  Stammzellen  als  solche  erarbeitet,  da 

dies  nicht  dem  von  der  Europäischen  Kommission  der  Gruppe  erteilten 

Auftrag entsprach.  

128  

129

Translations from the English original — only the English text is authentic. Translations in the 
EU-27 languages are available at: 
http://ec.europa.eu/european_group_ethics/activities/docs/opinion_22_final_follow_up_en.pdf, 
or upon request to the EGE Secretariat mailbox (bepa-ethics-group@ec.europa.eu) 
Schreiben  des  Präsidenten  der  Europäischen  Kommission,  Herrn  Barroso,  an  die  EGE  vom 
22.11.2006.  „Ich  möchte  die  Europäische  Ethikgruppe  auffordern,  für  die  Kommission  eine 
Stellungnahme  über  die  Durchführung  von  Maßnahmen  auszuarbeiten,  die  für  die  ethische 
Prüfung  von  Forschungsprojekten  mit  humanen  embryonalen  Stammzellen  erforderlich  sind,  um 
sicherzustellen, dass die ethischen Regeln und Anforderungen vollständig eingehalten werden.“ 

65

01_2007_5944_txt_EN.indd   65

12-02-2008   13:58:37

 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
                                                 
  
IV.2 
Forschungsprojekten mit hES-Zellen 

Empfehlungen 

zur 

ethischen 

Prüfung 

von 

FP7-Forschungsprojekte,  in  denen  hES-Zellen  verwendet  werden,  unterliegen 

bei  der  Auswahl  strengen  Regeln,  werden  sowohl  auf  nationaler  wie  auf  EU-

Ebene  überwacht  und  durchlaufen  sowohl  wissenschaftliche  als  auch  ethische 

Prüfungen. 

Forschungsanträge  im  Rahmen  des  FP7  müssen  Informationen  über  ethische 

Aspekte der vorgeschlagenen Arbeit enthalten; die Projektgestaltung ist detailliert 

zu  erläutern  und  es  ist  nachzuweisen,  dass  der  Antrag  den  rechtlichen  und 

ethischen  Anforderungen  des  Landes  entspricht,  in  denen  die  Forschung 

durchgeführt wird. 

Nachdem  die  Forschungsvorhaben  die  wissenschaftliche  Prüfung  erfolgreich 

durchlaufen  haben,  werden  die  Forschungsprojekte  mit  hES-Zellen  einer 

speziellen  von  der  Kommission  organisierten  ethischen  Einzelfallprüfung 

unterzogen. Das Ziel dieser Prüfung ist es sicherzustellen, dass die Europäische 

Union  keine  Forschung  unterstützt,  die  mit  grundlegenden  ethischen  Prinzipien 
unvereinbar  ist130,  und  es  soll  überprüft  werden,  ob  die  im  FP7  festgelegten 

ethischen Regeln eingehalten werden.  

Dem 

transnational 

zusammengesetzten  Gremium 

gehören  Experten 

unterschiedlicher  Disziplinen  an.  Es  erarbeitet  einen  Bericht,  in  dem  die 

verschiedenen  ethischen  Fragen  aufgeführt  werden  und  beschrieben  wird,  wie 

die  Antragsteller  mit  ihnen  umgehen;  außerdem  enthält  der  Bericht  die 

Empfehlungen des Gremiums.  

130  Siebtes  Rahmenprogramm 
(Beschluss  Nr. 1982/2006/EG),  Artikel 6  Absatz 1:  „Bei  allen 
Forschungsmaßnahmen 
innerhalb  des  Siebten  Rahmenprogramms  werden  die  ethischen 
Grundprinzipien beachtet.“ Regeln  für  die  Beteiligung,  Artikel 14 Absatz 2: „Ein Vorschlag,  der 
im  Widerspruch  zu  grundlegenden  ethischen  Prinzipien  steht  […],  wird  nicht  ausgewählt.  Ein 

66

01_2007_5944_txt_EN.indd   66

12-02-2008   13:58:38

 
 
  
 
 
 
 
 
 
                                                 
IV.2 

Empfehlungen 

zur 

ethischen 

Prüfung 

von 

Forschungsprojekten mit hES-Zellen 

FP7-Forschungsprojekte,  in  denen  hES-Zellen  verwendet  werden,  unterliegen 

bei  der  Auswahl  strengen  Regeln,  werden  sowohl  auf  nationaler  wie  auf  EU-

Ebene  überwacht  und  durchlaufen  sowohl  wissenschaftliche  als  auch  ethische 

Prüfungen. 

Forschungsanträge  im  Rahmen  des  FP7  müssen  Informationen  über  ethische 

Aspekte der vorgeschlagenen Arbeit enthalten; die Projektgestaltung ist detailliert 

zu  erläutern  und  es  ist  nachzuweisen,  dass  der  Antrag  den  rechtlichen  und 

ethischen  Anforderungen  des  Landes  entspricht,  in  denen  die  Forschung 

durchgeführt wird. 

durchlaufen  haben,  werden  die  Forschungsprojekte  mit  hES-Zellen  einer 

speziellen  von  der  Kommission  organisierten  ethischen  Einzelfallprüfung 

unterzogen. Das Ziel dieser Prüfung ist es sicherzustellen, dass die Europäische 

Union  keine  Forschung  unterstützt,  die  mit  grundlegenden  ethischen  Prinzipien 

unvereinbar  ist130,  und  es  soll  überprüft  werden,  ob  die  im  FP7  festgelegten 

ethischen Regeln eingehalten werden.  

Dem 

transnational 

zusammengesetzten  Gremium 

gehören  Experten 

unterschiedlicher  Disziplinen  an.  Es  erarbeitet  einen  Bericht,  in  dem  die 

verschiedenen  ethischen  Fragen  aufgeführt  werden  und  beschrieben  wird,  wie 

die  Antragsteller  mit  ihnen  umgehen;  außerdem  enthält  der  Bericht  die 

Empfehlungen des Gremiums.  

130  Siebtes  Rahmenprogramm 

(Beschluss  Nr. 1982/2006/EG),  Artikel 6  Absatz 1:  „Bei  allen 

Forschungsmaßnahmen 

innerhalb  des  Siebten  Rahmenprogramms  werden  die  ethischen 

Grundprinzipien beachtet.“ Regeln  für  die  Beteiligung,  Artikel 14 Absatz 2: „Ein Vorschlag,  der 

im  Widerspruch  zu  grundlegenden  ethischen  Prinzipien  steht  […],  wird  nicht  ausgewählt.  Ein 

Vorschläge  für  hES-Zellforschungen  werden,  sobald  sie  die  wissenschaftliche 

und  die  ethische  Prüfung  durchlaufen  haben,  einem  Regelungsausschuss 

vorgelegt,  der  aus  Vertretern  der  EU-Mitgliedstaaten  besteht  und  auf 

Einzelfallbasis über die Projekte entscheidet.  

Für  die  Mitglieder  der  Gremien,  die  im  Rahmen  des  FP7  die  ethische  Prüfung 

von  Forschungsprojekten  mit  hES-Zelllinien  vornehmen  sollen,  hat  die  EGE 

entsprechend  dem  konkreten  Mandat  und  den  Bedingungen,  die  im  politischen 

Beschluss des Europäischen Parlaments und des Rates über das FP7 festgelegt 

sind,  sowie  auf  die  konkrete  Aufforderung  des  Präsidenten  der  Europäischen 

Kommission, Herrn J. M. Barroso, hin (siehe oben), für die Durchführung solcher 

ethischer  Prüfungen  von  FP7-Projekten  die  folgenden  Leitlinien  und  Kriterien 
erarbeitet131.  

Nachdem  die  Forschungsvorhaben  die  wissenschaftliche  Prüfung  erfolgreich 

IV.2.1 Allgemeine Kriterien 

Die  Europäische  Kommission  hat  erklärt,  dass  sie  „Maßnahmen  und  Initiativen 

fördern  (wird),  die  dazu  beitragen,  dass  Forschungsarbeiten  mit  humanen 

embryonalen Stammzellen auf ethisch vertretbare Art und Weise koordiniert und 
rationalisiert werden können“132. Übereinstimmend mit dieser Erklärung ist auch 

die  EGE  der  Ansicht,  dass  nur  ethisch  vertretbare  Forschung  gefördert  werden 

kann,  die  transparent  ist,  dem  öffentlichen  Interesse  dient,  die  Autonomie  der 

Mitgliedstaaten 

respektiert,  das  Vertrauen  der  Öffentlichkeit  wahrt,  die 

internationale  Zusammenarbeit 
Forschungspraxis verankert133. 

fördert  und  die  ethischen  Fragen 

in  der 

solcher  Vorschlag  kann  jederzeit  von  den  Bewertungs-,  Auswahl-  und  Gewährungsverfahren 
ausgeschlossen werden.“  
Nach  den  Regeln  für  die  Beteiligung  am  FP7  unterzeichnen  die  Bewerter  eine  Erklärung  zum 
Interessenkonflikt,  und  die  Kommissionsdienststelle  überprüft  bei  jedem  Vorschlag,  den  sie 
bewertet,  ob  ein  Interessenkonflikt  besteht.  Die  Evaluationsgremien  der  ethischen  und 
wissenschaftlichen Bewertungen sind anonym. 
Erklärung der Europäischen Kommission vom 24. Juli 2006 während der Ministerratstagung über 
das FP7. Siehe ABl. L 412/43 vom 30. Dezember 2006. 
Siehe beispielsweise das Übereinkommen von Oviedo des Europarats (Artikel 2).  

131  

132  

133  

67

01_2007_5944_txt_EN.indd   67

12-02-2008   13:58:38

 
 
  
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
                                                                                                                                                 
Ethisch  vertretbare  Forschung  mit  humanen  embryonalen  Stammzellen  muss 
von der Beschaffung der Stammzellen134 bis zu der auf hES-Zellen basierenden 

klinischen  Forschung  den  grundlegenden  ethischen  Prinzipien  und 
Menschenrechten der Europäischen Union entsprechen135.  

Zu den Grundrechten gehören: Schutzrechte, etwa das Recht auf Leben und auf 

körperliche  Unversehrtheit  und  der  Schutz  von  Gesundheit  und  Freiheit, 

politische  Rechte, etwa das Recht auf Schutz vor ungerechtfertigtem Eingreifen 

des Staates oder das Recht auf politische Betätigung, und positive Rechte, etwa 

grundlegende soziale und wirtschaftliche Rechte, soweit sie zur Gesundheit und 

zum  Erreichen  einer  Entwicklungsschwelle  beitragen  und  die  Einführung 
gesundheitsbezogener Steuerungsmechanismen erfordern.136 

Der  Ausgleich  zwischen  diesen  drei  Gruppen  von  Grundrechten  ist  keineswegs 

leicht  herzustellen  oder  gar  vorgegeben.  Eher 

ist  es  so,  dass 

laufend 

Bemühungen  erforderlich  sind,  um  ihren  Schutz  sicherzustellen  und  die 

Menschenwürde  und  die  Menschenrechte  zu  gewährleisten  und  zu  fördern. 

Konkret  bedeutet  dies  im  Zusammenhang  mit  gesundheitsrelevanter  Forschung 

auch, Prioritäten zu setzen.  

Die  allgemeinen  Kriterien,  nach  denen  Forschungsförderung  betrieben  wird, 

beinhalten  eine  solche  Prioritätensetzung.  Diese  Kriterien 

lassen  sich 

folgendermaßen zusammenfassen:  

134  

135  

136  

Die Gewinnung humaner embryonaler Stammzellen wird laut FP7 nicht mit Gemeinschaftsmitteln 
finanziert (siehe Abschnitt II.2). Siehe Beschluss Nr. 1982/2006/EG des Europäischen Parlaments 
und  des  Rates  vom  18. Dezember  2006  über  das  Siebte  Rahmenprogramm  der  Europäischen 
Gemeinschaft  für  Forschung,  technologische  Entwicklung  und  Demonstration  (2007  bis  2013), 
ABl. L 412 vom 30. Dezember 2006, S.1-41. 
Einzelheiten  siehe  Abschnitt I  dieser  Stellungnahme  über  die  relevanten  Dokumente  im  Kontext 
der medizinischen Forschung. 
Siehe  die  Millenniumsziele  der  Vereinten  Nationen,  zu  deren  Realisierung  sich  die  Europäische 
Union verpflichtet hat. 

68

01_2007_5944_txt_EN.indd   68

12-02-2008   13:58:38

 
 
  
 
 
 
 
 
 
                                                 
Ethisch  vertretbare  Forschung  mit  humanen  embryonalen  Stammzellen  muss 

von der Beschaffung der Stammzellen134 bis zu der auf hES-Zellen basierenden 

klinischen  Forschung  den  grundlegenden  ethischen  Prinzipien  und 

Menschenrechten der Europäischen Union entsprechen135.  

Zu den Grundrechten gehören: Schutzrechte, etwa das Recht auf Leben und auf 

körperliche  Unversehrtheit  und  der  Schutz  von  Gesundheit  und  Freiheit, 

politische  Rechte, etwa das Recht auf Schutz vor ungerechtfertigtem Eingreifen 

des Staates oder das Recht auf politische Betätigung, und positive Rechte, etwa 

grundlegende soziale und wirtschaftliche Rechte, soweit sie zur Gesundheit und 

zum  Erreichen  einer  Entwicklungsschwelle  beitragen  und  die  Einführung 

gesundheitsbezogener Steuerungsmechanismen erfordern.136 

Der  Ausgleich  zwischen  diesen  drei  Gruppen  von  Grundrechten  ist  keineswegs 

leicht  herzustellen  oder  gar  vorgegeben.  Eher 

ist  es  so,  dass 

laufend 

Bemühungen  erforderlich  sind,  um  ihren  Schutz  sicherzustellen  und  die 

Menschenwürde  und  die  Menschenrechte  zu  gewährleisten  und  zu  fördern. 

Konkret  bedeutet  dies  im  Zusammenhang  mit  gesundheitsrelevanter  Forschung 

auch, Prioritäten zu setzen.  

Die  allgemeinen  Kriterien,  nach  denen  Forschungsförderung  betrieben  wird, 

beinhalten  eine  solche  Prioritätensetzung.  Diese  Kriterien 

lassen  sich 

folgendermaßen zusammenfassen:  

134  

135  

136  

Die Gewinnung humaner embryonaler Stammzellen wird laut FP7 nicht mit Gemeinschaftsmitteln 

finanziert (siehe Abschnitt II.2). Siehe Beschluss Nr. 1982/2006/EG des Europäischen Parlaments 

und  des  Rates  vom  18. Dezember  2006  über  das  Siebte  Rahmenprogramm  der  Europäischen 

Gemeinschaft  für  Forschung,  technologische  Entwicklung  und  Demonstration  (2007  bis  2013), 

ABl. L 412 vom 30. Dezember 2006, S.1-41. 

Einzelheiten  siehe  Abschnitt I  dieser  Stellungnahme  über  die  relevanten  Dokumente  im  Kontext 

der medizinischen Forschung. 

Union verpflichtet hat. 

Siehe  die  Millenniumsziele  der  Vereinten  Nationen,  zu  deren  Realisierung  sich  die  Europäische 

(cid:120)  wissenschaftliche Notwendigkeit und hoher Rang der Forschung137, 
(cid:120)  Dringlichkeit138 und  
(cid:120)  gesellschaftliche Erwünschtheit,  

(cid:120)  Vorrang der Interessen und des Wohlbefindens des einzelnen Menschen 

vor rein gesellschaftlichen oder wissenschaftlichen Interessen. 

Die gesellschaftliche Erwünschtheit von Fördermaßnahmen wird im Rahmen des 

politischen  und  gesellschaftlichen  Diskurses  über  Ziele  und  Perspektiven  der 

Europäischen  Union  im  21. Jahrhundert  diskutiert;  dabei  geht  es  auch  um  die 

Beziehung  zwischen  Wirtschaftswachstum  und  sozialen  Zielen,  etwa  der 

Förderung  von  Gesundheitsstandards  und  ihrer  nachhaltigen  Anwendung  auf 

nationaler, internationaler und globaler Ebene.  

Was  die  hES-Zellforschung  betrifft,  gibt  es  in  der  Europäischen  Union  keinen 

Konsens über ihre gesellschaftliche Akzeptabilität, divergente Meinungen stehen 

nebeneinander.  Deshalb  werden  derzeit  in  mehreren  EU-Mitgliedstaaten  und 

auch  über 

ihre  Grenzen  hinweg  verschiedene  Modelle 

(z. B.  das 

„Minimalkonsens-Modell“  oder  das  „Subsidiaritäts-Modell“)  zur  Regulierung  der 

hES-Zellforschung auf EU-Ebene diskutiert. 

Wo moralisch sensible Mittel eingesetzt werden, um allgemein akzeptierte Ziele 

zu erreichen – wie im Falle der humanen embryonalen Stammzellen –, wo also 

nicht das Ziel therapieorientierter Forschung hinterfragt wird, sondern die „Mittel“, 

mit deren Hilfe es erreicht werden soll, gelten nach Ansicht der EGE zusätzliche 

Kriterien  hinsichtlich  der  Notwendigkeit  der  Forschung:  1)  das  Fehlen 
validierter Alternativen und 2) die Nichtredundanz von FP7-Projekten139. 

137  
138  
139  

http://ec.europa.eu/research/fp7/index_en.cfm?pg=documents. 
http://www.who.int/rpc/en/HealthResearchinPolicyMaking.pdf. 
Wiederholungen sind allerdings zuweilen notwendig, um den Erfolgsnachweis zu erbringen; diese 
werden nicht im obigen Sinne als redundant angesehen. 

69

01_2007_5944_txt_EN.indd   69

12-02-2008   13:58:39

 
 
  
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
                                                 
Diese  zentralen  wissenschaftlichen  Bewertungskriterien  müssen  jedoch  im 

Rahmen  der  ethischen  Prüfung  aus  ethischer  Sicht  bewertet  werden. 

Selbstverständlich  kann  und  soll  die  ethische  Prüfung  nicht  eine  Wiederholung 

der  wissenschaftlichen  Prüfung  sein,  die  nach  wie  vor  für  die  Beurteilung  der 

wissenschaftlichen  Qualität  von  Projektvorschlägen  am  wichtigsten  ist.  Die 

beiden  Prüfungen  ergänzen  sich  vielmehr.  Soweit  FP7-Projekte  mit  hES-Zellen 

betroffen  sind,  sollte  die  Kommission  sicherstellen,  dass  der  Bericht  über  die 

wissenschaftliche Prüfung dem mit der ethischen Prüfung beauftragten Gremium 

vorliegt und dass die beiden Gremien erforderlichenfalls ungehindert miteinander 

kommunizieren können. 

Um die Komplementarität der beiden Prüfungen zu gewährleisten, sollte aus dem 

Bericht  über  die  wissenschaftliche  Bewertung  mindestens  Folgendes 

hervorgehen: 

(cid:120)  Die Antragsteller haben deutlich gemacht, dass mit der Forschung an 

humanen  Stammzellen  anderer  Herkunft,  also  adulten  Stammzellen, 

Stammzellen  aus  Fruchtwasser,  Nabelschnurblut  o. Ä.,  die 

angestrebten  Ziele  des  Forschungsvorhabens  nicht  erreicht  werden 

können.  Dies  gilt  nicht  für  Forschung  zum  Vergleich  von  hES-Zellen 

mit humanen Stammzellen aus anderen Quellen. 

(cid:120)  Die  Antragsteller  haben  die  Tatsache  dokumentiert,  dass 

in 

Übereinstimmung  mit  den  grundlegenden  ethischen  Prinzipien  der 

medizinischen Forschung einschlägige Forschungen an Tieren und an 

Zelllinien  anderer (tierischer  und  humaner)  Herkunft in  angemessener 

Weise durchgeführt wurden, ehe an hES-Zellen geforscht wird.  

(cid:120)  Die Antragsteller haben deutlich gemacht, dass sie mit ihrer Forschung 

künftigen Nutzen für die menschliche Gesundheit oder biomedizinische 

Erkenntnisse anstreben und dass dies mit alternativen Methoden nicht 

70

01_2007_5944_txt_EN.indd   70

12-02-2008   13:58:39

 
 
  
 
 
 
 
 
Selbstverständlich  kann  und  soll  die  ethische  Prüfung  nicht  eine  Wiederholung 

wissenschaftlichen  Qualität  von  Projektvorschlägen  am  wichtigsten  ist.  Die 

beiden  Prüfungen  ergänzen  sich  vielmehr.  Soweit  FP7-Projekte  mit  hES-Zellen 

betroffen  sind,  sollte  die  Kommission  sicherstellen,  dass  der  Bericht  über  die 

wissenschaftliche Prüfung dem mit der ethischen Prüfung beauftragten Gremium 

vorliegt und dass die beiden Gremien erforderlichenfalls ungehindert miteinander 

kommunizieren können. 

Bericht  über  die  wissenschaftliche  Bewertung  mindestens  Folgendes 

hervorgehen: 

(cid:120)  Die Antragsteller haben deutlich gemacht, dass mit der Forschung an 

humanen  Stammzellen  anderer  Herkunft,  also  adulten  Stammzellen, 

Stammzellen  aus  Fruchtwasser,  Nabelschnurblut  o. Ä.,  die 

angestrebten  Ziele  des  Forschungsvorhabens  nicht  erreicht  werden 

mit humanen Stammzellen aus anderen Quellen. 

Diese  zentralen  wissenschaftlichen  Bewertungskriterien  müssen  jedoch  im 

erreicht  werden  kann.  Dies  gilt  auch  für  die  Grundlagenforschung  mit 

Rahmen  der  ethischen  Prüfung  aus  ethischer  Sicht  bewertet  werden. 

hES-Zellen, die im Rahmen des FP7 erlaubt ist. 

der  wissenschaftlichen  Prüfung  sein,  die  nach  wie  vor  für  die  Beurteilung  der 

(cid:120)  Die Antragsteller haben nachgewiesen, dass die Projektziele mit keiner 

alternativen  Methode  erreicht  werden  können.  Auch  wenn  sich  die 

Gruppe der Bedeutung des Tierschutzes bewusst ist, hat sie Bedenken 

dahingehend,  dass  die  Achtung  der  Menschenwürde  nicht 

gewährleistet  wäre,  wenn  hES-Zellen  in  Toxizitätstests  für  industrielle 

oder  andere  kommerziell  hergestellte  nicht  arzneimittelrelevante 

chemische  Produkte  wie  etwa  Kosmetika,  oder  als  Ersatz  von 

Tierversuchen  verwendet  werden.  Dieser  Frage  ist  daher  besondere 

Um die Komplementarität der beiden Prüfungen zu gewährleisten, sollte aus dem 

Beachtung zu schenken (siehe Nummer 2 von Absatz IV.3). 

(cid:120)  Die  Antragsteller  haben  eine  umfassende  wissenschaftliche 

Begründung  vorgelegt,  wenn  in  ihrem  Projekt  Toxizitätstests  für 

Arzneimittel  vorgesehen  sind;  aus  dieser  Begründung  sollte  klar 

hervorgehen,  welche  Art  zusätzlicher  Erkenntnisse  bei  Verwendung 

von hES-Zellen im Vergleich zu etablierten Tests erwartet wird.  

können.  Dies  gilt  nicht  für  Forschung  zum  Vergleich  von  hES-Zellen 

Das  mit  der  wissenschaftlichen  Bewertung  beauftragte  Gremium  sollte 

sicherstellen,  dass  die  Forscher,  die  an  FP7-Projekten  mit  hES-Zellen  arbeiten, 

national  und  international  kooperieren,  um  die  Verwendung  von  hES-Zellen  im 

(cid:120)  Die  Antragsteller  haben  die  Tatsache  dokumentiert,  dass 

in 

Rahmen FP7-finanzierter Projekte zu minimieren. Bei dieser Forschung geht es 

Übereinstimmung  mit  den  grundlegenden  ethischen  Prinzipien  der 

mehr darum, Komplementarität und Synergieeffekte anzustreben als Wettbewerb 

medizinischen Forschung einschlägige Forschungen an Tieren und an 

zu fördern. 

Zelllinien  anderer (tierischer  und  humaner)  Herkunft in  angemessener 

Weise durchgeführt wurden, ehe an hES-Zellen geforscht wird.  

IV.2.2 Ethische Kriterien für Forschungsprojekte im Rahmen des FP6 

(cid:120)  Die Antragsteller haben deutlich gemacht, dass sie mit ihrer Forschung 

sicherzustellen,  dass  ethischen  Anforderungen  entsprochen  wird,  und  diese 

künftigen Nutzen für die menschliche Gesundheit oder biomedizinische 

Bedingungen können für das FP7 übernommen werden:  

Einige wenige Bedingungen wurden bereits im Rahmen des FP6 festgelegt, um 

Erkenntnisse anstreben und dass dies mit alternativen Methoden nicht 

71

01_2007_5944_txt_EN.indd   71

12-02-2008   13:58:40

 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
1.  Antragsteller  müssen  ausdrücklich  nachweisen,  dass  bei  dem 

betreffenden  Projekt  die  Regulierungskriterien  eingehalten  werden,  und 

sie  müssen  die  einschlägigen  Rechts-  und/oder  Verwaltungsvorschriften 

des  Landes/der  Länder  angeben, 

in  dem/denen  die  Forschung 
(Artikel 6  Absatz 3  des  FP7)140.  Für  weitere 

durchgeführt  wird 

Informationen siehe Anhang 1. 

2.  Antragsteller  müssen  angeben,  dass  die 

im  betreffenden  Projekt 

verwendeten  hES-Zellen  nichtimplantierten  IVF-Embryonen  entnommen 

wurden 

(siehe  den  nachfolgenden  Absatz  über  die  Rechte  der 

Spenderinnen). 

3.  Antragsteller müssen Angaben über den Schutz der personenbezogenen 

Daten  und  der  Privatsphäre  der  Spenderinnen  von  Embryonen  für  die 

Gewinnung von Stammzelllinien machen. 

4.  Antragsteller müssen Angaben über die Umstände der Embryonenspende 

machen  (z. B.  keine  finanziellen  Anreize,  Zahl  der  gewonnen  Eizellen 

usw.).  Um  die  Nicht-Kommerzialisierbarkeit  des  menschlichen  Körpers 

und  den  Schutz  der  freiwilligen  Spende  gemäß  Artikel 12  der  Richtlinie 

2004/23/EG  zu  gewährleisten,  sollte  nach  Auffassung  der  EGE  die 

Spende menschlicher Embryonen nicht durch finanzielle Anreize gefördert 

werden  und  sollten  die  Spenderinnen  nur  eine  Entschädigung  zum 

Ausgleich  der  in  Verbindung  mit  der  Spende  entstandenen  Ausgaben 

erhalten.  

Zusätzlich  empfiehlt  die  EGE,  das  mit  der  ethischen  Prüfung  beauftragte 

Gremium  solle  sicherstellen,  dass  die  Antragsteller  Angaben  zu  den 

nachstehend aufgeführten Punkten machen. 

140  

Artikel 6 Absatz 3, http://cordis.europa.eu/fp7/ethics-ict_en.html. 

72

01_2007_5944_txt_EN.indd   72

12-02-2008   13:58:40

 
 
  
 
 
 
 
 
                                                 
1.  Antragsteller  müssen  ausdrücklich  nachweisen,  dass  bei  dem 

IV.2.3 ZUSÄTZLICHE KRITERIEN FÜR DAS FP7 

betreffenden  Projekt  die  Regulierungskriterien  eingehalten  werden,  und 

sie  müssen  die  einschlägigen  Rechts-  und/oder  Verwaltungsvorschriften 

IV.2.3.1 Verwendung von Alternativen zu hES-Zellen 

2.  Antragsteller  müssen  angeben,  dass  die 

im  betreffenden  Projekt 

möglich Berücksichtigung finden.  

Falls  in  Zukunft  Alternativen  zu  hES-Zellen  gefunden  werden,  die  das  gleiche 

Potenzial  aufweisen  wie  die  aus  Embryonen  gewonnenen  Stammzellen,  sollten 

die  Folgen  dieser  Entwicklungen  für  die  wissenschaftlichen  und  ethischen 

Aspekte  der  auf  hES-Zellen  basierenden  Forschungsprojekte  so  bald  wie 

IV.2.3.2 Rechte der Spendenden 

Die  Spende  von  Humanembryonen  zur  Gewinnung  von  hES-Zellen 

für 

Forschungszwecke  wirft  ein  moralisches  Dilemma  auf.  Dies  ergibt  sich  aus  der 

Tatsache,  dass  Humanembryonen  keine  „neutralen  Objekte“  sind.  Im  Rahmen 

der  informierten  Einwilligung  sollte  dieses  moralische  Dilemma  ausdrücklich 

angesprochen  werden  und  die  Entscheidung  den  Spendenden  überlassen 

bleiben. 

Den  Schutzrechten  der  Spendenden  muss  besondere  Aufmerksamkeit  gelten, 

was  konkret  bedeutet,  dass  diejenigen  Länder,  die  die  Beschaffung  von  hES-

Zellen erlauben, Angaben über das vom Antragsteller angewandte Verfahren zur 

Beschaffung  vorlegen  müssen.  Die  Informationen  müssen  Aussagen  darüber 

enthalten, dass die entsprechenden Maßnahmen den in der Europäischen Union 

geltenden  grundlegenden  ethischen  Prinzipien  und  Menschenrechten,  den  zum 

Zeitpunkt  der  Spende 

im  Land, 

in  dem  die  Spende  erfolgt,  geltenden 

einzelstaatlichen Rechtsvorschriften und anderen einschlägigen EU-Regelungen 
entsprechen141. Die Antragsteller müssen Angaben der Institutionen vorlegen, in 

denen  die  Stammzelllinien  gewonnen  wurden,  aus  denen  hervorgeht,  dass  bei 

der Gewinnung der hES-Zellen folgende Kriterien eingehalten wurden:  

des  Landes/der  Länder  angeben, 

in  dem/denen  die  Forschung 

durchgeführt  wird 

(Artikel 6  Absatz 3  des  FP7)140.  Für  weitere 

Informationen siehe Anhang 1. 

verwendeten  hES-Zellen  nichtimplantierten  IVF-Embryonen  entnommen 

wurden 

(siehe  den  nachfolgenden  Absatz  über  die  Rechte  der 

Spenderinnen). 

3.  Antragsteller müssen Angaben über den Schutz der personenbezogenen 

Daten  und  der  Privatsphäre  der  Spenderinnen  von  Embryonen  für  die 

Gewinnung von Stammzelllinien machen. 

4.  Antragsteller müssen Angaben über die Umstände der Embryonenspende 

machen  (z. B.  keine  finanziellen  Anreize,  Zahl  der  gewonnen  Eizellen 

usw.).  Um  die  Nicht-Kommerzialisierbarkeit  des  menschlichen  Körpers 

und  den  Schutz  der  freiwilligen  Spende  gemäß  Artikel 12  der  Richtlinie 

2004/23/EG  zu  gewährleisten,  sollte  nach  Auffassung  der  EGE  die 

Spende menschlicher Embryonen nicht durch finanzielle Anreize gefördert 

werden  und  sollten  die  Spenderinnen  nur  eine  Entschädigung  zum 

Ausgleich  der  in  Verbindung  mit  der  Spende  entstandenen  Ausgaben 

erhalten.  

Zusätzlich  empfiehlt  die  EGE,  das  mit  der  ethischen  Prüfung  beauftragte 

Gremium  solle  sicherstellen,  dass  die  Antragsteller  Angaben  zu  den 

nachstehend aufgeführten Punkten machen. 

140  

Artikel 6 Absatz 3, http://cordis.europa.eu/fp7/ethics-ict_en.html. 

141  

Siehe Richtlinie 2004/23/EG. 

73

01_2007_5944_txt_EN.indd   73

12-02-2008   13:58:40

 
 
  
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
                                                 
(cid:120)  Die Spendenden wurden in keiner Phase unter Druck gesetzt142. 

(cid:120)  Die  Gesundheit  der  Spenderin  wurde  nicht  durch  ovarielle  Überstimulation 

gefährdet. 

(cid:120)  Soweit neue hES-Zelllinien betroffen sind, erfolgte die informierte Einwilligung 

zur  Spende  eines  ursprünglich  für  die  Reproduktion  vorgesehenen  Embryos 
zu  Forschungszwecken  in  Kenntnis  der  Art  der  geplanten  Forschung143  und 

ihrer  (auch  kommerziellen)  Implikationen  sowie  in  Übereinstimmung  mit  den 

zum  Zeitpunkt  der  Spende  in  dem  Land,  in  dem  die  Spende  durchgeführt 

wurde, geltenden Bedingungen. 

(cid:120)  Die  Spendenden  wurden  informiert,  dass  sie  bis  zur  Phase  der  Gewinnung 

von Stammzellen ihre Einwilligung zurückziehen können.144 

(cid:120)  Unfruchtbarkeitsbehandlung und Forschung wurden in angemessener Weise 

voneinander getrennt. 

(cid:120)  Für  die  Spende  von  Embryonen  zu  Forschungszwecken  wurden  gemäß 

Artikel 12  der  Richtlinie  2004/23/EG  in  keiner  Phase  finanzielle  Anreize 

142  

143  
144  

für  Stammzellforschung 

Internationalen  Gesellschaft 

Siehe:  die  Leitlinien  der 
ISSCR 
(http://www.isscr.org/guidelines/,  S. 9:  Gewinnung  von  ‚Material‘:  Spende  von  Embryonen  und 
Gameten, die während einer klinischen Behandlung erzeugt wurden. Außer wenn im Rahmen des 
SCRO-Prozesses (SCRO = zuständiges Ethikgremium) ausdrücklich erlaubt, darf keine Erstattung 
der  direkten  Ausgaben  und  keine  finanzielle  Vergütung  irgendwelcher  Art  für  die  Spende  von 
Embryonen  oder  Gameten  gewährt  werden,  die  im  Laufe  einer  klinischen  Behandlung  erzeugt 
wurden und die über den klinischen Bedarf hinausgehen oder deren Qualität als für die klinische 
Verwendung nicht ausreichend angesehen wird. Forscher dürfen nicht verlangen, dass Mitglieder 
des für die Unfruchtbarkeitsbehandlung zuständigen Teams mehr Embryonen erzeugen oder mehr 
Oozyten gewinnen, als für eine optimale Chance auf Reproduktionserfolg erforderlich. Personen, 
die beschließen, ‚gelagertes Material‘ für Forschungszwecke zu spenden, sollten die Lagerkosten, 
die vor der Spendenentscheidung entstanden sind,  nicht erstattet werden.  Die Erstattung direkter 
Kosten,  die  den  Spendern  als  Folge  des  Einwilligungsprozesses  entstanden  sind,  kann  im  Laufe 
des SCRO-Prozesses festgelegt werden). 
Leitlinien der ISSCR, 11.3-11.3a (http://www.isscr.org/guidelines/). 
Bei der informierten Einwilligung ist die Tatsache zu berücksichtigen, dass das ‚Material‘ für die 
Gewinnung von Zellen für Forschungszwecke verwendet wird: „Die Einwilligung zur Spende von 
‚Material‘ für Forschungszwecke sollte zum Zeitpunkt der geplanten Übergabe des Materials an 
das Forscherteam eingeholt werden. Nur nach einer strengen Prüfung im Rahmen eines SCRO-
Mechanismus oder durch ein SCRO-Gremium kann die Verwendung von Material erlaubt werden, 
für das zwar eine frühere Einwilligung vorliegt, aber die Einholung einer neuen Einwilligung 
prohibitiv schwierig wäre.“ (Leitlinien der ISSCR, http://www.isscr.org/guidelines/). 

74

01_2007_5944_txt_EN.indd   74

12-02-2008   13:58:41

 
 
  
 
                                                 
gefährdet. 

zur  Spende  eines  ursprünglich  für  die  Reproduktion  vorgesehenen  Embryos 

zu  Forschungszwecken  in  Kenntnis  der  Art  der  geplanten  Forschung143  und 

ihrer  (auch  kommerziellen)  Implikationen  sowie  in  Übereinstimmung  mit  den 

zum  Zeitpunkt  der  Spende  in  dem  Land,  in  dem  die  Spende  durchgeführt 

(cid:120)  Die  Spendenden  wurden  informiert,  dass  sie  bis  zur  Phase  der  Gewinnung 

von Stammzellen ihre Einwilligung zurückziehen können.144 

(cid:120)  Unfruchtbarkeitsbehandlung und Forschung wurden in angemessener Weise 

voneinander getrennt. 

(cid:120)  Für  die  Spende  von  Embryonen  zu  Forschungszwecken  wurden  gemäß 

Artikel 12  der  Richtlinie  2004/23/EG  in  keiner  Phase  finanzielle  Anreize 

142  

143  

144  

Siehe:  die  Leitlinien  der 

Internationalen  Gesellschaft 

für  Stammzellforschung 

ISSCR 

(http://www.isscr.org/guidelines/,  S. 9:  Gewinnung  von  ‚Material‘:  Spende  von  Embryonen  und 

Gameten, die während einer klinischen Behandlung erzeugt wurden. Außer wenn im Rahmen des 

SCRO-Prozesses (SCRO = zuständiges Ethikgremium) ausdrücklich erlaubt, darf keine Erstattung 

der  direkten  Ausgaben  und  keine  finanzielle  Vergütung  irgendwelcher  Art  für  die  Spende  von 

Embryonen  oder  Gameten  gewährt  werden,  die  im  Laufe  einer  klinischen  Behandlung  erzeugt 

wurden und die über den klinischen Bedarf hinausgehen oder deren Qualität als für die klinische 

Verwendung nicht ausreichend angesehen wird. Forscher dürfen nicht verlangen, dass Mitglieder 

des für die Unfruchtbarkeitsbehandlung zuständigen Teams mehr Embryonen erzeugen oder mehr 

Oozyten gewinnen, als für eine optimale Chance auf Reproduktionserfolg erforderlich. Personen, 

die beschließen, ‚gelagertes Material‘ für Forschungszwecke zu spenden, sollten die Lagerkosten, 

die vor der Spendenentscheidung entstanden sind,  nicht erstattet werden.  Die Erstattung direkter 

Kosten,  die  den  Spendern  als  Folge  des  Einwilligungsprozesses  entstanden  sind,  kann  im  Laufe 

des SCRO-Prozesses festgelegt werden). 

Leitlinien der ISSCR, 11.3-11.3a (http://www.isscr.org/guidelines/). 

Bei der informierten Einwilligung ist die Tatsache zu berücksichtigen, dass das ‚Material‘ für die 

Gewinnung von Zellen für Forschungszwecke verwendet wird: „Die Einwilligung zur Spende von 

‚Material‘ für Forschungszwecke sollte zum Zeitpunkt der geplanten Übergabe des Materials an 

das Forscherteam eingeholt werden. Nur nach einer strengen Prüfung im Rahmen eines SCRO-

Mechanismus oder durch ein SCRO-Gremium kann die Verwendung von Material erlaubt werden, 

für das zwar eine frühere Einwilligung vorliegt, aber die Einholung einer neuen Einwilligung 

prohibitiv schwierig wäre.“ (Leitlinien der ISSCR, http://www.isscr.org/guidelines/). 

(cid:120)  Die Spendenden wurden in keiner Phase unter Druck gesetzt142. 

geboten145. Allerdings halten einige Mitglieder der EGE eine Reduzierung der 

(cid:120)  Die  Gesundheit  der  Spenderin  wurde  nicht  durch  ovarielle  Überstimulation 

IVF-Kosten für akzeptabel. 

(cid:120)  Soweit neue hES-Zelllinien betroffen sind, erfolgte die informierte Einwilligung 

Kann  irgendeines  dieser  Kriterien  wegen  früherer  Umstände,  unter  denen 

Zelllinien  gewonnen  wurden,  nicht  erfüllt  werden,  muss  der  Antragsteller  die 

Gründe  erläutern.  Das  für  die  ethische  Prüfung  zuständige  Gremium  hat  bei 

jedem  Einzelfall  zu  entscheiden,  wie  in  der  Angelegenheit  vorzugehen  ist.  Für 

neue hES-Zelllinien werden die obigen Kriterien nachdrücklich empfohlen (siehe 

wurde, geltenden Bedingungen. 

Absatz IV.2.4). 

Forscher  müssen  alle  die  Spendenden  betreffenden  Daten  in  anonymisierter 

Form  vorlegen.  Das  Verfahren  zur  Kodierung  der  Daten  ist  zu  erläutern  und 
entsprechend den einschlägigen Bestimmungen zu dokumentieren146,147. 

IV.2.4  Die  Notwendigkeit,  die  öffentliche  Steuerung  und  den  Dialog 

zwischen Wissenschaft und Gesellschaft kontinuierlich zu fördern 

Abgesehen von der Einwilligung der Spendenden und der Wahrung ihrer Rechte 

sind  geeignete  Maßnahmen  vorzusehen,  um  die  öffentliche  Steuerung  und  den 

Dialog zwischen Wissenschaft und Gesellschaft über die Ziele, Errungenschaften 

und Fehlschläge dieser Forschung zu fördern. Es sollten angemessene Mittel für 

den Zugriff der Öffentlichkeit auf relevante und verständliche Informationen über 

die  hES-Zellforschung  im  Rahmen  des  FP7  bereitgestellt  werden,  damit  diese 

Ziele kontinuierlich verfolgt und erreicht werden können. 

Wie der Ministerrat erklärt hat, unterstützt die Kommission die Einrichtung eines 

Europäischen  Registers  für  humane  embryonale  Stammzelllinien.  Mit  diesem 

Register  soll  die  Kontrolle  der  vorhandenen  hES-Zellen  in  Europa  ermöglicht 

145  

146  
147  

Artikel 12  der  Richtlinie  2004/23/EG:  „Die  Mitgliedstaaten  streben  danach,  freiwillige  und 
unentgeltliche Spenden von Geweben und Zellen sicherzustellen.“ 
Richtlinie über den Schutz personenbezogener Daten (95/46/EG). 
Bioethik-Übereinkommen  und  Zusatzprotokolle  des  Europarats,  Übereinkommen  des  Europarats 
zum  Schutz  des  Menschen  bei  der  automatischen  Verarbeitung  personenbezogener  Daten 
(Nr. 108). 

75

01_2007_5944_txt_EN.indd   75

12-02-2008   13:58:41

 
 
  
 
                                                 
 
 
  
 
 
 
 
 
                                                 
werden,  und  es  soll  dazu  beitragen,  dass  ihre  Verwendung  durch  Vermeidung 

unnötiger Generierung neuer hES-Zelllinien maximiert wird.  

In  absehbarer  Zeit  werden  die  Antragsteller  aufgefordert,  für  das  Register 

einschlägige Daten über hES-Zellen vorzulegen. Sie werden dann entsprechend 

wissenschaftlichen  und  ethischen  Standards  gespeichert,  die  von  den  dafür 

eigens neu eingesetzten Wissenschafts- und Ethikbeiräten festgelegt werden.  

Hinsichtlich  der  Verwendung  der  im  Register  eingetragenen  hES-Zelllinien 

empfiehlt die EGE Folgendes:  

(cid:120)  Sobald  das  Register  eingerichtet 

ist,  sollte  nach  der  erforderlichen 

Übergangszeit  die  Verwendung  der  eingetragenen  hES-Zelllinien  den  unter 

IV.2.3  angegebenen  Kriterien  entsprechen.  Die  Kommission  sollte  die 

Maßnahmen  entwickeln  und  Mittel  bereitstellen,  die  notwendig  sind,  damit 

diese  Anforderung  erfüllt  werden  kann,  und  aktiv  für  ihre  Aufrechterhaltung 

sorgen.  

(cid:120)  Die  Antragsteller  sollten  die  im  EU-Register  eingetragenen  hES-Zellen 

verwenden. Wenn andere hES-Zelllinien für FP7-Projekte verwendet werden 

sollen,  muss  dies  mit  wissenschaftlichen  und  ethischen  Gründen  begründet 

werden.  

(cid:120)  Auf der Website des Registers sollten Informationen über die eingetragenen 

hES-Zellen und über die positiven und negativen Ergebnisse der mit/an den 

zur  Verfügung  gestellten  hES-Zelllinien  durchgeführten  Forschungen 

veröffentlicht  werden.  Nachdrücklich  empfohlen  wird  auch,  dass  nach 

Abschluss eines Projekts zusätzlich zu den wissenschaftlichen, insbesondere 

gesundheitsbezogenen  Daten  benutzerfreundliche,  allen  EU-Bürgern  frei 

zugängliche  Informationen  über  die  Forschung  an  hES-Zellen  veröffentlicht 

werden. Das Portal sollte möglichst auch interaktive Elemente umfassen. 

Forscher,  die  in  diesem  Bereich  arbeiten,  haben  zum  einen  die  Verantwortung, 

die Öffentlichkeit über ihre Arbeit zu informieren, zum anderen sollen sie sich an 

den  gesellschaftlichen,  politischen  und  ethischen  Diskussionen  beteiligen.  Bei 

76

01_2007_5944_txt_EN.indd   76

12-02-2008   13:58:41

 
 
  
 
 
 
werden,  und  es  soll  dazu  beitragen,  dass  ihre  Verwendung  durch  Vermeidung 

den  offenen  Fragen,  etwa  wie  unterschiedliche  Rechte  gegeneinander 

unnötiger Generierung neuer hES-Zelllinien maximiert wird.  

abzuwägen sind und wie die Rangfolge widersprüchlicher Interessen festzulegen 

In  absehbarer  Zeit  werden  die  Antragsteller  aufgefordert,  für  das  Register 

ist, sollten Forscher am öffentlichen Diskurs teilnehmen und den demokratischen 

einschlägige Daten über hES-Zellen vorzulegen. Sie werden dann entsprechend 

Entscheidungsprozess  über  gemeinsame  gesellschaftliche  Ziele  respektieren. 

wissenschaftlichen  und  ethischen  Standards  gespeichert,  die  von  den  dafür 

Die  Antragsteller  sollten  Zeit,  Geld  und  Energie  investieren,  um  den  Dialog 

eigens neu eingesetzten Wissenschafts- und Ethikbeiräten festgelegt werden.  

zwischen Wissenschaft und Gesellschaft im Bereich der Forschung an humanen 

Hinsichtlich  der  Verwendung  der  im  Register  eingetragenen  hES-Zelllinien 

FP7  Projekte  für  Forschungen  an  hES-Zellen  einreichen,  werden  deshalb  mit 

empfiehlt die EGE Folgendes:  

Nachdruck  ermutigt,  den  Dialog  zwischen  Natur-  und  Geisteswissenschaften, 

(cid:120)  Sobald  das  Register  eingerichtet 

ist,  sollte  nach  der  erforderlichen 

also  die  soziale,  kulturell/religiöse,  philosophische  und  ethische  Reflexion  über 

Übergangszeit  die  Verwendung  der  eingetragenen  hES-Zelllinien  den  unter 

die  Forschung  an  hES-Zellen,  in  ihren  Projekten  zu  berücksichtigen  und  zu 

IV.2.3  angegebenen  Kriterien  entsprechen.  Die  Kommission  sollte  die 

diesem Zweck mit geisteswissenschaftlichen Disziplinen zusammenzuarbeiten.  

embryonalen  Stammzellen  voranzutreiben.  Antragsteller,  die  im  Rahmen  des 

Maßnahmen  entwickeln  und  Mittel  bereitstellen,  die  notwendig  sind,  damit 

diese  Anforderung  erfüllt  werden  kann,  und  aktiv  für  ihre  Aufrechterhaltung 

(cid:120)  Die  Antragsteller  sollten  die  im  EU-Register  eingetragenen  hES-Zellen 

verwenden. Wenn andere hES-Zelllinien für FP7-Projekte verwendet werden 

sorgen.  

werden.  

IV.3  Notwendigkeit  weiterer  Forschung  und  einer  kontinuierlichen 

öffentlichen Debatte  

sollen,  muss  dies  mit  wissenschaftlichen  und  ethischen  Gründen  begründet 

Da die ethischen Auseinandersetzungen über hES-Zellen weder wissenschaftlich 

(cid:120)  Auf der Website des Registers sollten Informationen über die eingetragenen 

finanzielle  Mittel  bereitzustellen,  um  weitere  multidisziplinäre,  internationale 

hES-Zellen und über die positiven und negativen Ergebnisse der mit/an den 

Forschungskooperationen  zu  den  ethischen  Implikationen  der  embryonalen 

zur  Verfügung  gestellten  hES-Zelllinien  durchgeführten  Forschungen 

Stammzellforschung zu fördern sowie eine fundierte öffentliche Debatte darüber 

veröffentlicht  werden.  Nachdrücklich  empfohlen  wird  auch,  dass  nach 

anzustoßen.  

Abschluss eines Projekts zusätzlich zu den wissenschaftlichen, insbesondere 

Die EGE betrachtet folgende Themen für diese Forschung und den öffentlichen 

gesundheitsbezogenen  Daten  benutzerfreundliche,  allen  EU-Bürgern  frei 

Diskurs als von besonderem und unmittelbarem Interesse: 

zugängliche  Informationen  über  die  Forschung  an  hES-Zellen  veröffentlicht 

(cid:120)  die  potentiell  konfligierenden  Ziele  von  wirtschaftlicher  Wettbewerbsfähigkeit 

werden. Das Portal sollte möglichst auch interaktive Elemente umfassen. 

und Vereinbarkeit mit ethischen Standards;  

noch  politisch  gelöst  worden  sind,  empfiehlt  die  EGE,  im  Rahmen  des  FP7 

Forscher,  die  in  diesem  Bereich  arbeiten,  haben  zum  einen  die  Verantwortung, 

einschließlich  der  Vermarktung  von  Produkten  und  Verfahren,  die  aus  der 

die Öffentlichkeit über ihre Arbeit zu informieren, zum anderen sollen sie sich an 

Verwendung humaner embryonaler Stammzelllinien resultieren;  

den  gesellschaftlichen,  politischen  und  ethischen  Diskussionen  beteiligen.  Bei 

(cid:120)  die  Verwendung  des  menschlichen  Körpers  für  die  moderne  Medizin 

77

01_2007_5944_txt_EN.indd   77

12-02-2008   13:58:42

 
 
  
 
 
 
 
 
  
 
 
 
 
(cid:120)  die Anthropologie, die der Forschung an humanen embryonalen Stammzellen 

zugrunde 

liegt, 

insbesondere  unter  Berücksichtigung  der  mit  der 

Stammzellenforschung verbundenen Chimären- und Hybridforschung;  

(cid:120)  die  Verbesserung  der  klinischen  und 

therapeutischen  Betreuung  von 

Patienten,  die  unter  den  am  häufigsten  auftretenden  Krankheiten  leiden,  mit 

denen sich die therapeutische und/oder auf bestimmte Krankheiten bezogene 

hES-Zellforschung befasst, hinsichtlich ihrer Bedürfnisse; 

(cid:120)  die  langfristige  Strategie  im  Hinblick  auf  die  Anzahl  der  für  erfolgreiche 

Therapien erforderlichen Stammzelllinien und ihres Gewinnungsprozesses;  

(cid:120)  der  Zusammenhang  zwischen  hES-Zellforschung  und  Fragen  der 

regenerativen  Medizin  und  der  gesundheitsbezogenen  Gerechtigkeit 

einschließlich des Aspekts der globalen Gerechtigkeit; 

(cid:120)  die  Beziehungen  zwischen  Natur-  und  Geisteswissenschaften  sowie 

zwischen  Wissenschaft  und  Gesellschaft 

im  Zusammenhang  mit  der 

Entwicklung neuer Technologien;  

(cid:120)  die laufenden Bemühungen um wissenschaftliche Alternativen zur Forschung 

an hES-Zellen und deren anthropologische und ethische Interpretation. 

Die  EGE  bekräftigt,  dass 

für  zahlreiche  Fragen  noch  weitere  Klärung, 

interdisziplinäre Forschung, gründliche ethische Bewertung und, falls künftig als 

notwendig  erachtet,  auch  angemessene  rechtliche  Schritte  erforderlich  sind. 

Momentan  erfordern  nach  Ansicht  der  EGE  folgende  Fragen  besondere 

Beachtung:  

1.  Die  derzeitigen  Bestimmungen  für  die  Patentierung  von  aus  hES-Zellen 

gewonnenem  Material  müssen  angegangen  werden.  Angesichts  der 

neuesten Entwicklungen in der Forschung und unter Berücksichtigung der 

laufenden  Debatte  über  die  Grenzen  der  Patentierung  biologischen 

78

01_2007_5944_txt_EN.indd   78

12-02-2008   13:58:42

 
 
  
 
 
 
(cid:120)  die Anthropologie, die der Forschung an humanen embryonalen Stammzellen 

zugrunde 

liegt, 

insbesondere  unter  Berücksichtigung  der  mit  der 

Stammzellenforschung verbundenen Chimären- und Hybridforschung;  

Materials  möchte  sich  die  EGE  mit  dieser  Frage  zu  einem  späteren 
Zeitpunkt befassen148.  

(cid:120)  die  Verbesserung  der  klinischen  und 

therapeutischen  Betreuung  von 

2.  Die durch eine sowohl die freiwillige Spende149 als auch die kommerzielle 

Patienten,  die  unter  den  am  häufigsten  auftretenden  Krankheiten  leiden,  mit 

Verwendung  von  Derivaten  humaner  Substanzen 

fördernde  Politik 

denen sich die therapeutische und/oder auf bestimmte Krankheiten bezogene 

verursachte Spannung muss behandelt werden. 

hES-Zellforschung befasst, hinsichtlich ihrer Bedürfnisse; 

(cid:120)  die  langfristige  Strategie  im  Hinblick  auf  die  Anzahl  der  für  erfolgreiche 

Die  EGE  unterstreicht,  dass  ihrer  Auffassung  nach  die  Verwendung  humaner 

Therapien erforderlichen Stammzelllinien und ihres Gewinnungsprozesses;  

Embryonen  zur  Erzeugung  von  Stammzellen  so  weit  wie  möglich  reduziert 

(cid:120)  der  Zusammenhang  zwischen  hES-Zellforschung  und  Fragen  der 

werden  sollte.  Die  EGE  ruft  die  Europäische  Union  auf,  geeignete  Systeme  zu 

regenerativen  Medizin  und  der  gesundheitsbezogenen  Gerechtigkeit 

entwickeln, um die Verwendung humaner Embryonen auf Fälle zu reduzieren, in 

einschließlich des Aspekts der globalen Gerechtigkeit; 

denen es keine Alternative gibt. 

(cid:120)  die  Beziehungen  zwischen  Natur-  und  Geisteswissenschaften  sowie 

zwischen  Wissenschaft  und  Gesellschaft 

im  Zusammenhang  mit  der 

Entwicklung neuer Technologien;  

(cid:120)  die laufenden Bemühungen um wissenschaftliche Alternativen zur Forschung 

an hES-Zellen und deren anthropologische und ethische Interpretation. 

Die  EGE  bekräftigt,  dass 

für  zahlreiche  Fragen  noch  weitere  Klärung, 

interdisziplinäre Forschung, gründliche ethische Bewertung und, falls künftig als 

notwendig  erachtet,  auch  angemessene  rechtliche  Schritte  erforderlich  sind. 

Beachtung:  

IV.4  Prüfung  der  Empfehlungen  und  Kommunikation  mit  dem 
Beirat  des  Europäischen  Registers  für  humane  embryonale 
Stammzelllinien 
Die  EGE  würde  einen  intensiven  Austausch  mit  dem  Beirat  des  Europäischen 

Registers  für  humane  embryonale  Stammzelllinien  begrüßen,  insbesondere  mit 

dem  Ethik-Beirat  des  Registers.  Das  Ziel  wäre  es,  die  ethischen  Bedenken 

hinsichtlich  der  Beschaffung  von  Stammzellen  und  der  Speicherung  von  Daten 

im Lichte der laufenden Fortschritte in diesem Bereich gemeinsam behandeln zu 

Momentan  erfordern  nach  Ansicht  der  EGE  folgende  Fragen  besondere 

können.  

Die  konkrete  Art  und  Weise  dieser  Zusammenarbeit  sollte  spezifiziert  und 

etabliert  werden,  und  sie  sollte  von  der  Kommission  entsprechend  unterstützt 

1.  Die  derzeitigen  Bestimmungen  für  die  Patentierung  von  aus  hES-Zellen 

und finanziert werden. 

gewonnenem  Material  müssen  angegangen  werden.  Angesichts  der 

neuesten Entwicklungen in der Forschung und unter Berücksichtigung der 

laufenden  Debatte  über  die  Grenzen  der  Patentierung  biologischen 

148  

149  

Die EGE hat eine Stellungnahme über „Ethische Aspekte der Patentierung von Erfindungen unter 
Nutzung humaner Stammzellen“ herausgegeben, 
http://www.ec.europa.eu/european_group_ethics/docs/avis16_en.pdf 
Artikel 12  der  Richtlinie  2004/23/EG:  „Die  Mitgliedstaaten  streben  danach,  freiwillige  und 
unentgeltliche Spenden von Geweben und Zellen sicherzustellen.“. 

79

01_2007_5944_txt_EN.indd   79

12-02-2008   13:58:42

 
 
  
 
 
 
 
 
  
 
 
 
 
                                                 
 
IV.4.1 Prüfungsbedarf 

Die  EGE  schlägt  vor,  die  beschlossenen  ethischen  Leitlinien  im  Lichte  der 

wissenschaftlichen, 

rechtlichen  und  gesellschaftlichen  Entwicklungen  zu 

überprüfen.  

Die Europäische Gruppe für Ethik in Naturwissenschaften  
und neuen Technologien150 

Der Vorsitzende: Göran Hermerén 

Die Mitglieder: 

Emmanuel Agius 

Diana Banati 

Anne Cambon-Thomsen 

Rafael Capurro 

Inez de Beaufort 

Jozef Glasa 

Hille Haker 

Julian Kinderlerer 

Krzysztof Marczewski 

Paula Martinho Da Silva 

Linda Nielsen 

Pere Puigdomenech-Rosell 

Günter Virt 

150  

Translation from the English original — only the English text is authentic — available at: 
http://ec.europa.eu/european_group_ethics/activities/docs/opinion_22_final_follow_up_en.pdf 

80

01_2007_5944_txt_EN.indd   80

12-02-2008   13:58:43

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 
ANNEXES 

IV.4.1 Prüfungsbedarf 

Die  EGE  schlägt  vor,  die  beschlossenen  ethischen  Leitlinien  im  Lichte  der 

wissenschaftlichen, 

rechtlichen  und  gesellschaftlichen  Entwicklungen  zu 

überprüfen.  

Die Europäische Gruppe für Ethik in Naturwissenschaften  

und neuen Technologien150 

Der Vorsitzende: Göran Hermerén 

Die Mitglieder: 

Emmanuel Agius 

Diana Banati 

Anne Cambon-Thomsen 

Rafael Capurro 

Inez de Beaufort 

Jozef Glasa 

Hille Haker 

Julian Kinderlerer 

Krzysztof Marczewski 

Paula Martinho Da Silva 

Linda Nielsen 

Pere Puigdomenech-Rosell 

Günter Virt 

150  

Translation from the English original — only the English text is authentic — available at: 

http://ec.europa.eu/european_group_ethics/activities/docs/opinion_22_final_follow_up_en.pdf 

01_2007_5944_txt_EN.indd   81

12-02-2008   13:58:43

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
 
 
 
  
 
 
 
 
 
ANNEX I 

THE SIXTH FRAMEWORK PROGRAMME 
The sixth framework programme covers Community 

activities in the field of research, technological development 

and demonstration (RTD) for the period 2002 to 2006 

PROCEDURAL MODALITIES FOR RESEARCH ACTIVITIES INVOLVING 
BANKED OR ISOLATED HUMAN EMBRYONIC STEM CELLS IN CULTURE TO 
BE FUNDED UNDER COUNCIL DECISION 2002/834/EC  

Introduction  

Pursuant  to  the  Council  decision  adopting  a  specific  programme  for  research, 
technological development and demonstration, ‘Integrating and strengthening the 
European  research  area’  (2002–06) (151),  and  in  particular  Article  6(3),  the 
Commission  has  adopted  procedural  modalities  to  clarify  the  procedure  which 
the  Commission  will  follow  when  evaluating,  selecting  and  supporting  research 
projects involving  the  use  of  banked or  isolated human  embryonic  stem  cells  in 
culture.  

in  culture 

Procedural modalities for research activities involving banked or isolated human 
embryonic  stem  cells 
funded  under  Council  Decision 
to  be 
2002/834/EC (152) 
When evaluating, and selecting proposals involving the use of banked or isolated 
human  embryonic  stem  cells  (hESCs)  in  culture  and  negotiating  the  related 
contracts, the Commission uses the following procedure: 

1.  Proposal:  Proposers  are  requested  to  address,  in  the  application  form,  the 
potential  ethical  aspects  of  the  proposed  research  in  terms  of  its  objectives, 
methodology  and  the  possible  implications  of  the  results.  Pursuant  to  the 
decision on the work programme in the framework of the specific programme for 
‘Integrating  and 
research, 
the  work 
strengthening 
programme),  they  should  justify  the  research  design,  explain  how  ethical 
requirements  will  be  fulfilled  and  indicate  the  relevant  national  legal  and/or 
regulatory requirements of the country(ies) where the research takes place. 

technical  development  and  demonstration  on 

research  area’ (153) 

the  European 

(hereinafter 

(151)  
(152)  
(153)  

OJ L 294, 29.10.2002, p. 1. 
C(2003) 2952 of 11.11.2003. 
C(2002) 4789 of 9.12.2002.  

82

01_2007_5944_txt_EN.indd   82

12-02-2008   13:58:43

 
 
  
 
 
 
 
 
 
 
                                                 
ANNEX I 

THE SIXTH FRAMEWORK PROGRAMME 

The sixth framework programme covers Community 

activities in the field of research, technological development 

and demonstration (RTD) for the period 2002 to 2006 

PROCEDURAL MODALITIES FOR RESEARCH ACTIVITIES INVOLVING 

BANKED OR ISOLATED HUMAN EMBRYONIC STEM CELLS IN CULTURE TO 

BE FUNDED UNDER COUNCIL DECISION 2002/834/EC  

Introduction  

Pursuant  to  the  Council  decision  adopting  a  specific  programme  for  research, 

technological development and demonstration, ‘Integrating and strengthening the 

European  research  area’  (2002–06) (151),  and  in  particular  Article  6(3),  the 

Commission  has  adopted  procedural  modalities  to  clarify  the  procedure  which 

the  Commission  will  follow  when  evaluating,  selecting  and  supporting  research 

projects involving  the  use  of  banked or  isolated human  embryonic  stem  cells  in 

culture.  

Procedural modalities for research activities involving banked or isolated human 

embryonic  stem  cells 

in  culture 

to  be 

funded  under  Council  Decision 

2002/834/EC (152) 

When evaluating, and selecting proposals involving the use of banked or isolated 

human  embryonic  stem  cells  (hESCs)  in  culture  and  negotiating  the  related 

contracts, the Commission uses the following procedure: 

1.  Proposal:  Proposers  are  requested  to  address,  in  the  application  form,  the 

potential  ethical  aspects  of  the  proposed  research  in  terms  of  its  objectives, 

methodology  and  the  possible  implications  of  the  results.  Pursuant  to  the 

decision on the work programme in the framework of the specific programme for 

research, 

technical  development  and  demonstration  on 

‘Integrating  and 

strengthening 

the  European 

research  area’ (153) 

(hereinafter 

the  work 

programme),  they  should  justify  the  research  design,  explain  how  ethical 

requirements  will  be  fulfilled  and  indicate  the  relevant  national  legal  and/or 

regulatory requirements of the country(ies) where the research takes place. 

(151)  

(152)  

(153)  

OJ L 294, 29.10.2002, p. 1. 

C(2003) 2952 of 11.11.2003. 

C(2002) 4789 of 9.12.2002.  

2. Evaluation: Proposals are evaluated in accordance with the procedure set out 
in  the  ‘Guidelines  on  proposal  evaluation  and  selection  procedures’  established 
by Decision C(2003) 883 (hereinafter the guidelines) by a panel of independent 
experts, after those experts have individually examined the projects in the light of 
each block of evaluation criteria.  

The experts also assess whether the use of banked or isolated hESCs in culture 
is necessary in order to achieve the scientific objectives set forth in the proposal. 
This point is documented in the consensus report provided for in the guidelines 

3.  Ethical  review:  The  ethical  review  is  conducted  in  accordance  with  the 
procedure  set  out  in  the  guidelines  and  the  common  evaluation  criteria  for 
evaluating proposals set out in Annex B to the work programme. 

In  the  course  of  that  review,  the  ethical  review  panel  examines  whether  the 
proposal  complies  with  the  rules  relating  to  ethics  set  out  in  Decision  No 
1513/2002/EC (154) and Decision 2002/834/EC. 

In addition, that panel assesses: 

(a)  whether  the  proposers  have  taken  into  account  the  legislation, 
regulations,  ethical  rules  and/or  codes  of  conduct  in  place  in  the 
country(ies)  where  the  research  using  banked  or  isolated  hESC  in 
culture  is  to  take  place,  including  the  procedures  for  obtaining 
informed consent; 

(b) 

the source of the banked or isolated hESCs in culture;  

(c) 

the measures taken to protect personal data, including genetic data, 
and privacy; 

(d) 

the nature of financial inducements, if any. 

When  preparing  the  ethical  review,  the  Commission  may  request  that  the 
proposers provide additional information on the way the ethical issues raised by 
the project will be handled. 

4.  National  approvals  and  opinions  of  competent  ethics  committee:  The 
Commission ascertains that the participants have received appropriate approval 
from the national authority and/or a favourable opinion from the competent ethics 
committee before the signature of the contract, or before the banked or isolated 
hESCs in culture are to be used in the project. 

5.  Negotiation:  During  the  negotiation  of  the  contract,  account  is  taken  of  the 
results  of  the  ethical  review.  The  result  of  the  ethical  review  is  reflected  in  the 

(154)  

OJ L 231, 29.8.2002, p. 1. 

83

01_2007_5944_txt_EN.indd   83

12-02-2008   13:58:44

 
 
  
 
 
 
 
 
 
 
                                                 
 
 
  
 
 
 
 
 
 
 
 
                                                 
technical  annex  of  the  contract.  Where  the  approval  of  the  national  authority 
and/or  a  favourable  opinion  from  a  local  ethical  committee  is/are  not  obtained 
before  the  start  of  the  contract,  the  contract  includes  a  special  clause  requiring 
that  the  relevant  authorisation  or  opinion  be  obtained  before  the  start  of  the 
corresponding research. 

6.  Selection:  In  accordance  with  Article  6(3)  of  Decision  2002/834/EC  any 
proposal  involving  the  use  of  human  embryonic  stem  cells  is  submitted  for  an 
opinion  to  the  Programme  Committee  established  by  Article  7(1)  of  Decision 
2002/834/EC. 

84

01_2007_5944_txt_EN.indd   84

12-02-2008   13:58:44

 
 
  
 
 
technical  annex  of  the  contract.  Where  the  approval  of  the  national  authority 

and/or  a  favourable  opinion  from  a  local  ethical  committee  is/are  not  obtained 

before  the  start  of  the  contract,  the  contract  includes  a  special  clause  requiring 

that  the  relevant  authorisation  or  opinion  be  obtained  before  the  start  of  the 

corresponding research. 

6.  Selection:  In  accordance  with  Article  6(3)  of  Decision  2002/834/EC  any 

proposal  involving  the  use  of  human  embryonic  stem  cells  is  submitted  for  an 

opinion  to  the  Programme  Committee  established  by  Article  7(1)  of  Decision 

2002/834/EC. 

ANNEX II 

Ethical review procedures in FP7 

Ethical issues  

Describe any ethical issues that may arise in their proposal. In particular, you should explain the 
benefit and burden of their experiments and the effects it may have on the research subject.  

The following special issues should be taken into account. 

Informed consent: When describing issues relating to informed consent, it will be necessary to 
illustrate  an  appropriate  level  of  ethical  sensitivity,  and  consider  issues  of  insurance,  incidental 
findings and the consequences of leaving the study.  

Data protection issues: Avoid the unnecessary collection and use of personal data. Identify the 
source  of  the  data,  describing  whether  it  is  collected  as  part  of  the  research  or  is  previously 
collected  data  being  used.  Consider  issues  of  informed  consent  for  any  data  being  used. 
Describe how the personal identity of the data is protected.  

Use of animals: Where animals are used in research, the application of the 3Rs (‘replace, reduce, 
refine’) must be convincingly addressed. Numbers of animals should be specified. Describe what 
happens to the animals after the research experiments.  
Human  embryonic  stem  cells:  Research  proposals  that  will  involve  human  embryonic  stem 
cells (hESCs) will have to address all the following specific points:  
(cid:120) 

the  necessity  to  use  hESCs  in  order  to  achieve  the  scientific  objectives  set  forth  in  the 
proposal; 

(cid:120)  whether  the  applicants  have  taken  into  account  the  legislation,  regulations,  ethical  rules 
and/or  codes  of  conduct  in  place  in  the  country(ies)  where  the  research  using  hESCs  is  to 
take place, including the procedures for obtaining informed consent;  
the source of the hESCs; 
the measures taken to protect personal data, including genetic data, and privacy;  
the nature of financial inducements, if any.  

(cid:120) 
(cid:120) 
(cid:120) 

Identify  the  countries  where  research  will  be  undertaken  and  which  ethical  committees  and 
regulatory organisations will need to be approached during the life of the project.   

Include the ethical issues table below. If you indicate YES to any issue, please identify the pages 
in  the  proposal  where  this  ethical  issue  is  described.  Answering  ‘YES’  to  some  of  these  boxes 
does not automatically lead to an ethical review. It enables the independent experts to decide if 
an ethical review is required. If you are sure that none of the issues apply to your proposal, simply 
tick the YES box in the last row.  

(No recommended length for section 4 — depends on the number of such issues involved.)  

Notes:  Only  in  exceptional  cases  will  additional  information  be  sought  for  clarification,  which 
means that any ethical review will be performed solely on the basis of the information available in 
the proposal (1). Projects raising specific ethical issues such as research intervention on human 
beings, research on human embryos and human embryonic stem cells and non-human primates 
are automatically submitted for ethical review.  

85

01_2007_5944_txt_EN.indd   85

12-02-2008   13:58:44

 
 
  
 
 
 
 
  
 
 
 
 
 
To ensure compliance with ethical principles, the Commission services will undertake ethics  
audit(s) of selected projects at its discretion. A website is being prepared aiming to provide clear, 
helpful information on ethical issues.  

(1) 

Such as clinical trials, and research involving invasive techniques on persons (e.g. taking of tissue 
samples, examinations of the brain).  

86

01_2007_5944_txt_EN.indd   86

12-02-2008   13:58:45

 
 
  
 
 
  
To ensure compliance with ethical principles, the Commission services will undertake ethics  

audit(s) of selected projects at its discretion. A website is being prepared aiming to provide clear, 

helpful information on ethical issues.  

ETHICAL ISSUES TABLE 

PAGE  

YES  

Informed consent  
• Does the proposal involve children?  
• Does the proposal involve patients or persons not 
able to give consent?  
• Does the proposal involve adult healthy volunteers?  

• Does the proposal involve human genetic material?  

• Does the proposal involve human biological 
samples?  
• Does the proposal involve human data collection?  

Research on human embryos/foetuses 
• Does the proposal involve human embryos?  
• Does the proposal involve human foetal tissue/cells?  

• Does the proposal involve human embryonic stem 
cells?  

Privacy  
• Does the proposal involve processing of genetic 
information or personal data (e.g. health, sexual 
lifestyle, ethnicity, political opinion, religious or 
philosophical conviction)?  
• Does the proposal involve tracking the location or 
observation of people?  

Research on animals  
• Does the proposal involve research on animals?  

• Are those animals transgenic small laboratory 
animals?  

• Are those animals transgenic farm animals?  
• Are those animals cloning farm animals?  
• Are those animals non-human primates?  
Research involving developing countries  
• Use of local resources (genetic, animal, plant, etc.)  

• Benefit to local community (capacity building, i.e. 
access to healthcare, education, etc.)  
Dual use  
• Research having potential military/terrorist application 

I CONFIRM THAT NONE OF THE ABOVE ISSUES 
APPLY TO MY PROPOSAL  

87

01_2007_5944_txt_EN.indd   87

12-02-2008   13:58:45

(1) 

Such as clinical trials, and research involving invasive techniques on persons (e.g. taking of tissue 

samples, examinations of the brain).  

 
 
  
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEX III  

LIST  OF  PROJECTS  SUPPORTED  WITHIN  THE  SIXTH  FRAMEWORK 
PROGRAMME AND WITHIN THE HEALTH DIRECTORATE, INVOLVING HESCS 

1.  LYMPHANGIOGENOMICS:  fundamental  research  to  better  understand 
the  lymphatic  vasculature  with  a  view  to  developing  therapies  to  control 
the  growth  of  lymphatic  vessels  (e.g.  cancer,  inflammatory  diseases,  for 
tissue  ischæmia,  lymphœdema)/EUR 9 million,  13  partners,  8  different 
countries (FI, FR, SE, AT, IT, CH, DE, BE) 

2.  REPROTECT: model to study reproductive toxicity by a combination of in 
vitro  and  sensor  technologies/EUR  9.1 million,  26  partners,  9  different 
countries (DE, NL, BE, IT, UK, FR, SE, BG, AT)  

3.  BETACELL  THERAPY: 

to  generate  insulin-
producing  beta  cells/EUR 11.8 million,  29  partners,  7  different  countries 
(BE, DK, IL, ES, SE, CH, UK)  

treatment  of  diabetes: 

4.  EUROSTEMCELL:  comparison  of  the  properties  of  adult,  foetal  and 
embryonic  stem  cells 
including 
medicines in  different  set  of diseases/disorders  (skin,  musculoskeletal, 
neurodegenerative  diseases)/EUR 11.9 million,  14  partners,  7  different 
countries (UK, SE, FR, IT, DE, CH, DK)  

the  development  of 

therapies 

for 

5.  HEART REPAIR: underlying principles of cardiac muscle cell formation for 
stem  cell  replacement  therapies  for  heart  failure  and  cardiac  repair. 
Comparison  of  the  potential  of  bone  marrow  derived  stem  cells  and 
embryonic  stem  cells/EUR 11.4 million,  27  partners,  8  different  countries 
(NL, DE, UK, IT, FR, ES, CH, SE)  

6.  OSTEOCORD:  comparison  of 

the  properties  of  embryonic  stem 
cells and umbilical  cord  blood  stem  cells  in  view  of  new  applications  and 
better characterisation of umbilical cord blood stem cells/EUR  2.5 million, 
9 partners, 5 different countries (UK, DK, DE, IL, PT)  

7.  THERCORD:  development  and  preclinical  testing  of  cord  blood-derived 
cell  therapy  products,  where  comparative  research  on  the  potential  of 
umbilical  cord  blood  stem  cells  and  embryonic  stem  cell 
is 
performed/EUR 1.8 million,  9  partners,  6  different  countries  (IT,  UK,  DE, 
NL, ES, IL) 

88

01_2007_5944_txt_EN.indd   88

12-02-2008   13:58:46

 
 
  
 
 
 
 
ANNEX III  

LIST  OF  PROJECTS  SUPPORTED  WITHIN  THE  SIXTH  FRAMEWORK 

PROGRAMME AND WITHIN THE HEALTH DIRECTORATE, INVOLVING HESCS 

1.  LYMPHANGIOGENOMICS:  fundamental  research  to  better  understand 

the  lymphatic  vasculature  with  a  view  to  developing  therapies  to  control 

the  growth  of  lymphatic  vessels  (e.g.  cancer,  inflammatory  diseases,  for 

tissue  ischæmia,  lymphœdema)/EUR 9 million,  13  partners,  8  different 

countries (FI, FR, SE, AT, IT, CH, DE, BE) 

2.  REPROTECT: model to study reproductive toxicity by a combination of in 

vitro  and  sensor  technologies/EUR  9.1 million,  26  partners,  9  different 

countries (DE, NL, BE, IT, UK, FR, SE, BG, AT)  

3.  BETACELL  THERAPY: 

treatment  of  diabetes: 

to  generate  insulin-

producing  beta  cells/EUR 11.8 million,  29  partners,  7  different  countries 

(BE, DK, IL, ES, SE, CH, UK)  

4.  EUROSTEMCELL:  comparison  of  the  properties  of  adult,  foetal  and 

embryonic  stem  cells 

for 

the  development  of 

therapies 

including 

medicines in  different  set  of diseases/disorders  (skin,  musculoskeletal, 

neurodegenerative  diseases)/EUR 11.9 million,  14  partners,  7  different 

countries (UK, SE, FR, IT, DE, CH, DK)  

5.  HEART REPAIR: underlying principles of cardiac muscle cell formation for 

stem  cell  replacement  therapies  for  heart  failure  and  cardiac  repair. 

Comparison  of  the  potential  of  bone  marrow  derived  stem  cells  and 

embryonic  stem  cells/EUR 11.4 million,  27  partners,  8  different  countries 

(NL, DE, UK, IT, FR, ES, CH, SE)  

6.  OSTEOCORD:  comparison  of 

the  properties  of  embryonic  stem 

cells and umbilical  cord  blood  stem  cells  in  view  of  new  applications  and 

better characterisation of umbilical cord blood stem cells/EUR  2.5 million, 

9 partners, 5 different countries (UK, DK, DE, IL, PT)  

7.  THERCORD:  development  and  preclinical  testing  of  cord  blood-derived 

cell  therapy  products,  where  comparative  research  on  the  potential  of 

umbilical  cord  blood  stem  cells  and  embryonic  stem  cell 

is 

performed/EUR 1.8 million,  9  partners,  6  different  countries  (IT,  UK,  DE, 

NL, ES, IL) 

8.  VITROCELLOMICS:  on  reducing  animal  experimentation  in  preclinical 
predictive  drug  testing  by  human  hepatic  in  vitro  models  derived  from 
embryonic  stem  cells/EUR 2.9 million,  9  partners,  4  different  countries 
(SE, DE, PT, IT) 

9.  ESTOOLS:  better  characterisation  of  52  different  existing  human 
embryonic  stem  cell  lines  from  all  over  the  world  to  generate  knowledge 
on the fundamental processes governing stem cell differentiation in view of 
biomedical  discovery.  This  project  will  bring  a  major  contribution  to  the 
various 
issue  of 
characterisation/EUR 12 million,  20  partners,  10  different  countries  (UK, 
CH, IL, FI, DE, IT, ES, CZ, SE, NL) 

launched  around 

the  world  on 

initiatives 

the 

10. EUROHEAR:  fundamental  research  on  the  development  and  function  of 
the 
hearing 
impairments/EUR 12.5 million, 26 partners, 12 different countries (FR, UK, 
IL, NL, DE, IT, ES, FI, SE, BE, HU, TN) 

hereditary 

including 

genetics 

inner 

ear 

of 

11. STEMS:  preclinical  evaluation  of  stem  cell 

therapy 

in  stroke/ 

EUR 2.4 million, 9 partners, 5 different countries (FR, SE, DK, DE, CZ) 

12. STEMSTROKE:  stem  cell  therapy  for  stroke.  Outcome  expected:  first 
in 

clinical 
therapy 
stroke/EUR 2.5 million, 6 partners, 3 different countries (UK, SE, DE) 

application 

protocol 

stem 

cell 

for 

of 

13. STEM-HD: using mutant hESC line (with the Huntington genetic defect) to 
to  perform  drug  screening/ 

understand  Huntington’s  disease  and 
EUR 2.5 million, 8 partners, 5 different countries (FR, IL, IT, UK, BE) 

14. CARCINOGENOMICS: 

to  assess  genotoxic  and 
carcinogenomic  properties  of  chemical  compounds/EUR 10.4 million,  20 
partners, 12 different countries (NL, ES, BE, SE, IE, DK, UK, DE, IT, AT, 
CH, FR) 

in  vitro 

testing 

15. CRYSTAL:  cryobanking  of  stem  cells 

therapeutic 
applications/EUR 2.4 million, 8 partners, 6 different countries (DE, NL, AT, 
CH, BE, FR) 

for  human 

16. SIROCCO:  fundamental  research  on  regulatory  RNAs/EUR 11.8 million, 
18 partners, 10 different countries (UK, HU, FR, CH, NL, DE, IT, DK, ES, 
IL) 

17. INVITROHEART: 

cardiotoxicity  and  drug 
development/EUR 2.7 million,  9  partners,  4  different  countries  (SE,  DE, 
DK, BE) 

testing 

vitro 

for 

in 

18. NEUROCREEN: 

screening 

of 

neuro-therapeutic 

molecules/ 

EUR 2.6 million, 9 partners, 4 different countries (UK, IT, DE, HU) 

89

01_2007_5944_txt_EN.indd   89

12-02-2008   13:58:46

 
 
  
 
 
 
 
 
 
  
 
  ANNEX IV 

  EU MEMBER STATES’ REGULATORY FRAMEWORK 

  FOR HESC RESEARCH 

Information provided by EU-27 national 

ethics councils, updated May 2007  

90

01_2007_5944_txt_EN.indd   90

12-02-2008   13:58:46

 
 
  
 
 
 
 
 
 
 
 
 
  ANNEX IV 

  EU MEMBER STATES’ REGULATORY FRAMEWORK 

  FOR HESC RESEARCH 

Information provided by EU-27 national 

ethics councils, updated May 2007  

Regulatory frame applying to AUSTRIA 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

7 

8 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
The hESC research (Untersuchung/Behandlung rather in the sense of medical 
examination and treatment) is limited to the field of reproductive medicine. It is therefore 
covered in the legislation applying to reproductive medicine 
(Fortplanzungsmedizingesetz §9.(1); http://www.ris.bka.gv.at/bundesrecht/) 

Does the regulation provide a definition of 'embryo', if so which one? 
No 

Is hESC research allowed and in what terms and conditions? 
hESC research in the above mentioned sense is limited to the field of reproductive 
medicine; other research is not allowed; 

If yes, which body is in charge of the approval of hESC research (ethics review)? 
--- 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
No 

Is the source of hESC used in research traceable and well documented? 
--- 
 What are the formal ethical and legal requirements for hESC research approval? 
--- 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
--- 

9 

 Is financial inducement allowed? If so, in what terms? 

--- 

10 

11 

12 

 Are ad hoc data protection provisions be defined for hESC research? 
--- 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
---- 

How is patenting of hESC lines regulated? 
---- 

91

01_2007_5944_txt_EN.indd   91

12-02-2008   13:58:47

 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory frame applying to BELGIUM 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

Please list existing regulation applying to human embryonic stem cells (hESC) research 
(web address where to get the texts would be welcomed). 
There are several regulations applying on hESC research: 

1: Law on organ transplantation 13/06/1986 (applicable on tissues, Published 14/02/1987) 
2: Royal Decree on tissue banks of 15/04/1988 (Published 29/04/1988) 
3: Embryo Law of 11/05/2003 (Published BS 28/05/2003) 

Does the regulation provide a definition of 'embryo', if so which one? 
Yes:  An embryo is a cell or a group of coherent cells that have the capacity to develop into a 
human being (see Embryo law, Art. 2, cited:) 

Loi du 11 mai 2003. Article 2. Pour l'application de la présente loi, on entend par:  
1)  «embryon»: la cellule ou l'ensemble organique de cellules susceptibles, en se développant, 

de donner un être humain 

3 

Is hESC research allowed and in what terms and conditions? 
Yes:    

At universities or in cooperation with universities,  
after consent of the local ethical commission and  
after positive advice (within 2 months) of the Federal Commission for medical and scientific 
research on embryos in vitro 
Loi du 11 mai 2003. Article 7, paragraphe 1. Toute recherche sur des embryons in vitro doit 
être soumise au préalable au comité local d'éthique de l'établissement universitaire concerné et 
à la Commission fédérale pour la recherche médicale et scientifique sur les embryons in vitro 
visée à l'article 9. 
La demande d'avis est introduite conjointement par le chercheur et le chef du laboratoire de 
procréation médicalement assistée ou de génétique humaine agréé de l'établissement 
universitaire concerné ou de l'établissement qui a conclu une convention avec un établissement 
universitaire. 
La demande d'avis comporte une description détaillée de l'objectif, de la méthodologie et de la 
durée de la recherche. Elle indique spécialement si la recherche a lieu sur des embryons 
surnuméraires ou des embryons créés à des fins de recherche. 
Paragraphe 2. L'avis du comité local d'éthique est rendu dans un délai de deux mois suivant la 
demande d'avis. 
Si l'avis du comité local d'éthique est négatif, le projet de recherche est abandonné. 
Le chercheur et le chef de laboratoire portent à la connaissance de la Commission fédérale pour 
la recherche médicale et scientifique sur les embryons in vitro, visée à l'article 9, leur demande 
d'avis ainsi que l'avis positif du comité local d'éthique. Si, dans un délai de deux mois après cette 
transmission, la Commission n'a pas émis d'avis négatif à la majorité de ses membres, le projet 
de recherche est autorisé et peut être entamé. Toutes les décisions de la Commission fédérale 
pour la recherche médicale et scientifique sur les embryons in vitro sont motivées. 

92

01_2007_5944_txt_EN.indd   92

12-02-2008   13:58:47

 
 
  
 
 
 
 
 
 
 
 
 
 
Regulatory frame applying to BELGIUM 

Please the information here provided should concern current regulatory 

requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) research 

(web address where to get the texts would be welcomed). 

There are several regulations applying on hESC research: 

1: Law on organ transplantation 13/06/1986 (applicable on tissues, Published 14/02/1987) 

2: Royal Decree on tissue banks of 15/04/1988 (Published 29/04/1988) 

3: Embryo Law of 11/05/2003 (Published BS 28/05/2003) 

2 

Does the regulation provide a definition of 'embryo', if so which one? 

Yes:  An embryo is a cell or a group of coherent cells that have the capacity to develop into a 

human being (see Embryo law, Art. 2, cited:) 

Loi du 11 mai 2003. Article 2. Pour l'application de la présente loi, on entend par:  

1)  «embryon»: la cellule ou l'ensemble organique de cellules susceptibles, en se développant, 

de donner un être humain 

3 

Is hESC research allowed and in what terms and conditions? 

Yes:    

At universities or in cooperation with universities,  

after consent of the local ethical commission and  

after positive advice (within 2 months) of the Federal Commission for medical and scientific 

research on embryos in vitro 

Loi du 11 mai 2003. Article 7, paragraphe 1. Toute recherche sur des embryons in vitro doit 

être soumise au préalable au comité local d'éthique de l'établissement universitaire concerné et 

à la Commission fédérale pour la recherche médicale et scientifique sur les embryons in vitro 

La demande d'avis est introduite conjointement par le chercheur et le chef du laboratoire de 

procréation médicalement assistée ou de génétique humaine agréé de l'établissement 

universitaire concerné ou de l'établissement qui a conclu une convention avec un établissement 

La demande d'avis comporte une description détaillée de l'objectif, de la méthodologie et de la 

durée de la recherche. Elle indique spécialement si la recherche a lieu sur des embryons 

surnuméraires ou des embryons créés à des fins de recherche. 

Paragraphe 2. L'avis du comité local d'éthique est rendu dans un délai de deux mois suivant la 

visée à l'article 9. 

universitaire. 

demande d'avis. 

Si l'avis du comité local d'éthique est négatif, le projet de recherche est abandonné. 

Le chercheur et le chef de laboratoire portent à la connaissance de la Commission fédérale pour 

la recherche médicale et scientifique sur les embryons in vitro, visée à l'article 9, leur demande 

d'avis ainsi que l'avis positif du comité local d'éthique. Si, dans un délai de deux mois après cette 

transmission, la Commission n'a pas émis d'avis négatif à la majorité de ses membres, le projet 

de recherche est autorisé et peut être entamé. Toutes les décisions de la Commission fédérale 

pour la recherche médicale et scientifique sur les embryons in vitro sont motivées. 

4 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

The Federal Commission for medical and scientific research on embryos in vitro  

5 

6 

7 

8 

Is the creation of embryos for research purposes, or stem cells procurement, allowed in 
your country, if yes at what conditions? 
Yes, but ONLY if the objective of this research project can’t be achieved by using supernumerary 
embryos and this still under the conditions complying with the embryo law. 

Loi du 11 mai 2003. Article 4, paragraphe 1. La constitution d'embryons in vitro à des fins de 
recherche est interdite, sauf si l'objectif de la recherche ne peut être atteint par la recherche sur 
les embryons surnuméraires et pour autant que les conditions de la présente loi soient remplies. 
Is the source of hESC used in research traceable and well documented? 
Actually there is no mandatory traceability.  
In a short period of time, traceability will be assured by a new law dealing with storage and 
distribution of cells and tissues 
 What are the formal ethical and legal requirements for hESC research approval? 
Cf    question 4 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please describe 
them? 
Yes.  
Donors give their free and written consent for the use of their gametes for research purposes 
after being properly informed  

Loi du 11 mai 2003. Article 8. Les personnes concernées donnent leur consentement préalable 
libre, éclairé et consigné par écrit à l'utilisation des gamètes ou des embryons in vitro à des fins 
de recherche. 

9 

 Is financial inducement allowed? If so, in what terms? 

10 

Yes, for research 
No, for donation 
 Are ad hoc data protection provisions be defined for hESC research? 
Anonymity is guaranteed for the donors of gametes and/or embryos 
(Medical confidentiality and the law on rights of patients) 

93

01_2007_5944_txt_EN.indd   93

12-02-2008   13:58:48

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
11 

Are data deriving from hESC projects necessarily provided, whether positive or negative 
(in form of publications)? 
The Federal Commission for medical and scientific research on embryos in vitro can control the 
laboratories where research on embryos in vitro is ongoing. (Art 10) 

Every year, the researchers have to procure to the Federal Commission a progress report on 
their research on embryos (Art 11) 

Loi du 11 mai 2003. Article 10, paragraphe 2. […] Elle peut à tout moment visiter les 
laboratoires dans lesquels se déroulent les recherches pour lesquelles elle est compétente, afin 
de faire toutes les constatations utiles à l'exercice de ses missions. 

Loi du 11 mai 2003. Article 11. Chaque chercheur communique à la Commission, au plus tard 
le 30 avril de chaque année, un rapport décrivant l'état d'avancement de la recherche. 
Ce rapport mentionne: 

1) 
2) 
3) 

4) 

l'objectif, la méthodologie et la durée de la recherche; 
les modalités du respect des dispositions de la présente loi; 
la demande et les avis rendus par le comité local d'éthique et la Commission conformément 
à l'article 7; 
l'état d'avancement de la recherche. 

12 

How is patenting of hESC lines regulated? 
In Belgium, patenting of hESC is possible.  
Loi du 28 mars 1984 sur les brevets d'invention (Moniteur belge du 9.3.1985) modifiée par la loi 
du 9 mars 1995 (Moniteur belge du 7.6.1995), la loi du 28 janvier 1997 (Moniteur belge du 
4.4.1997), la loi du 26 juin 2000 (Moniteur belge du 29.7.2000) et la loi du 12 juin 2001 (Moniteur 
belge du 7.7.2001). 
Les droits (exploitation exclusive, intervention contre les contrefaçons) d’un titulaire d’un brevet 
d’invention sont limités dans le temps (maximum 20 ans) et limités au territoire belge. Pour 
bénéficier des mêmes droits dans d’autres pays, vous devez obtenir ces brevets d’invention 
dans ces pays aussi, par voie nationale, européenne ou internationale. 

94

01_2007_5944_txt_EN.indd   94

12-02-2008   13:58:48

 
 
  
 
 
 
 
 
 
11 

Are data deriving from hESC projects necessarily provided, whether positive or negative 

(in form of publications)? 

The Federal Commission for medical and scientific research on embryos in vitro can control the 

laboratories where research on embryos in vitro is ongoing. (Art 10) 

Every year, the researchers have to procure to the Federal Commission a progress report on 

their research on embryos (Art 11) 

Loi du 11 mai 2003. Article 10, paragraphe 2. […] Elle peut à tout moment visiter les 

laboratoires dans lesquels se déroulent les recherches pour lesquelles elle est compétente, afin 

de faire toutes les constatations utiles à l'exercice de ses missions. 

Loi du 11 mai 2003. Article 11. Chaque chercheur communique à la Commission, au plus tard 

le 30 avril de chaque année, un rapport décrivant l'état d'avancement de la recherche. 

Ce rapport mentionne: 

1) 

2) 

3) 

l'objectif, la méthodologie et la durée de la recherche; 

les modalités du respect des dispositions de la présente loi; 

la demande et les avis rendus par le comité local d'éthique et la Commission conformément 

à l'article 7; 

4) 

l'état d'avancement de la recherche. 

12 

How is patenting of hESC lines regulated? 

In Belgium, patenting of hESC is possible.  

Loi du 28 mars 1984 sur les brevets d'invention (Moniteur belge du 9.3.1985) modifiée par la loi 

du 9 mars 1995 (Moniteur belge du 7.6.1995), la loi du 28 janvier 1997 (Moniteur belge du 

4.4.1997), la loi du 26 juin 2000 (Moniteur belge du 29.7.2000) et la loi du 12 juin 2001 (Moniteur 

belge du 7.7.2001). 

Les droits (exploitation exclusive, intervention contre les contrefaçons) d’un titulaire d’un brevet 

d’invention sont limités dans le temps (maximum 20 ans) et limités au territoire belge. Pour 

bénéficier des mêmes droits dans d’autres pays, vous devez obtenir ces brevets d’invention 

dans ces pays aussi, par voie nationale, européenne ou internationale. 

Regulatory frame applying to BULGARIA 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells 
(hESC) research (web address where to get the texts would be welcomed). 

Healthcare Act /Chapter IV, Div. III – ‘Artificial Reproduction’/ In force 
from 01.01.2005 ./ SG N.70/2004., adopt. N.46/2005., N.76/2005., 
N.85/2005., N.88/ 2005., N.94/2005., N.103/2005., N.18/2006., 
N.30/2006., N.34/2006., N.59/2006., N.71/2006., N.75/ 2006., 
N.81/2006., N.95/2006., N.102/ 2006./.  
Transplantation organ, tissue & cells Act In force from 01.01.2004 ./ SG 
N.83/2003., adopt..N88/2005.,N.71/2006./.;  
Ordinance N 37/28.09.2004 for the conditions and order for taking an 
embryos organs, tissue and somatic, amniotic and placenta cells for 
transplantation aims.  

/ SG N.88/8.10.2004(cid:605).,adopt. SG N..89/ 12.10. 2004(cid:605)./ 

/ the object of Ordinance regulation is only the ‘embryonic organs, tissue 
and cells’ after abortion — Art.1 and Art.4/ 

Remark: To my opinion, the term ‘human embryonic stem sells’ have an 
wide and narrow understanding.. The ‘wide’ meaning comprises zygotes 
and life embryo as a source of stem cells. 
The narrow meaning comprises only life embryo as a source of stem 
cells. 
Therefore it will be useful to specify what meaning should be the right 
contents of the term ‘hESC’. 

Web address: 
www.bultransplant.bg ; www.mh.government.bg/iat.php; 
Does the regulation provide a definition of 'embryo', if so which one? 
“Embryo’ is not defined explicitly. 
There is a definition of ‘embryonic organs, tissue and cells’ — 
Transplantation organ, tissue & cells Act, Additional provisions, &1, 
point.9. 

Is hESC research allowed and in what terms and conditions? 
No. 

2 

3 

95

01_2007_5944_txt_EN.indd   95

12-02-2008   13:58:49

 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 

5 

6 

7 

8 

If yes, which body is in charge of the approval of hESC research (ethics 
review)? 
see.point.3 

Is the creation of embryos for research purposes, or stem cells 
procurement, allowed in your country, if yes at what conditions? 
No. 

Is the source of hESC used in research traceable and well documented? 
See point.5 
 What are the formal ethical and legal requirements for hESC research 
approval? 
Healthcare Act — Art. 134 — ‘Gametes and zygotes, which are not used 
for the purpose of human creation, can be given to the research, 
academic and medicine entities in the country and outside, for the 
medicine, scientific and teaching purposes, after written inform consent 
of the donor, but concerning zygotes – the consent should be taken by 
the two donors, according to the Ordinance, issued by the Minister of 
healthcare. 

 Does the relevant regulatory frame foresee informed consent procedures 
from individuals involved in embryo donation for research, if so could you 
please describe them? 
See.point.7. 

9 

 Is financial inducement allowed? If so, in what terms? 

No 

10 

11 

12 

 Are ad hoc data protection provisions be defined for hESC research? 
No 

Are data deriving from hESC projects necessarily provided, whether 
positive or negative (in form of publications)? 
N/A 

How is patenting of hESC lines regulated? 
N/A 

96

01_2007_5944_txt_EN.indd   96

12-02-2008   13:58:49

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 

If yes, which body is in charge of the approval of hESC research (ethics 

review)? 

see.point.3 

No. 

See point.5 

approval? 

5 

6 

7 

Is the creation of embryos for research purposes, or stem cells 

procurement, allowed in your country, if yes at what conditions? 

Is the source of hESC used in research traceable and well documented? 

 What are the formal ethical and legal requirements for hESC research 

Healthcare Act — Art. 134 — ‘Gametes and zygotes, which are not used 

for the purpose of human creation, can be given to the research, 

academic and medicine entities in the country and outside, for the 

medicine, scientific and teaching purposes, after written inform consent 

of the donor, but concerning zygotes – the consent should be taken by 

the two donors, according to the Ordinance, issued by the Minister of 

healthcare. 

8 

 Does the relevant regulatory frame foresee informed consent procedures 

from individuals involved in embryo donation for research, if so could you 

please describe them? 

See.point.7. 

9 

 Is financial inducement allowed? If so, in what terms? 

No 

No 

N/A 

N/A 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

11 

Are data deriving from hESC projects necessarily provided, whether 

positive or negative (in form of publications)? 

12 

How is patenting of hESC lines regulated? 

Regulatory frame applying to CYPRUS 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
There is no specific law for hESC in the Republic of Cyprus. 

However,  the  Republic  of  Cyprus  has  ratified  the  ‘Convention  for  the  Protection  of 
Human Rights and Dignity of the Human Being with regard to the Application of Biology 
and Medicine: Convention on Human Rights and Biomedicine, Oviedo Convention’ with 
the Ratification Law N.31(III)/2001.  

Article 18 of the Convention and the Ratification Law, in relation to the research on 
embryos in vitro, states that: 

1.  Where the law allows research on embryos in vitro, it shall ensure 

adequate protection of the embryo.  

2.  The creation of human embryos for research purposes is prohibited.  

2 

3 

4 

5 

6 

7 

Does the regulation provide a definition of 'embryo', if so which one? 
No, it does not provide a definition of ‘embryo’. 

Is hESC research allowed and in what terms and conditions? 
There is no law in the Republic of Cyprus allowing research on embryos in-vitro under 
any circumstances. 
The hESC research is not allowed in the Republic of Cyprus. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
The creation of embryos for research purposes is absolutely prohibited in the Republic 

of Cyprus in accordance with Article 18 (2) of the Convention for the Protection of 

Human Rights and Dignity of the Human Being with regard to the Application of Biology 

and Medicine: Convention on Human Rights and Biomedicine, Oviedo Convention’. The 

Article 18 (2) of the Oviedo Convention states that ‘The creation of human embryos for 

research purposes is prohibited'. The Convention has been ratified by the Law 31 

(III)/2001. 

Is the source of hESC used in research traceable and well documented? 
The extraction of embryonic stem cells from embryos in-vitro is prohibited in accordance 
with Article 18 of the Oviedo Convention and Article 7 of its Ratification Law (No. 31 
(III)/2001). 
 What are the formal ethical and legal requirements for hESC research approval? 
Having in mind all the above mentioned and in accordance with the information given in 
paragraphs 3, 5 and 6 above, research on embryonic stem cells is neither legally nor 
ethically approved by the legislation currently in force, in the Republic of Cyprus. 

97

01_2007_5944_txt_EN.indd   97

12-02-2008   13:58:50

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
Not applicable 

9 

 Is financial inducement allowed? If so, in what terms? 

Not applicable 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

11 

12 

Not applicable 
Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
Not applicable 

How is patenting of hESC lines regulated? 
Not applicable 

98

01_2007_5944_txt_EN.indd   98

12-02-2008   13:58:50

 
 
  
 
 
 
 
 
 
 
 
 
8 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

Regulatory frame applying to CZECH REPUBLIC 

describe them? 

Not applicable 

Not applicable 

Not applicable 

9 

 Is financial inducement allowed? If so, in what terms? 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

Not applicable 

12 

How is patenting of hESC lines regulated? 

Not applicable 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

7 

8 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
Act on Human Embryonic Stem Cell Research (law no. 227/2006 Coll.) passed by the 
Czech Parliament on 26th of April 2006, in force since June 1 2006. 
Text available here: http://www.mvcr.cz/sbirka/2006/sb075-06.pdf (also attached) 

Does the regulation provide a definition of 'embryo', if so which one? 
“Human embryo is a totopotent cell or a grouping of cells which are capable develop 
into human individuum’ (law no. 227/2006 Coll., § 2) 

Is hESC research allowed and in what terms and conditions? 
Yes. 
Conditions: State licensing (given by the Ministry of Education, after approval of the 
Bioethics Committee of the Research and Development Council of the Czech 
Government and after positive appraisal of the Research and Development Council) 
Preconditions: 

a)  Scientific criteria 

scientifically justifiable – new medical knowledge with applications for humans;  
scientific necessity (usage of in vitro models, animal cells or animals does not 
provide the necessary knowledge); 
no alternative research 
scientific quality of the research team 
b)  Ethical criteria 

Research project is ethically acceptable (informed consent, donation…) 

If yes, which body is in charge of the approval of hESC research (ethics review)? 
Ministry of Education 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 

No. The Czech Republic ratified Oviedo Convention (2001). 
Is the source of hESC used in research traceable and well documented? 
Yes. 
 What are the formal ethical and legal requirements for hESC research approval? 
Source of embryos: ‘surplus embryos’ from IVF (only from licensed IVF centres), no 
longer than 7 day of development, export of embryos prohibited 
Informed consent 
Donation (reimbursement of expenses possible) 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
Yes. Detailed description in § 9 Act no. 227/2006 Coll. 

99

01_2007_5944_txt_EN.indd   99

12-02-2008   13:58:51

 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 

 Is financial inducement allowed? If so, in what terms? 

No. 
Only reimbursement of real expenses (to the IVF Centre) 
Reimbursement of real expenses related to the embryo donation (to the donor, payment 
and other compensation explicitly prohibited) 

 Are ad hoc data protection provisions be defined for hESC research? 
Yes. The Act on Personal Data Protection applies. 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
No 

How is patenting of hESC lines regulated? 
No regulation. 

10 

11 

12 

100

01_2007_5944_txt_EN.indd   100

12-02-2008   13:58:51

 
 
  
 
 
 
 
 
 
 
 
 
 
 
9 

 Is financial inducement allowed? If so, in what terms? 

No. 

Only reimbursement of real expenses (to the IVF Centre) 

Reimbursement of real expenses related to the embryo donation (to the donor, payment 

and other compensation explicitly prohibited) 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

Yes. The Act on Personal Data Protection applies. 

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

No 

12 

How is patenting of hESC lines regulated? 

No regulation. 

Regulatory frame applying to DENMARK 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
Yes  
www.retsinfo.dk 

Does the regulation provide a definition of 'embryo', if so which one? 
No 

Is hESC research allowed and in what terms and conditions? 
Research is allowed on human fertilized eggs meant for fertilisation of a woman under 
the conditions mentioned in  
Lovbekendtgørelse af lov om kunstig befrugtning i forbindelse med lægelig behandling, 
diagnostic og forskning LBK nr. 923 af 04//09/2006 chapter 7, paragraph 25-27 

Kapitel 7  

Forbud mod forskning og forsøg  

§ 25. Biomedicinske forsøg på befrugtede menneskelige æg samt på kønsceller, der 

agtes anvendt til befrugtning, må kun foretages i følgende tilfælde:  
1) Hvis de har til formål at forbedre in vitro-befrugtning eller lignende teknikker med 

henblik på at fremkalde en graviditet.  

2) Hvis de har til formål at forbedre teknikker til genetisk undersøgelse af et befrugtet 

æg med henblik på at fastslå, om der foreligger en alvorlig arvelig sygdom eller en 
væsentlig kromosomabnormitet (præimplantationsdiagnostik).  

3) Hvis forsøgene ved anvendelse af befrugtede æg og stamceller herfra har til formål 

at opnå ny viden, som vil kunne forbedre mulighederne for behandling af 
sygdomme hos mennesker.  

Stk. 2. Udtagning og befrugtning af æg med henblik på at gennemføre andre forsøg 

end de i stk. 1 nævnte er ikke tilladt.  

§ 26. Befrugtede æg må kun holdes i live uden for en kvindes livmoder i 14 dage, fra 

befrugtningen er sket. Den tid, hvori de befrugtede menneskelige æg har været 
nedfrosset, medregnes ikke.  

§ 27. Befrugtede menneskelige æg, der har været gjort til genstand for biomedicinsk 

forskning, herunder almindelig kvalitetssikrende forskning ved ægopsætning, må kun 
opsættes i en kvindes livmoder, hvis det befrugtede æg er genetisk uændret 
(umodificeret) og den forudgående forskning efter en faglig vurdering i øvrigt ikke må 
antages at have beskadiget ægget i dets videre udvikling.  

Stk. 2. Forskningsprojekter efter § 25 skal godkendes i det videnskabsetiske 

komitesystem, der forud for eventuel godkendelse vurderer, om projekterne har det 
tilladte formål.  

§ 28. Følgende forsøg må ikke foretages:  

1) Forsøg, der har til formål at muliggøre fremstilling af arvemæssigt identiske 

menneskelige individer.  

2) Forsøg, der har til formål at muliggøre fremstilling af menneskelige individer ved 

sammensmeltning af genetisk forskellige fosteranlæg eller dele af fosteranlæg, før 

101

01_2007_5944_txt_EN.indd   101

12-02-2008   13:58:52

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
de sætter sig fast i livmoderen.  

3) Forsøg, der har til formål at muliggøre fremstilling af levende menneskelige individer, 
som er hybrider, med en arvemasse, hvori indgår bestanddele fra andre arter.  

4) Forsøg, der har til formål at muliggøre udvikling af et menneskeligt individ i 

artsfremmed livmoder.  

If yes, which body is in charge of the approval of hESC research (ethics review)? 
The Danish Committees on Biomedical 
Researchhttp://www.cvk.im.dk/cvk/site.aspx?p=23 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
No 

Is the source of hESC used in research traceable and well documented? 
Yes see provisions of Act on a Biomedical Research Ethics Committee System and the 
Processing of Biomedical Research Projects 
http://www.cvk.im.dk/cvk/site.aspx?p=150 

 What are the formal ethical and legal requirements for hESC research approval? 
See the Danish act on a Biomedical Research Ethics Committees System and the 
Processing of Biomedical Research Projects 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? See the Danish act on a Biomedical Research Ethics Committees 
System and the Processing of Biomedical Research Projects 

 Is financial inducement allowed? If so, in what terms? 
No 

 Are ad hoc data protection provisions be defined for hESC research? 
Yes, see the Danish act on a Biomedical Research Ethics Committees System and the 
Processing of Biomedical Research Projects  

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
Yes, see the Danish act on a Biomedical Research Ethics Committees System and the 
Processing of Biomedical Research Projects  

4 

5 

6 

7 

8 

9 

10 

11 

12 

How is patenting of hESC lines regulated? 
See Danish Law on Patents Paragraph 1A 

§ 1 a. Det menneskelige legeme på alle de forskellige stadier af dets opståen og 

udvikling og den blotte opdagelse af en del af det, herunder en sekvens eller 
delsekvens af et gen, kan ikke udgøre patenterbare opfindelser.  

Stk. 2. Uanset stk. 1 kan en del af det menneskelige legeme, der er isoleret herfra 
eller på anden måde fremstillet ved en teknisk fremgangsmåde, herunder en sekvens 

102

01_2007_5944_txt_EN.indd   102

12-02-2008   13:58:52

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eller delsekvens af et gen, udgøre en patenterbar opfindelse, selv om en sådan del i sin 
opbygning er identisk med opbygningen i en naturligt forekommende del.  

Unofficial translation of the paragraph: 
“The human body, at the various stages of its formation and development, and the 
simple discovery of one of its elements, including a sequence or partial sequence of a 
gene, cannot constitute patentable inventions. 
Subs. 2. Notwithstanding subsection 1 hereof, an element isolated from the human 
body or otherwise produced by means of a technical process, including a sequence or 
partial sequence of a gene, may constitute a patentable invention, even if the structure 
of that element is identical to that of a natural element.’ 

In the Danish regulations, Article 5, subs. 3 of the EU directive on patenting of human 
stem cells has been set out in the statutory instrument on patents. 

de sætter sig fast i livmoderen.  

3) Forsøg, der har til formål at muliggøre fremstilling af levende menneskelige individer, 

som er hybrider, med en arvemasse, hvori indgår bestanddele fra andre arter.  

4) Forsøg, der har til formål at muliggøre udvikling af et menneskeligt individ i 

artsfremmed livmoder.  

4 

5 

6 

7 

8 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

The Danish Committees on Biomedical 

Researchhttp://www.cvk.im.dk/cvk/site.aspx?p=23 

Is the creation of embryos for research purposes, or stem cells procurement, 

allowed in your country, if yes at what conditions? 

No 

Is the source of hESC used in research traceable and well documented? 

Yes see provisions of Act on a Biomedical Research Ethics Committee System and the 

Processing of Biomedical Research Projects 

http://www.cvk.im.dk/cvk/site.aspx?p=150 

 What are the formal ethical and legal requirements for hESC research approval? 

See the Danish act on a Biomedical Research Ethics Committees System and the 

Processing of Biomedical Research Projects 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

describe them? See the Danish act on a Biomedical Research Ethics Committees 

System and the Processing of Biomedical Research Projects 

9 

 Is financial inducement allowed? If so, in what terms? 

No 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

Yes, see the Danish act on a Biomedical Research Ethics Committees System and the 

Processing of Biomedical Research Projects  

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

Yes, see the Danish act on a Biomedical Research Ethics Committees System and the 

Processing of Biomedical Research Projects  

12 

How is patenting of hESC lines regulated? 

See Danish Law on Patents Paragraph 1A 

§ 1 a. Det menneskelige legeme på alle de forskellige stadier af dets opståen og 

udvikling og den blotte opdagelse af en del af det, herunder en sekvens eller 

delsekvens af et gen, kan ikke udgøre patenterbare opfindelser.  

Stk. 2. Uanset stk. 1 kan en del af det menneskelige legeme, der er isoleret herfra 

eller på anden måde fremstillet ved en teknisk fremgangsmåde, herunder en sekvens 

103

01_2007_5944_txt_EN.indd   103

12-02-2008   13:58:53

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Regulatory frame applying to ESTONIA 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

7 

8 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
We have no special regulations of hESC research in Estonia and if needed we take into 
consideration relevant international documents.. 

Does the regulation provide a definition of 'embryo', if so which one? 
_ 

Is hESC research allowed and in what terms and conditions? 
The Estonian Council on Bioethics is on the position, that in principle hESC research is 
acceptable in Estonia. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 
In needed cases the approval will be given by research ethics committees 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
The creation of embryos for research purposes is not allowed by the Estonian law of 
artificial procreation and embryo protection 

Is the source of hESC used in research traceable and well documented? 
We have no special system for this yet 
 What are the formal ethical and legal requirements for hESC research approval? 
They are not fixed yet in Estonia 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
No regulations on it 

9 

 Is financial inducement allowed? If so, in what terms? 

It is not regulated 

10 

11 

12 

 Are ad hoc data protection provisions be defined for hESC research? 
No 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
No 

How is patenting of hESC lines regulated? 
It is not regulated in Estonia 

104

01_2007_5944_txt_EN.indd   104

12-02-2008   13:58:53

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory frame applying to ESTONIA 

Regulatory frame applying to FINLAND 

Please the information here provided should concern current regulatory 

requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 

research (web address where to get the texts would be welcomed). 

We have no special regulations of hESC research in Estonia and if needed we take into 

consideration relevant international documents.. 

2 

3 

4 

5 

6 

7 

8 

Does the regulation provide a definition of 'embryo', if so which one? 

_ 

Is hESC research allowed and in what terms and conditions? 

The Estonian Council on Bioethics is on the position, that in principle hESC research is 

acceptable in Estonia. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

In needed cases the approval will be given by research ethics committees 

Is the creation of embryos for research purposes, or stem cells procurement, 

allowed in your country, if yes at what conditions? 

The creation of embryos for research purposes is not allowed by the Estonian law of 

artificial procreation and embryo protection 

Is the source of hESC used in research traceable and well documented? 

We have no special system for this yet 

They are not fixed yet in Estonia 

 What are the formal ethical and legal requirements for hESC research approval? 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

describe them? 

No regulations on it 

It is not regulated 

No 

No 

9 

 Is financial inducement allowed? If so, in what terms? 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

12 

How is patenting of hESC lines regulated? 

It is not regulated in Estonia 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

7 

8 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
Medical Research Act, 488/1999. www.finlex.fi  
Translation: see: http://www.finlex.fi/en/laki/kaannokset/1999/en19990488.pdf 
Does the regulation provide a definition of 'embryo', if so which one? 
Yes. ‘embryo’ means a living group of cells resulting from fertilisation not implanted in a 
woman’s body 

Is hESC research allowed and in what terms and conditions? 
It is allowed. Embryos shall be used for research only with a written informed consent 
from the donors of the gametes. Consent can be withdrawn in any time (Act on medical 
Research, section 12) Only supernumerary embryos shall be used for research. The 
production of embryos exclusively for the purpose of research is forbidden. (Act on 
Medical Research, section 13). When hESC lines have been produced, the law does 
not make any further provisions on the use of these cells. The production of hESC 
needs the favourable opinion of an ethics committee of a hospital district, and the 
research on embryos can be done only in the institutions that have got an authorisation 
from the National Authority of Medicolegal Affairs (TEO) The use of embryos for 
research is allowed only for 14 days after fertilisation 
If yes, which body is in charge of the approval of hESC research (ethics review)? 
Ethics committees of hospital districts evaluate the research projects, although the 
research of cell lines is not specifically regulated in the Medical Research Act. The 
Ministry of Social Affairs and Health has established a working group on Biobanks that 
is working on the issue of biobanks including ethics evaluation of establishment of 
biobank and ethics evaluation of the research projects. 
Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
Medical Research Act states that The production of embryos exclusively for the purpose 
of research shall be forbidden. However, the Act also determines the embryo as ‘the 
living group of cells resulting from fertilisation’. This can be interpreted so that cells 
produced by the somatic cell nuclear transfer are not considered as embryos. 
Is the source of hESC used in research traceable and well documented? 
Anonymisation and coding as far as possible should be used in each project 
 What are the formal ethical and legal requirements for hESC research approval? 
We have formal ethical and legal requirements for embryo research stated in the 
Medical Research Act. Further requirements concerning hESC lines have not been 
established. The working group is working on this issue concerning research on 
biological sample collections.  
 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
Ethics committees approve information and consent forms before they can be used in 
the informed consent procedure 

9 

 Is financial inducement allowed? If so, in what terms? 

105

01_2007_5944_txt_EN.indd   105

12-02-2008   13:58:54

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
10 

11 

12 

No; donation must be voluntary. Only compensation of the expenses and harms 
(healthy donors) is allowed according to Decree 1390/2006. There are not such 
expenses or harm related to hESC while embryos that could be donated for research 
are surplus embryos. 

 Are ad hoc data protection provisions be defined for hESC research? 
No, regular data protection provisions similar to medical research in general are applied 
to hESC research. 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
Not necessarily, only when they are published. 

How is patenting of hESC lines regulated? 
We have Act on Patenting (550/1967, amendment 650/2000) that has implemented the 
EU Directive of biopatenting. It states that (Section 1a and b) human body or its part, 
whole or partial sequence of a gene or similar finding cannot be patented, but isolated 
or otherwise produced item, sequence or partial sequence of a single gene form an 
invention that can be patented, if provisions otherwise are fulfilled, although the 
structure of this item would be similar to natural item. However, section 1 b states that 
(3) uses of human embryos for industrial or commercial purposes cannot be patented 
See translation at: http://www.finlex.fi/en/laki/kaannokset/1967/en19670550.pdf 

106

01_2007_5944_txt_EN.indd   106

12-02-2008   13:58:54

 
 
  
 
 
 
 
 
 
 
 
 
No; donation must be voluntary. Only compensation of the expenses and harms 

(healthy donors) is allowed according to Decree 1390/2006. There are not such 

expenses or harm related to hESC while embryos that could be donated for research 

are surplus embryos. 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

No, regular data protection provisions similar to medical research in general are applied 

to hESC research. 

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

Not necessarily, only when they are published. 

12 

How is patenting of hESC lines regulated? 

We have Act on Patenting (550/1967, amendment 650/2000) that has implemented the 

EU Directive of biopatenting. It states that (Section 1a and b) human body or its part, 

whole or partial sequence of a gene or similar finding cannot be patented, but isolated 

or otherwise produced item, sequence or partial sequence of a single gene form an 

invention that can be patented, if provisions otherwise are fulfilled, although the 

structure of this item would be similar to natural item. However, section 1 b states that 

(3) uses of human embryos for industrial or commercial purposes cannot be patented 

See translation at: http://www.finlex.fi/en/laki/kaannokset/1967/en19670550.pdf 

Regulatory frame applying to FRANCE 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

7 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
www.agence-biomedecine.fr 
http://www.agence-biomedecine.fr/fr/experts/pegh-recherche.aspx 
Demande d'autorisation de protocoles d'étude et de recherche, d'importation ou de 
conservation 
Le décret n° 2006-121 du 6 février 2006 relatif aux recherches sur l'embryon et les 
cellules embryonnaires, précisant les conditions d'application de la loi du 6 août 2004, 
prévoit que le directeur général de l'Agence de la biomédecine notifie à l'établissement 
ou à l'organisme demandeur sa décision d'autorisation ou de refus d'autorisation dans 
les 4 mois suivant la clôture de la période au cours de laquelle a été déposé le dossier 
complet. 
www.legifrance.gouv.fr 
Does the regulation provide a definition of 'embryo', if so which one? 
The embryo in this law is :  
Obtained during an ART protocol and is no more subject to a parental (pregnancy) 
project 
Up to implantation stage 

Is hESC research allowed and in what terms and conditions? 
Subjected to the obtention of a licence for  
-research project 
-importation 
-conservation/storage 

If yes, which body is in charge of the approval of hESC research (ethics review)? 
The agency of biomedicine 
www.agence-biomedecine.fr 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
No 

Is the source of hESC used in research traceable and well documented? 
 It is a condition to fulfil in order to obtain a licence to be able to keep a local registry 
and tracks of cell culture; 
The agence de la biomedicine has also to keep a national hESC registry 
 What are the formal ethical and legal requirements for hESC research approval? 
The research project should benefit to the progress towards a potential therapeutic use 
of to progress on human embryo development and medicine. 
The team involved has to provide proof if feasibility of this research, and to documents 
the composition of the team, the lab rooms scheme, the traceability of the Es cell lines 
See décret n°2006-121 du 6 février 2006  

107

01_2007_5944_txt_EN.indd   107

12-02-2008   13:58:55

 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
8 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
Yes 
The law does ask to document the origin of the cell line and to provide the consent form 
model : both parents should have signed for the use of the embryo for research,  

9 

 Is financial inducement allowed? If so, in what terms? 

No 
The authority in charge of giving licences does not provide funds for research on those 
topics. 

 Are ad hoc data protection provisions be defined for hESC research? 
Yes 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
Yes, they are asked for every licence given, a yearly progress report is asked, and a 
final report. 

How is patenting of hESC lines regulated? 
Not authorized 

10 

11 

12 

108

01_2007_5944_txt_EN.indd   108

12-02-2008   13:58:55

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
8 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

describe them? 

Yes 

The law does ask to document the origin of the cell line and to provide the consent form 

model : both parents should have signed for the use of the embryo for research,  

9 

 Is financial inducement allowed? If so, in what terms? 

The authority in charge of giving licences does not provide funds for research on those 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

No 

topics. 

Yes 

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

Yes, they are asked for every licence given, a yearly progress report is asked, and a 

12 

How is patenting of hESC lines regulated? 

final report. 

Not authorized 

Regulatory frame applying to GERMANY 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
1) Act for the Protection of Embryos (Embryo Protection Act), 
Gesetz zum Schutz von Embryonen (Embryonenschutzgesetz – EschG) 

http://bundesrecht.juris.de/eschg/BJNR027460990.html,  

2) Act ensuring protection of embryos in connection with the importation and utilisation 
of human embryonic stem cells (Stem Cell Act), Gesetz zur Sicherstellung des 
Embryonenschutzes im Zusammenhang mit Einfuhr und Verwendung menschlicher 
embryonaler Stammzellen (Stammzellgesetz – StZG) 

http://bundesrecht.juris.de/stzg/index.html 

Does the regulation provide a definition of 'embryo', if so which one? 
For the purpose of the Embryo Protection Act, an embryo means a fertilised human egg 
capable of developing from the time of fusion of the nuclei, and further each totipotent 
cell removed from an embryo that is capable of dividing and developing into an 
individual human being if the necessary conditions prevail. (ESchG §8 (1)). 

For the Stem Cell Act embryo means any human totipotent cell which has the potential 
to divide and to develop into a human being if the necessary conditions prevail (StZG §3 
(4)). 
Is hESC research allowed and in what terms and conditions? 
According to the Embryo Protection Act the production of hESCs is forbidden. The Stem 
Cell Act ensures the protection of embryos in connection with the importation and 
utilisation of human embryonic stem cells. hESC research is only permitted using cell 
lines created before 1 January 2002 in the country of origin in accordance with relevant 
national legislation there and kept in culture or subsequently stored using 
cryopreservation methods. The embryos from which they were derived must have been 
produced by medically-assisted in vitro fertilisation in order to induce pregnancy and 
definitely no longer used for this purpose and no evidence that this was due to reasons 
inherent in the embryos themselves. No compensation or other benefit in money’s worth 
may have been granted or promised for the donation of embryos for the purpose of 
stem cell derivation.  
If yes, which body is in charge of the approval of hESC research (ethics review)? 
The Central Ethics Committee for Stem Cell Research at the Robert Koch Institute (RKI) 
is in charge of the approval of applications to import hESCs.  

The RKI is the federal institution responsible for disease control and prevention and the 
central federal reference institution for applied and response-orientated research as well 
as for the Public Health Sector. 
Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
The creation of embryos for research purposes is forbidden in Germany. 

Is the source of hESC used in research traceable and well documented? 
Information on the requested NIH embryonic stem cell lines for the project is registered 
by the competent agency, the Robert Koch Institute, in a publicly accessible registry on 
their website 

109

01_2007_5944_txt_EN.indd   109

12-02-2008   13:58:56

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
7 

8 

9 

10 

11 

12 

(http://www.rki.de/cln_049/nn_207250/DE/Content/Gesund/Stammzellen/Register/reg-
20060725-IBMT.html). 
 What are the formal ethical and legal requirements for hESC research approval? 
The hESC research has to serve eminent research aims to generate scientific 
knowledge in basic research or to increase medical knowledge for the development of 
diagnostic, preventive or therapeutic methods to be applied to humans and according to 
the state-of-the-art of science and technology. Firstly the questions to be studied in the 
research project concerned must been clarified as far as possible through in vitro 
models using animal cells or through animal experiments and secondly the scientific 
knowledge to be obtained from the research project concerned cannot be expected to 
be gained by using cells other than embryonic stem cells. 

Any importation and any utilisation of embryonic stem cells has to be subject to 
approval by the stem cell ethics committee for stem cell research at the Robert Koch 
Institute. Applications for approval must be submitted in writing. In the documents 
accompanying the application, the applicant shall provide the following information in 
particular: 
1. Name and official address of the person responsible for the research project 
concerned, 2. a description of the research project including scientific reasons showing 
that the research project meets the requirements described,3. a documentation 
concerning the embryonic stem cells to be imported or used showing that the 
requirements have been complied with equivalent evidence. 

The embryonic stem cells to be imported or used must be identical with those registered 
in a scientifically recognized, publicly accessible registry maintained by government 
agencies or agencies authorized by the government. 
 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
n/a 
 Is financial inducement allowed? If so, in what terms? 

For the stem cell lines to be imported no compensation or other benefit in money’s 
worth may have been granted for the donation of embryos for the purpose of stem cell 
derivation. 

 Are ad hoc data protection provisions be defined for hESC research? 
Ad hoc data protection provisions are not mentioned in the Stem Cell Act. 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
An obligation for publication is not mentioned in the Stem Cell Act. 

How is patenting of hESC lines regulated? 
The Biotechnology Patenting Directive (98/44/EC) negotiated by the European 
Parliament and the European Council on 6 July 1998 provides a uniform procedure for 
the patenting of biotechnological inventions in all EU Member States. 

In December 2004 Germany implemented the Biotechnology Patenting Directive and 
enacted the law 28 February 2005 (Gesetz zur Umsetzung der Richtlinie über den 
rechtlichen Schutz biotechnologischer Erfindungen (BioPatG), Act Implementing the 
Directive on the Legal Protection of Biotechnological Inventions in Germany).  
In December 2006 the German Federal Patent Court partially reversed their 1999 
decision on Professor Oliver Brüstle’s patent, saying that anything made from human 
tissue cannot be patented.  

110

01_2007_5944_txt_EN.indd   110

12-02-2008   13:58:56

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
(http://www.rki.de/cln_049/nn_207250/DE/Content/Gesund/Stammzellen/Register/reg-

20060725-IBMT.html). 

7 

 What are the formal ethical and legal requirements for hESC research approval? 

The hESC research has to serve eminent research aims to generate scientific 

knowledge in basic research or to increase medical knowledge for the development of 

diagnostic, preventive or therapeutic methods to be applied to humans and according to 

the state-of-the-art of science and technology. Firstly the questions to be studied in the 

research project concerned must been clarified as far as possible through in vitro 

models using animal cells or through animal experiments and secondly the scientific 

knowledge to be obtained from the research project concerned cannot be expected to 

be gained by using cells other than embryonic stem cells. 

Any importation and any utilisation of embryonic stem cells has to be subject to 

approval by the stem cell ethics committee for stem cell research at the Robert Koch 

Institute. Applications for approval must be submitted in writing. In the documents 

accompanying the application, the applicant shall provide the following information in 

particular: 

1. Name and official address of the person responsible for the research project 

concerned, 2. a description of the research project including scientific reasons showing 

that the research project meets the requirements described,3. a documentation 

concerning the embryonic stem cells to be imported or used showing that the 

requirements have been complied with equivalent evidence. 

The embryonic stem cells to be imported or used must be identical with those registered 

in a scientifically recognized, publicly accessible registry maintained by government 

agencies or agencies authorized by the government. 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

8 

9 

describe them? 

n/a 

 Is financial inducement allowed? If so, in what terms? 

For the stem cell lines to be imported no compensation or other benefit in money’s 

worth may have been granted for the donation of embryos for the purpose of stem cell 

derivation. 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

Ad hoc data protection provisions are not mentioned in the Stem Cell Act. 

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

An obligation for publication is not mentioned in the Stem Cell Act. 

12 

How is patenting of hESC lines regulated? 

The Biotechnology Patenting Directive (98/44/EC) negotiated by the European 

Parliament and the European Council on 6 July 1998 provides a uniform procedure for 

the patenting of biotechnological inventions in all EU Member States. 

In December 2004 Germany implemented the Biotechnology Patenting Directive and 

enacted the law 28 February 2005 (Gesetz zur Umsetzung der Richtlinie über den 

rechtlichen Schutz biotechnologischer Erfindungen (BioPatG), Act Implementing the 

Directive on the Legal Protection of Biotechnological Inventions in Germany).  

In December 2006 the German Federal Patent Court partially reversed their 1999 

decision on Professor Oliver Brüstle’s patent, saying that anything made from human 

tissue cannot be patented.  

Regulatory frame applying to GREECE 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) research 
(web address where to get the texts would be welcomed). 

-  Article 1459 c of the Civil Code (Act n. 3089/2002) 
-  Article 11 par. 1 (e) of the Act n. 3305/2005 (“Application of M.A.R.) 
- 
- 

http://www.bioethics.gr/media/pdf/biolaw/human/law_3089_en.pdf?PHPSESSID=c730
cd74d93449cca3750bb51c50a228 

2 

Does the regulation provide a definition of 'embryo', if so which one? 

Yes, (article 3 of the Act n. 3305/2005, for the terms ‘zygote’ and ‘fertilized egg’ 

 ‘Zygote’: an ovum from its fertilisation until the merger of the two haploid nuclei 
“Fertilized egg’: an ovum after the penetration or initiation of sperm 

3 

Is hESC research allowed and in what terms and conditions? 
Yes. 
Under certain conditions: 

-  Only on surplus embryos (up to the 14th day after fertilisation) 
-  Prior written informed consent of the donors 
-  Prior approval of the protocol (from the National Authority on M.A.R.) 
-  Prior research on laboratory animals (if possible) 
-  The research team should possess the necessary equipment and know-how 
- 

It is not allowed to implant the embryos that have been used 

4 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

The National Authority on Medically Assisted Reproduction (an independent regulatory agent,  
nominated by the Parliament) 

5 

Is the creation of embryos for research purposes, or stem cells procurement, allowed in 
your country, if yes at what conditions? 

No  

6 

Is the source of hESC used in research traceable and well documented? 

Yes  

111

01_2007_5944_txt_EN.indd   111

12-02-2008   13:58:57

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 

 What are the formal ethical and legal requirements for hESC research approval? 

See above (3)  

8 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please describe 
them? 

See above (3) 

9 

 Is financial inducement allowed? If so, in what terms? 

No (only compensation for justifiable expenses, medical services or undue damages is 
allowed) 

 Are ad hoc data protection provisions be defined for hESC research? 

1
0 

No. The law on sensitive data protection (Act n. 2472/1997) is applicable, binding the research 
team.  
The Data Protection Authority is responsible for relevant controls. 

1
1 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 

No  

How is patenting of hESC lines regulated? 

1
2 

By the presidential decree n. 321/2001 (on the Directive 98/44/EC) 

112

01_2007_5944_txt_EN.indd   112

12-02-2008   13:58:57

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 

 What are the formal ethical and legal requirements for hESC research approval? 

8 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please describe 

See above (3)  

them? 

See above (3) 

allowed) 

team.  

No  

1

0 

1

1 

1

2 

9 

 Is financial inducement allowed? If so, in what terms? 

No (only compensation for justifiable expenses, medical services or undue damages is 

 Are ad hoc data protection provisions be defined for hESC research? 

No. The law on sensitive data protection (Act n. 2472/1997) is applicable, binding the research 

The Data Protection Authority is responsible for relevant controls. 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

How is patenting of hESC lines regulated? 

By the presidential decree n. 321/2001 (on the Directive 98/44/EC) 

Regulatory frame applying to HUNGARY 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 

The human embryonic stem cells research and use is regulated by law and five 
decrees. 
The 1997. CLIV. law about the health regulated the general conditions of the use and 
research of the human embryonic stem cells (180- 182 paragraphs.( 
The 2006 CXV. law about the health reform. 
The 21/1998. (VI.3.) MH decree contains the minimum conditions of the use of human 
embryonic stem cells ( 15/B attachment). 
The 22/1998. (VI.3.) MH decree contains the detailed regulation of the transplantation of 
different organs and tissues.  
The 31/1998. (VI.24.) MH decree regulated the ethical approval system of biomedical 
research. 
The 22/2002. (V.9.) MH decree regulated the ethical approval system of biomedical 
research. 
The 1/2007. (I.24.) MH decree regulated the ethical approval system of biomedical 
research. 

2 

Does the regulation provide a definition of 'embryo', if so which one? 

embryo is defined as every living human embryo following the completion of fertilisation 
until 12th week of pregnancy. The foetus is the human being developing within the 
uterus after the 12th week of pregnancy.  

3 

Is hESC research allowed and in what terms and conditions? 

Research on embryos can be carried out on the basis of an authorisation of the 
Hungarian Reproduction Commission. Embryos can only be used for research purposes 
and experiments can only be made on embryos for the research purposes that the 
Health Care Act fixes with regard to medical research.   

If yes, which body is in charge of the approval of hESC research (ethics review)? 

Hungarian Reproduction Commission 
Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 

Embryos cannot be created for research purposes, only embryos created in medically 
assisted human procreation procedures (MAP) can be used for research and 
experiments, either on the basis of the decision of those entitled to decide, or in case of 
damage of the embryo. If an embryo was donated for a MAP procedure, but not used 
within 10 years following the donation, the embryo can be used for research purposes.  

Is the source of hESC used in research traceable and well documented? 

The source of the hESC is traceable and well documented in every cases.  

 What are the formal ethical and legal requirements for hESC research approval? 

The formal ethical and legal requirements for hESC research approval are regulated in 
the 1/2007. (I.24.) MH decree.  
The decree accepted the EC recommendations.  

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 

113

4 

5 

6 

7 

8 

01_2007_5944_txt_EN.indd   113

12-02-2008   13:58:58

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is no embryo donation for research. 

9 

 Is financial inducement allowed? If so, in what terms? 

Financial inducement is not allowed.  

10 

 Are ad hoc data protection provisions be defined for hESC research? 

Data protection is according to EU regulations. 

11 

12 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
It is not. 
How is patenting of hESC lines regulated? 

Patenting of hESC lines is not regulated. 

114

01_2007_5944_txt_EN.indd   114

12-02-2008   13:58:59

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There is no embryo donation for research. 

9 

 Is financial inducement allowed? If so, in what terms? 

Financial inducement is not allowed.  

10 

 Are ad hoc data protection provisions be defined for hESC research? 

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

Data protection is according to EU regulations. 

negative (in form of publications)? 

It is not. 

12 

How is patenting of hESC lines regulated? 

Patenting of hESC lines is not regulated. 

Regulatory frame applying to IRELAND 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 

Ireland  currently  has  no  specific  legislation  dealing  with  embryonic  stem  cell  research 
and furthermore does not have a legislative basis for the practice of IVF and therefore 
has  no  legislation  pertaining  to  use  of  embryos  (supernumerary  or  otherwise)  for 
research.  The  Medical  Council’s  Guide  to  Ethical  Conduct  and  Behaviour  6th  edition 
2004  states  that  in  relation  to  IVF  ‘that  any  fertilised  ovum  must  be  used  for  normal 
implantation  and  must  not  be  deliberately  destroyed".  They  also  state  ‘the  creation  of 
new life forms for experimental purposes or the deliberate and intentional destruction of 
in-vitro  human  life  already  formed  is  professional  misconduct".  It  should  be  noted  that 
the Medical Council only regulate physicians and therefore scientists are not bound by 
the guide, e.g. it would appear that there is currently no legal impediment on importation 
or use of embryonic stem cells lines by scientists.  

Following  a  referendum  some  years  ago,  The  Irish  Constitution  was  amended  and 
Article 40.3.3 of the Constitution acknowledges the right to life of the unborn. However, 
no  legislation  followed  this  amendment  e.g.  to  articulate  what  is  defined  as  ‘unborn’, 
would  this  include  supernumerary  embryos  in  storage  etc.  This  Constitutional 
Amendment has been interpreted by some to mean that embryonic stem cell research 
would be prohibited by our constitution. A recent high court judgment (Nov 2006) found 
that  three  frozen  embryos  resulting  from  IVF  are  not  ‘unborn"  as  defined  under  the 
Constitution. This judgment has been appealed to the Supreme Court. 

Does the regulation provide a definition of 'embryo', if so which one? 
N/A 

Is hESC research allowed and in what terms and conditions? 
There is no legislation prohibiting ESC research in Ireland. It would appear from the 
Recent High Court Judgement that ESC research is also not prohibited under the Irish 
Constitution. Further clarification will be forthcoming following a decision from the 
Supreme Court 

If yes, which body is in charge of the approval of hESC research (ethics review)? 
Situation has not arisen to legal uncertainty in this area but it would come under 
research ethics committee review. 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
No legislation/Regulation in this area. 

Is the source of hESC used in research traceable and well documented? 
N/A 
 What are the formal ethical and legal requirements for hESC research approval? 
N/A 

2 

3 

4 

5 

6 

7 

115

01_2007_5944_txt_EN.indd   115

12-02-2008   13:58:59

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
N/A 

9 

 Is financial inducement allowed? If so, in what terms? 

N/A 

10 

11 

12 

 Are ad hoc data protection provisions be defined for hESC research? 
N/A 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
N/A 

How is patenting of hESC lines regulated? 
N/A 

116

01_2007_5944_txt_EN.indd   116

12-02-2008   13:58:59

 
 
  
 
 
 
 
 
 
 
 
 
 
 
8 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

Regulatory frame applying to ITALY 

describe them? 

N/A 

9 

 Is financial inducement allowed? If so, in what terms? 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

12 

How is patenting of hESC lines regulated? 

N/A 

N/A 

N/A 

N/A 

1 

2 

3 

4 

5 

6 

7 

8 

Please list existing regulation applying to human embryonic stem cells 
(hESC) research (web address where to get the texts would be welcomed). 
Italian discipline applying to human embryonic stem cells research consists in 
Law 19 February 2004, n. 40 (Law 40/2004), on medically assisted reproduction 
(“Norme in materia di procreazione medicalmente assistita’), published in 
Gazzetta Ufficiale n. 45, February 24, 2004. 

Does the regulation provide a definition of 'embryo', if so which one? 
The law does not provide a definition of ‘embryo’. However, it aims to protect 
the rights of all the subjects involved in the medical assisted reproduction, 
included the conceived subject (see Art. 1, No 1, which specifies the scopes of 
the law).  

Is hESC research allowed and in what terms and conditions? 
Art. 13, n. 1, of Law 40/2004 that has regards to the experimentation on human 
embryos (“Sperimentazione sugli embroni umani’) expressly prohibits any 
experimentation on human embryos. 

If yes, which body is in charge of the approval of hESC research (ethics 
review)? 
See answer No 3.   

Is the creation of embryos for research purposes, or stem cells 
procurement, allowed in your country, if yes at what conditions? 
Art. 13, n. 3 a), of Law 40/2004 expressly prohibits the creation of human 
embryos for research purposes or for experimentation. 

Is the source of hESC used in research traceable and well documented? 
See answers No 3 and 5.  
 What are the formal ethical and legal requirements for hESC research 
approval? 
See answers No 3 and 5. 

 Does the relevant regulatory frame foresee informed consent procedures 
from individuals involved in embryo donation for research, if so could you 
please describe them? 
The donation of embryos for research is not allowed by Italian law. 

9 

 Is financial inducement allowed? If so, in what terms? 

See answer No 8. 

10 

 Are ad hoc data protection provisions be defined for hESC research? 
See answers No 3 and 5. 

117

01_2007_5944_txt_EN.indd   117

12-02-2008   13:59:00

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 

Are data deriving from hESC projects necessarily provided, whether 
positive or negative (in form of publications)? 
See answers No 3 and 5. 

12 

How is patenting of hESC lines regulated? 
See answers No 3, 5, 8. 

118

01_2007_5944_txt_EN.indd   118

12-02-2008   13:59:00

 
 
  
 
 
 
 
 
11 

Are data deriving from hESC projects necessarily provided, whether 

positive or negative (in form of publications)? 

See answers No 3 and 5. 

12 

How is patenting of hESC lines regulated? 

See answers No 3, 5, 8. 

Regulatory frame applying to LATVIA 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

7 

8 

9 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 

It is not regulated by legislation in Latvia 
Does the regulation provide a definition of 'embryo', if so which one? 
No 

Is hESC research allowed and in what terms and conditions? 
It is not prohibited by legislation 

If yes, which body is in charge of the approval of hESC research (ethics review)? 
Central Medical Ethics Committee 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
It is prohibited by Latvian Reproductive Medicine Act; 
“The creation of human embryos for research purposes is prohibited.  

The human biological material or embryo shall not, as such, give rise to financial 
gain. ‘ 

Is the source of hESC used in research traceable and well documented? 
We have no experience 
 What are the formal ethical and legal requirements for hESC research approval? 

It is not regulated by legislation 
 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 

It is not regulated by legislation  
 Is financial inducement allowed? If so, in what terms? 

It is not regulated by legislation 

10 

 Are ad hoc data protection provisions be defined for hESC research? 
It is regulated for any research 
Law on Data Protection 

Personal  data  processing  is  permitted  only  if  not  prescribed  otherwise  by  law,  and  at 
least one of the following conditions exist: 

1) the data subject has given his or her consent; 

119

01_2007_5944_txt_EN.indd   119

12-02-2008   13:59:01

 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2) the personal data processing results from contractual obligations of the data subject; 

3) the data processing is necessary to a system controller for the performance of his or 
her lawful obligations; 

4)  the  data  processing  is  necessary  to  protect  vitally  important  interests  of  the  data 
subject, including life and health; 

5)  the  data  processing  is  necessary  in  order  to  ensure  that  the  public  interest  is 
complied  with,  or  to  fulfil  functions  of  public  authority  for  whose  performance  the 
personal  data  have  been  transferred  to  a  system  controller  or  transmitted  to  a  third 
person; and 

6) the data processing is necessary in order to, complying with the fundamental human 
rights and freedoms of the data subject, exercise lawful interests of the system 
controller or of such third person as the personal data have been disclosed to. 

The processing of sensitive personal data is prohibited, except in cases where: 

1) the data subject has given his or her written consent for the processing of his or her 
sensitive personal data; 

2) special processing of personal data, without requesting the consent of the data 
subject, is provided for by regulatory enactments which regulate 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
Yes, but it is not regulated by legislation. 

How is patenting of hESC lines regulated? 
It is not regulated 

11 

12 

120

01_2007_5944_txt_EN.indd   120

12-02-2008   13:59:01

 
 
  
 
 
  
 
 
 
 
 
 
2) the personal data processing results from contractual obligations of the data subject; 

3) the data processing is necessary to a system controller for the performance of his or 

her lawful obligations; 

4)  the  data  processing  is  necessary  to  protect  vitally  important  interests  of  the  data 

subject, including life and health; 

5)  the  data  processing  is  necessary  in  order  to  ensure  that  the  public  interest  is 

complied  with,  or  to  fulfil  functions  of  public  authority  for  whose  performance  the 

personal  data  have  been  transferred  to  a  system  controller  or  transmitted  to  a  third 

person; and 

6) the data processing is necessary in order to, complying with the fundamental human 

rights and freedoms of the data subject, exercise lawful interests of the system 

controller or of such third person as the personal data have been disclosed to. 

The processing of sensitive personal data is prohibited, except in cases where: 

1) the data subject has given his or her written consent for the processing of his or her 

sensitive personal data; 

2) special processing of personal data, without requesting the consent of the data 

subject, is provided for by regulatory enactments which regulate 

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

Yes, but it is not regulated by legislation. 

12 

How is patenting of hESC lines regulated? 

It is not regulated 

Regulatory frame applying to LITHUANIA 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

7 

8 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
As for today (16 March, 2007) embryonic stem cell research has not been specifically 
addressed in the law. However, Lithuanian Law on Ethics of Biomedical Research allows 
only observational studies on human embryo, all other research activities on human 
embryo are prohibited (Article 3, Paragraph 2; 
http://www3.lrs.lt/pls/inter2/dokpaieska.showdoc_l?p_id=148740) 
Does the regulation provide a definition of 'embryo', if so which one? 
As for today (16 March, 2007) the regulation does not provide a definition of embryo 

Is hESC research allowed and in what terms and conditions? 
hESC would not be allowed in the country because Lithuanian Law on Ethics of 
Biomedical Research allows only observational studies on human embryo, all other 
research activities on human embryo are prohibited. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 
NA 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
The creation of human embryos is prohibited by the law (Law on Ethics of Biomedical 
Research, Article 3, Paragraph 2) 

Is the source of hESC used in research traceable and well documented? 
NA 
 What are the formal ethical and legal requirements for hESC research approval? 
NA 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
NA 

9 

 Is financial inducement allowed? If so, in what terms? 

NA 

10 

11 

12 

 Are ad hoc data protection provisions be defined for hESC research? 
NA 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
NA 

How is patenting of hESC lines regulated? 
NA 

121

01_2007_5944_txt_EN.indd   121

12-02-2008   13:59:02

 
 
  
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory frame applying to GRAND-DUCHÉ DE 
LUXEMBOURG 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
There is, at present, no legal or regulatory framework for human embryonic stem cells 
research in Luxembourg. However, a new law is under preparation: 

Projet de loi 5528/00 portant approbation: 
—  de la convention pour la protection des droits de l’homme et de la dignité de l’être 
humain à l’égard des applications de la biologie et de la médecine: convention sur 
les droits de l’homme et la biomédecine, ouverte à la signature, à Oviedo, le 4 avril 
1997; 

—  du protocole additionnel à la convention pour la protection des droits de l’homme et 
de la dignité de l’être humain à l’égard des applications de la biologie et de la 
médecine, portant interdiction du clonage d’êtres humains, ouvert à la signature, à 
Paris, le 12 janvier 1998; 

—  du protocole additionnel à la convention sur les droits de l’homme et la 

biomédecine relatif à la transplantation d’organes et de tissus d’origine humaine, 
ouvert à la signature, à Strasbourg, le 24janvier 2002; 

—  du protocole additionnel à la convention sur les droits de l’homme et la 

biomédecine, relatif à la recherche biomédicale, ouvert à la signature, à 
Strasbourg, le 25 janvier 2005, 

et modifiant la loi du 25 novembre 1982 réglant le prélèvement de substances d’origine 
humaine. 

2 

3 

4 

5 

6 

7 

8 

Does the regulation provide a definition of ‘embryo’, if so which one? 
No definition of ‘embryo’ is provided in the draft law. 

Is hESC research allowed and in what terms and conditions? 
No human embryonic stem cells research is being done in Luxembourg at this time. 
If yes, which body is in charge of the approval of hESC research (ethics review)? 
n/a 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
n/a 
The draft law mentioned above doesn’t allow research on human embryos in vitro 
(article 6). 
Is the source of hESC used in research traceable and well documented? 
n/a 
 What are the formal ethical and legal requirements for hESC research approval? 
n/a 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
n/a 

122

01_2007_5944_txt_EN.indd   122

12-02-2008   13:59:03

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
9 

 Is financial inducement allowed? If so, in what terms? 

n/a 

10 

11 

12 

 Are ad hoc data protection provisions be defined for hESC research? 
n/a 
Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
n/a 

How is patenting of hESC lines regulated? 
n/a 
However, ‘the use of human embryos for industrial and commercial purposes is not 
patentable.’ 
(«les utilisations d’embryons humains à des fins industrielles ou commerciales ne sont 
pas brevetables»), article 5, loi du 7 avril 2006 modifiant la loi modifiée du 20 juillet 1992 
portant modification du régime des brevets d’invention. 

Regulatory frame applying to GRAND-DUCHÉ DE 

LUXEMBOURG 

Please the information here provided should concern current regulatory 

requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 

research (web address where to get the texts would be welcomed). 

There is, at present, no legal or regulatory framework for human embryonic stem cells 

research in Luxembourg. However, a new law is under preparation: 

Projet de loi 5528/00 portant approbation: 

—  de la convention pour la protection des droits de l’homme et de la dignité de l’être 

humain à l’égard des applications de la biologie et de la médecine: convention sur 

les droits de l’homme et la biomédecine, ouverte à la signature, à Oviedo, le 4 avril 

1997; 

—  du protocole additionnel à la convention pour la protection des droits de l’homme et 

de la dignité de l’être humain à l’égard des applications de la biologie et de la 

médecine, portant interdiction du clonage d’êtres humains, ouvert à la signature, à 

Paris, le 12 janvier 1998; 

—  du protocole additionnel à la convention sur les droits de l’homme et la 

biomédecine relatif à la transplantation d’organes et de tissus d’origine humaine, 

ouvert à la signature, à Strasbourg, le 24janvier 2002; 

—  du protocole additionnel à la convention sur les droits de l’homme et la 

biomédecine, relatif à la recherche biomédicale, ouvert à la signature, à 

Strasbourg, le 25 janvier 2005, 

et modifiant la loi du 25 novembre 1982 réglant le prélèvement de substances d’origine 

humaine. 

2 

3 

4 

5 

6 

7 

8 

Does the regulation provide a definition of ‘embryo’, if so which one? 

No definition of ‘embryo’ is provided in the draft law. 

Is hESC research allowed and in what terms and conditions? 

No human embryonic stem cells research is being done in Luxembourg at this time. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

Is the creation of embryos for research purposes, or stem cells procurement, 

allowed in your country, if yes at what conditions? 

The draft law mentioned above doesn’t allow research on human embryos in vitro 

(article 6). 

Is the source of hESC used in research traceable and well documented? 

 What are the formal ethical and legal requirements for hESC research approval? 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

describe them? 

n/a 

n/a 

n/a 

n/a 

n/a 

123

01_2007_5944_txt_EN.indd   123

12-02-2008   13:59:03

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Regulatory frame applying to MALTA 

Currently there is no Embryonic Stem Cell or other embryonic regulation at all in 
Malta. 

124

01_2007_5944_txt_EN.indd   124

12-02-2008   13:59:03

 
 
  
 
 
 
 
Regulatory frame applying to MALTA 

Regulatory frame applying to NETHERLANDS 

Currently there is no Embryonic Stem Cell or other embryonic regulation at all in 

Malta. 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 

The Dutch ‘Act containing rules relating to the use of human gametes and embryos’ (Embryos 
Act) came into force on September 1th 2002. A translation can be found at: 
http://www.minvws.nl/en/folders/ibe/2002/introduction-embryo-act.asp  
Does the regulation provide a definition of 'embryo', if so which one? 
Embryos Act, Section 1: 
In this Act the following words shall have the following meanings: 
(….) 
c. embryo: a cell or a complex of cells with the capacity to develop into a human being; 
(…) 
This definition is criticised as being too narrow (excluding non-viable embryos). Cf:  
-Health Council of the Netherlands: Embryonic stem cells without moral pain? (2005). 
Translated report: http://www.gr.nl/pdf.php?ID=1270&p=1  
-Report of the recent evaluation of the Embryos Act (2006). Translated summary: 
http://www.zonmw.nl/fileadmin/cm/vraagsturing/documenten/Evaluatie_regelgeving/embryos_
act_en_sum.pdf  
Is hESC research allowed and in what terms and conditions? 

2 

3 

hESC research is allowed. There are no special conditions for hESC research using existing 
stem cell lines. hESC involving the use of human embryos is subjected to the general 
conditions for research using human embryos set in the Embryos Act (including the 
moratorium regarding the creation of embryos for other purposes than pregnancy; cf sub 
question 5).  

4 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

Only hESC research involving the use of human embryos requires special approval. The 
Central Committee on Research Involving Human Subjects and Embryo Research (CCMO) is 
in charge of this. Website: www.ccmo.nl The head of the bureau of the national review 
committee (CCMO) is dr. Marcel Kenter; e-mail ccmo@ccmo.nl Tel +31 70 3406700.  

125

01_2007_5944_txt_EN.indd   125

12-02-2008   13:59:04

 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
5 

Is the creation of embryos for research purposes, or stem cells procurement, allowed 
in your country, if yes at what conditions? 

The Embryos Act prohibits the creation of embryos for purposes other than reproduction 
(section 24a). This also applies to ‘therapeutic cloning’ using human stem cells. However, the 
Act also contains the provision that this ban shall lapse on a date to be determined within five 
years after the coming into force of the Act (i.e. before September 2007), thus effectively 
turning the ban into a moratorium (section 33 sub 2). The Act already contains provisions for 
the handling of embryos created for purposes other than reproduction which would come into 
force after the lifting of the ban (sections 9 and 11). Section 11 limits the types of research for 
which embryos may then be created to 1) research which is reasonably likely to lead to new 
insights in the fields of infertility, 2) artificial reproduction techniques, 3) hereditary or 
congenital diseases or 4) transplant medicine. 

This complex construction was chosen in order to allow for making a reservation to Article 18 
of the European Convention on Human Rights and Biomedicine (forbidding the creation of 
embryos for research purposes) when ratifying that Convention (as the Netherlands intends 
to do).  

The report of the recent evaluation of the Embryos Act (2006) has called for a swift end to the 
present moratorium on creating embryos for other purposes than pregnancy. Translated 
summary of report: 
http://www.zonmw.nl/fileadmin/cm/vraagsturing/documenten/Evaluatie_regelgeving/embryos_
act_en_sum.pdf  

However, the new government coalition formed early 2007 (Labour & two Christian Democrat 
parties) has announced its intention to maintain the current ban (possibly in the form of 
extending the moratorium for some further years). No formal decision about this has as yet 
been taken.  

6 

Is the source of hESC used in research traceable and well documented? 
No special regulations 

7 

 What are the formal ethical and legal requirements for hESC research approval? 

Cf questions 4 and 8 

8 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please describe 
them? 

Yes. As specified in section 8.2 of the Embryos Act, embryos may be made available only by 
means of a written donation and without consideration, and only after the persons concerned 
(which may also include a gamete donor), have been informed by the person storing the 
embryos regarding the nature and the purpose thereof. Where a difference of opinion arises 
between the parties concerned, the embryos shall not be made available. Any of the persons 
concerned may revoke his/her decision at any time before the embryos have been used, 
without giving reasons. 
In the report of the recent evaluation of the Embryos Act (2006), it is pointed out that the Act 
does not provide sufficient guidance as to the required specificity of the information to be 
given about the nature of the research. Cf summary of report: 
http://www.zonmw.nl/fileadmin/cm/vraagsturing/documenten/Evaluatie_regelgeving/embryos_
act_en_sum.pdf 

126

01_2007_5944_txt_EN.indd   126

12-02-2008   13:59:04

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 

 Is financial inducement allowed? If so, in what terms? 

No, cf question 8: embryos may only be donated ‘without consideration’. The same holds for 
the donation of gametes. In practice, a remuneration of expenses is accepted.  
The report of the recent evaluation of the Embryos Act (2006) contains the recommendation 
to further debate the desirability/acceptability of a larger recompensation for women donating 
oocytes for research. Cf summary of report: 
http://www.zonmw.nl/fileadmin/cm/vraagsturing/documenten/Evaluatie_regelgeving/embryos_
act_en_sum.pdf 

 Are ad hoc data protection provisions be defined for hESC research? 

No special regulations  

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 

No special regulations 

How is patenting of hESC lines regulated? 

No special regulations 

1
0 

1
1 

1
2 

5 

Is the creation of embryos for research purposes, or stem cells procurement, allowed 

in your country, if yes at what conditions? 

The Embryos Act prohibits the creation of embryos for purposes other than reproduction 

(section 24a). This also applies to ‘therapeutic cloning’ using human stem cells. However, the 

Act also contains the provision that this ban shall lapse on a date to be determined within five 

years after the coming into force of the Act (i.e. before September 2007), thus effectively 

turning the ban into a moratorium (section 33 sub 2). The Act already contains provisions for 

the handling of embryos created for purposes other than reproduction which would come into 

force after the lifting of the ban (sections 9 and 11). Section 11 limits the types of research for 

which embryos may then be created to 1) research which is reasonably likely to lead to new 

insights in the fields of infertility, 2) artificial reproduction techniques, 3) hereditary or 

congenital diseases or 4) transplant medicine. 

This complex construction was chosen in order to allow for making a reservation to Article 18 

of the European Convention on Human Rights and Biomedicine (forbidding the creation of 

embryos for research purposes) when ratifying that Convention (as the Netherlands intends 

The report of the recent evaluation of the Embryos Act (2006) has called for a swift end to the 

present moratorium on creating embryos for other purposes than pregnancy. Translated 

http://www.zonmw.nl/fileadmin/cm/vraagsturing/documenten/Evaluatie_regelgeving/embryos_

However, the new government coalition formed early 2007 (Labour & two Christian Democrat 

parties) has announced its intention to maintain the current ban (possibly in the form of 

extending the moratorium for some further years). No formal decision about this has as yet 

6 

Is the source of hESC used in research traceable and well documented? 

7 

 What are the formal ethical and legal requirements for hESC research approval? 

to do).  

summary of report: 

act_en_sum.pdf  

been taken.  

No special regulations 

Cf questions 4 and 8 

them? 

8 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please describe 

Yes. As specified in section 8.2 of the Embryos Act, embryos may be made available only by 

means of a written donation and without consideration, and only after the persons concerned 

(which may also include a gamete donor), have been informed by the person storing the 

embryos regarding the nature and the purpose thereof. Where a difference of opinion arises 

between the parties concerned, the embryos shall not be made available. Any of the persons 

concerned may revoke his/her decision at any time before the embryos have been used, 

without giving reasons. 

In the report of the recent evaluation of the Embryos Act (2006), it is pointed out that the Act 

does not provide sufficient guidance as to the required specificity of the information to be 

given about the nature of the research. Cf summary of report: 

http://www.zonmw.nl/fileadmin/cm/vraagsturing/documenten/Evaluatie_regelgeving/embryos_

act_en_sum.pdf 

127

01_2007_5944_txt_EN.indd   127

12-02-2008   13:59:05

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory frame applying to POLAND 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
In Poland there is no research on embryonic stem cells. 

Polish legal rules do not include distinct regulations for human embryonic stem cells 
research. There is also no legal definition for embryo stage of life. 
The fundamental legal act in Poland is the Constitution of the Republic of Poland 
(http://www.sejm.gov.pl/prawo/konst/angielski/kon1.htm), which was passed by the 
National Assembly on April 2nd, 1997. In accordance with Art.38 of this Law the 
Republic of Poland shall ensure the legal protection of the life of every human being 
Regulations referring to legal protection and conduct rules in the pre-birth stage of 
human life are included in the Act of January 7th, 1993 on Family Planning, 
Protection of Human Foetus and Admissible Conditions for an Abortion. 
In accordance with Art.1 of this Law, the right to life is protected, including also the 
prenatal stage, in the scope stipulated by the Law. The Law also includes regulations 
concerning the conceived child that is from the moment of conception through the 
embryo and foetal stages until birth.  
According to Art.157a of the Criminal Code any person except for child’s mother who 
commits any infringement to a conceived child, will be punished. The rule does not 
include a physician who undertakes medical action necessary to exclude danger-
threatening mother’s or child’s health or life. 
What’s more, under the Act of December 5th, 1996 on Medical Profession’s, human 
embryos (conceived children) may not be used for therapeutic research (Art. 26 
paragraph 1).  
Not directly refers to this matter the ruling of the Constitutional Court of the 
Republic of Poland from the 28th May 1997, which says: ‘A democratic state 
governed by the rule of law holds man and his most precious weal as a supreme value. 
By this weal, we understand life which in a democratic state governed by the rule of law 
must enjoy constitutional protection in each stage of its development’. 

2 

Does the regulation provide a definition of 'embryo', if so which one? 

As mentioned above, there is no legal definition for embryo stage of life. 

3 

4 

5 

6 

7 

Is hESC research allowed and in what terms and conditions? 
In Poland, human embryo research is prohibited. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

NA 
Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
Is not allowed.  

Is the source of hESC used in research traceable and well documented? 
NA 
 What are the formal ethical and legal requirements for hESC research approval? 
NA 

128

01_2007_5944_txt_EN.indd   128

12-02-2008   13:59:06

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
NA 

9 

 Is financial inducement allowed? If so, in what terms? 

10 

11 

12 

NA 
 Are ad hoc data protection provisions be defined for hESC research? 
NA 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 

How is patenting of hESC lines regulated? 
NA 

Regulatory frame applying to POLAND 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 

research (web address where to get the texts would be welcomed). 

In Poland there is no research on embryonic stem cells. 

Polish legal rules do not include distinct regulations for human embryonic stem cells 

research. There is also no legal definition for embryo stage of life. 

The fundamental legal act in Poland is the Constitution of the Republic of Poland 

(http://www.sejm.gov.pl/prawo/konst/angielski/kon1.htm), which was passed by the 

National Assembly on April 2nd, 1997. In accordance with Art.38 of this Law the 

Republic of Poland shall ensure the legal protection of the life of every human being 

Regulations referring to legal protection and conduct rules in the pre-birth stage of 

human life are included in the Act of January 7th, 1993 on Family Planning, 

Protection of Human Foetus and Admissible Conditions for an Abortion. 

In accordance with Art.1 of this Law, the right to life is protected, including also the 

prenatal stage, in the scope stipulated by the Law. The Law also includes regulations 

concerning the conceived child that is from the moment of conception through the 

embryo and foetal stages until birth.  

According to Art.157a of the Criminal Code any person except for child’s mother who 

commits any infringement to a conceived child, will be punished. The rule does not 

include a physician who undertakes medical action necessary to exclude danger-

threatening mother’s or child’s health or life. 

What’s more, under the Act of December 5th, 1996 on Medical Profession’s, human 

embryos (conceived children) may not be used for therapeutic research (Art. 26 

paragraph 1).  

Not directly refers to this matter the ruling of the Constitutional Court of the 

Republic of Poland from the 28th May 1997, which says: ‘A democratic state 

governed by the rule of law holds man and his most precious weal as a supreme value. 

By this weal, we understand life which in a democratic state governed by the rule of law 

must enjoy constitutional protection in each stage of its development’. 

2 

Does the regulation provide a definition of 'embryo', if so which one? 

As mentioned above, there is no legal definition for embryo stage of life. 

3 

4 

5 

6 

7 

NA 

NA 

NA 

Is hESC research allowed and in what terms and conditions? 

In Poland, human embryo research is prohibited. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

Is the creation of embryos for research purposes, or stem cells procurement, 

allowed in your country, if yes at what conditions? 

Is not allowed.  

Is the source of hESC used in research traceable and well documented? 

 What are the formal ethical and legal requirements for hESC research approval? 

129

01_2007_5944_txt_EN.indd   129

12-02-2008   13:59:06

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory frame applying to PORTUGAL 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
In Portugal, Law n. 32/2006, of the 26th of July, concerning Medically Assisted 
Reproduction, addresses hESC research. 
The text is available on http://www.dre.pt/pdfgratisa5/2006/07/14300.pdf (Portuguese 
version only) 
Does the regulation provide a definition of 'embryo', if so which one? 

The Portuguese regulation doesn’t provide a definition of ‘embryo’. 
Is hESC research allowed and in what terms and conditions? 
The article n. 9 of the law forbids the deliberate production of human embryos 
specifically for research purposes. 
However, scientific hESC research can be allowed provided it is reasonable to expect 
that the investigation project will benefit mankind. Research must aim: 

Prevention, diagnosis or therapy on embryos; 

Perfection of Medically Assisted Reproduction techniques; 

Creation of stem cell banks for transplantation programs or other therapeutic 
purposes. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

The law n. º 36/2006 created the National Council for Medically Assisted Reproduction, 
in charge of the approval of the investigation projects for hESC research. 
Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 

As mentioned above, the deliberate production of human embryos specifically for 
research purposes is forbidden. 
According to Arts. 9, 24 and 25, IVF techniques must ensure only the necessary 
number of embryos for the success of the IVF process.  
Only embryos whit particularly severe genetic anomalies with no conditions to be 
preserved or implanted, embryos not derived by fertilisation of a human oocyte by 
human sperm, or those created to enhance the success rate of IVF who became 
supernumerary and no longer a part of a parental project, can be used for research 
purposes. 
Is the source of hESC used in research traceable and well documented? 

According to Art. 16, personal genetic and health data regarding medically assisted 
reproduction techniques is regulated by Law n.º 12/2005, of the 26th of January, 
concerning genetic and health personal information. 

The text is available on http://www.dre.pt/pdfgratisa5/2005/01/018A00.pdf (Portuguese 
version only) 

Further regulation on data documentation, storage and access is being prepared. 

130

01_2007_5944_txt_EN.indd   130

12-02-2008   13:59:07

 
 
  
 
 
 
 
 
 
 
 
 
Regulatory frame applying to PORTUGAL 

Please the information here provided should concern current regulatory 

requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 

research (web address where to get the texts would be welcomed). 

In Portugal, Law n. 32/2006, of the 26th of July, concerning Medically Assisted 

Reproduction, addresses hESC research. 

The text is available on http://www.dre.pt/pdfgratisa5/2006/07/14300.pdf (Portuguese 

2 

3 

4 

5 

version only) 

Does the regulation provide a definition of 'embryo', if so which one? 

The Portuguese regulation doesn’t provide a definition of ‘embryo’. 

Is hESC research allowed and in what terms and conditions? 

The article n. 9 of the law forbids the deliberate production of human embryos 

specifically for research purposes. 

However, scientific hESC research can be allowed provided it is reasonable to expect 

that the investigation project will benefit mankind. Research must aim: 

Prevention, diagnosis or therapy on embryos; 

Perfection of Medically Assisted Reproduction techniques; 

Creation of stem cell banks for transplantation programs or other therapeutic 

purposes. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

The law n. º 36/2006 created the National Council for Medically Assisted Reproduction, 

in charge of the approval of the investigation projects for hESC research. 

Is the creation of embryos for research purposes, or stem cells procurement, 

allowed in your country, if yes at what conditions? 

As mentioned above, the deliberate production of human embryos specifically for 

research purposes is forbidden. 

According to Arts. 9, 24 and 25, IVF techniques must ensure only the necessary 

number of embryos for the success of the IVF process.  

Only embryos whit particularly severe genetic anomalies with no conditions to be 

preserved or implanted, embryos not derived by fertilisation of a human oocyte by 

human sperm, or those created to enhance the success rate of IVF who became 

supernumerary and no longer a part of a parental project, can be used for research 

purposes. 

6 

Is the source of hESC used in research traceable and well documented? 

According to Art. 16, personal genetic and health data regarding medically assisted 

reproduction techniques is regulated by Law n.º 12/2005, of the 26th of January, 

concerning genetic and health personal information. 

The text is available on http://www.dre.pt/pdfgratisa5/2005/01/018A00.pdf (Portuguese 

version only) 

Further regulation on data documentation, storage and access is being prepared. 

7 

 What are the formal ethical and legal requirements for hESC research approval? 

The regulation of the conditions under which the investigation projects will be evaluated 
is being prepared. 

However, in Art. 9º the actual law still requires that scientific hESC research is made for 
prevention, diagnosis or therapy on embryos, for the perfection of Medically Assisted 
Reproduction techniques or for the creation of stem cell banks for transplantation 
programs or other therapeutic purposes. 

Additionally, research can be allowed provided it is reasonable to expect that the 
investigation project will benefit mankind. 
 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 

According to the present law, the use of supernumerary embryos or of embryos with 
particularly severe genetic anomalies entails previous informed consent from donors. 
This consent must also be express, free and conscientious. 

It is expected that the regulation to further to the law establishes further requirements 
for consent. 
 Is financial inducement allowed? If so, in what terms? 

Art. 18 states that the purchase or sell of embryos or any other biological material 
obtained from the use of Medically Assisted Reproduction techniques is forbidden. 

8 

9 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

11 

12 

This regulation is being prepared. 
Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
At this time, there is no knowledge of research involving human embryos being made in 
Portugal. 
The regulatory framework under which the investigation projects will be made is being 
prepared. 
How is patenting of hESC lines regulated? 
By the Decree-Law n.º 36/2003, of the 5th of March, Portugal transposed the Directive 
98/44/CE of the European Parliament and the Council of the 6th of July, regarding the 
legal protection of biotechnological inventions. 
Art. 53º of this decree-law states that the use of human embryos for industrial or 
commercial purposes, as well as the human body, in his various stages of development 
or by the mere discovery of one of his elements, aren’t patentable.  
The text is available on  
http://www.dre.pt/pdfgratisa5/2003/03/054A00.pdf (Portuguese version only) 

131

01_2007_5944_txt_EN.indd   131

12-02-2008   13:59:08

 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Regulatory frame applying to ROMANIA 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

7 

8 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
In Romania there is no specific regulation applying to hESC.  
In the field of research on hESC the following general regulation could be applied: 
1.  Law 206/2004 regarding good conduct in scientific research, technological 

development and innovation, www.cdep.ro 

2.  Law 17/2001 regarding the ratification of Oviedo Convention, www.cdep.ro 
3.  Law 95/2006 regarding the reform in health care system, www.cdep.ro 
4.  The Code of Deontology for Physicians of the Romanian College of Physicians, 

www.cmr.ro 

Does the regulation provide a definition of 'embryo', if so which one? 
No Romanian law provides a definition of ‘embryo’. 

Is hESC research allowed and in what terms and conditions? 
There is no specific legal provision to forbid hESC research.  

If yes, which body is in charge of the approval of hESC research (ethics review)? 
Ethics commissions organized according to law 206/2004 (art.12) must supervise the 
research projects in order to respect the protection of human being, including the 
protection of human embryos 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
No 

Is the source of hESC used in research traceable and well documented? 
No 
 What are the formal ethical and legal requirements for hESC research approval? 
There are not specific formal ethical and legal requirements for hESC research approval 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
In such situations the general legislation mentioned in point 1 could be applied. 

9 

 Is financial inducement allowed? If so, in what terms? 

The financial inducement is not allowed according to law 95/2006, title VI- organ and 
tissue donation must be purely altruistic 

132

01_2007_5944_txt_EN.indd   132

12-02-2008   13:59:08

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 

11 

12 

 Are ad hoc data protection provisions be defined for hESC research? 
There are not specific provisions for ad hoc data protection in hESC research.  
There are general laws regarding personal data protection: 

1.  Law 667/2001, www.cdep.ro 

2.  Law 676/2001, www.cdep.ro 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
I do not have such information 

How is patenting of hESC lines regulated? 
I do not have certain information regarding this issue. I do not think that in Romania 
there are specific provisions regarding this issue 

Regulatory frame applying to ROMANIA 

Please the information here provided should concern current regulatory 

requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 

research (web address where to get the texts would be welcomed). 

In Romania there is no specific regulation applying to hESC.  

In the field of research on hESC the following general regulation could be applied: 

1.  Law 206/2004 regarding good conduct in scientific research, technological 

development and innovation, www.cdep.ro 

2.  Law 17/2001 regarding the ratification of Oviedo Convention, www.cdep.ro 

3.  Law 95/2006 regarding the reform in health care system, www.cdep.ro 

4.  The Code of Deontology for Physicians of the Romanian College of Physicians, 

www.cmr.ro 

2 

3 

4 

5 

6 

7 

8 

Does the regulation provide a definition of 'embryo', if so which one? 

No Romanian law provides a definition of ‘embryo’. 

Is hESC research allowed and in what terms and conditions? 

There is no specific legal provision to forbid hESC research.  

If yes, which body is in charge of the approval of hESC research (ethics review)? 

Ethics commissions organized according to law 206/2004 (art.12) must supervise the 

research projects in order to respect the protection of human being, including the 

protection of human embryos 

Is the creation of embryos for research purposes, or stem cells procurement, 

allowed in your country, if yes at what conditions? 

No 

No 

Is the source of hESC used in research traceable and well documented? 

 What are the formal ethical and legal requirements for hESC research approval? 

There are not specific formal ethical and legal requirements for hESC research approval 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

describe them? 

In such situations the general legislation mentioned in point 1 could be applied. 

9 

 Is financial inducement allowed? If so, in what terms? 

The financial inducement is not allowed according to law 95/2006, title VI- organ and 

tissue donation must be purely altruistic 

133

01_2007_5944_txt_EN.indd   133

12-02-2008   13:59:09

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Regulatory frame applying to: SLOVAK REPUBLIC 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

7 

8 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
No specific regulations exist at present. There is an extensive governmental regulation 
in preparation, however, to deal with the ‘donation, procurement, testing and distribution 
of organs, tissues and cells, and processing, conservation and storage of tissues and 
cells’ (transposition of the requirements of the Dir. 2006/17/EC, ev. Dir. 2004/23/EC). It 
could tackle on some closely related issues, but probably not specifically on hESCs.  
Does the regulation provide a definition of 'embryo', if so which one? 
N.A. (non-applicable) 

Is hESC research allowed and in what terms and conditions? 
hESC research is not specifically prohibited by a law, however, according to the position 
the Slovak Republic (SR) has taken so far on the issue, it probably would not be 
allowed to take place in the country (as destroying of a human embryo is necessary to 
obtain the hESCs lines for research).  
The ‘non-therapeutic’ research on human embryo and fetus, as well as human cloning 
are prohibited both by the SR’s health law (law No. 576/2004 Coll. as later amended) 
and by SR’s Penal Code (law No. 300/2005 Coll.) – making both a criminal offence.   
If yes, which body is in charge of the approval of hESC research (ethics review)? 
N.A. (non-applicable) 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
NO, it is prohibited as a criminal act (see 3, above). 

Is the source of hESC used in research traceable and well documented? 
N.A. (non-applicable) 
 What are the formal ethical and legal requirements for hESC research approval? 
N.A. (non-applicable) 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
N.A. (non-applicable) 

9 

 Is financial inducement allowed? If so, in what terms? 

10 

11 

12 

N.A. (non-applicable) 

 Are ad hoc data protection provisions be defined for hESC research? 
N.A. (non-applicable) 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
N.A. (non-applicable) 

How is patenting of hESC lines regulated? 
N.A. (non-applicable) 

134

01_2007_5944_txt_EN.indd   134

12-02-2008   13:59:10

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory frame applying to: SLOVAK REPUBLIC 

Regulatory frame applying to SLOVENIA 

Please the information here provided should concern current regulatory 

requirements and not other reference documents having not a legal personality. 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 

research (web address where to get the texts would be welcomed). 

No specific regulations exist at present. There is an extensive governmental regulation 

in preparation, however, to deal with the ‘donation, procurement, testing and distribution 

of organs, tissues and cells, and processing, conservation and storage of tissues and 

cells’ (transposition of the requirements of the Dir. 2006/17/EC, ev. Dir. 2004/23/EC). It 

could tackle on some closely related issues, but probably not specifically on hESCs.  

Does the regulation provide a definition of 'embryo', if so which one? 

N.A. (non-applicable) 

Is hESC research allowed and in what terms and conditions? 

hESC research is not specifically prohibited by a law, however, according to the position 

the Slovak Republic (SR) has taken so far on the issue, it probably would not be 

allowed to take place in the country (as destroying of a human embryo is necessary to 

obtain the hESCs lines for research).  

The ‘non-therapeutic’ research on human embryo and fetus, as well as human cloning 

are prohibited both by the SR’s health law (law No. 576/2004 Coll. as later amended) 

and by SR’s Penal Code (law No. 300/2005 Coll.) – making both a criminal offence.   

If yes, which body is in charge of the approval of hESC research (ethics review)? 

N.A. (non-applicable) 

Is the creation of embryos for research purposes, or stem cells procurement, 

allowed in your country, if yes at what conditions? 

NO, it is prohibited as a criminal act (see 3, above). 

Is the source of hESC used in research traceable and well documented? 

 What are the formal ethical and legal requirements for hESC research approval? 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

2 

3 

4 

5 

6 

7 

8 

9 

 Is financial inducement allowed? If so, in what terms? 

10 

 Are ad hoc data protection provisions be defined for hESC research? 

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

N.A. (non-applicable) 

12 

How is patenting of hESC lines regulated? 

N.A. (non-applicable) 

N.A. (non-applicable) 

N.A. (non-applicable) 

describe them? 

N.A. (non-applicable) 

N.A. (non-applicable) 

N.A. (non-applicable) 

1 

2 

3 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
Explicit legal regulation on hESC does not exist. However, the Law on treatment of 
infertility and biomedically assisted fertilisation (Zakon o zdravljenju neplodnosti in 
postopkih oploditve z biomedicinsko pomocjo, /ZZNPOB/ 3307, Uradni list Republike 
Slovenije 70/2000, 8. 8. 2000, UL ONLINE) contains provisions that apply to research 
on embryos from IVF procedures and may apply to procurement of hESC.  
Web address (Ministry of Health): http://www.mz.gov.si 
Does the regulation provide a definition of 'embryo', if so which one? 
Article 4: The embryo is created by fertilisation of the ovum. For the purposes of this 
Law, the early embryo is a zygote or an embryo that has developed outside the uterus 
for less than 14 days or until the appearance of the primitive streak. 

Is hESC research allowed and in what terms and conditions? 
As said above, research on hESC is not specifically regulated.  

Slovenia is party to the Oviedo Convention and the protocol on prohibition of human 
cloning. Its Law on treatment of infertility and biomedically assisted fertilisation forbids 
the creation of human embryos for research, the production of cloned embryos and the 
use of in vitro fertilisation for any purpose other that birth of a child. Also prohibited is 
the use of parts of embryo for any purpose other than is explicitly allowed by law.  

However, the law allows research on surplus embryos from in vitro fertilisation 
procedures (and thus also procurement of hESC), if several conditions are fulfilled:  

Article 38 (unofficial translation) 

Scientific research on the gametes and early embryos (= in vitro embryos) is allowed 
exclusively for the purposes of (promoting knowledge on) protection and improvement 
of human health. It may be carried out on early embryos only if it cannot be done on 
animal embryos or otherwise with comparable efficiency. Early embryos may only be 
used for research after a written informed consent has been obtained for their parents 
who had undergone medically assisted reproduction. The research must be authorised 
by the National Commission for Assisted Reproduction and must be approved and 
supervised by the National Medical Ethics Committee (NMEC). Permission may be 
granted for embryos that, according to medical knowledge, are not suitable to be 
transferred into woman’s body or for storage, or would have to be left to perish 
according to the Article 35 of the Law (end of the maximum storage period). In research 
on embryos, current medical knowledge, experience, established practices and 
principles of general medical ethics must be taken into account.  

135

01_2007_5944_txt_EN.indd   135

12-02-2008   13:59:10

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
4 

5 

6 

7 

8 

If yes, which body is in charge of the approval of hESC research (ethics review)? 
The National Medical Ethics Committee, after authorisation has been obtained from the 
National Commission for Assisted Reproduction. 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
No. 

Is the source of hESC used in research traceable and well documented? 
Traceability  and  full  documentation  of  biological  materials  of  human  origin  is  legally 
required.  

 What are the formal ethical and legal requirements for hESC research approval? 
Full compliance with the law (see answer to Q 3).  

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
The regulatory framework (the Law on treatment of infertility and biomedically assisted 
fertilisation does not provide for any specific rules, except that written informed consent 
must be obtained from both partners. 

9 

 Is financial inducement allowed? If so, in what terms? 

All financial inducement is strictly forbidden.  

10 

11 

12 

 Are ad hoc data protection provisions be defined for hESC research? 
This  Q  is  slightly  difficult  to  understand  (syntactic  error?).  Until  now,  the  National 
Medical Ethics Committee has received only one application for approval of a study on 
hESC  derived  from  embryos  and  has  approved  harvesting  hESC  from  nonviable 
embryos from in vitro fertilisation procedures.  

The usual rules of confidentiality and data protection apply.  
Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
Yes. This is among the requirements of the NMEC. 

How is patenting of hESC lines regulated? 
Specific regulation does not exist. 

136

01_2007_5944_txt_EN.indd   136

12-02-2008   13:59:11

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

The National Medical Ethics Committee, after authorisation has been obtained from the 

National Commission for Assisted Reproduction. 

5 

Is the creation of embryos for research purposes, or stem cells procurement, 

allowed in your country, if yes at what conditions? 

6 

Is the source of hESC used in research traceable and well documented? 

Traceability  and  full  documentation  of  biological  materials  of  human  origin  is  legally 

No. 

required.  

7 

8 

 What are the formal ethical and legal requirements for hESC research approval? 

Full compliance with the law (see answer to Q 3).  

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

describe them? 

The regulatory framework (the Law on treatment of infertility and biomedically assisted 

fertilisation does not provide for any specific rules, except that written informed consent 

must be obtained from both partners. 

9 

 Is financial inducement allowed? If so, in what terms? 

All financial inducement is strictly forbidden.  

10 

 Are ad hoc data protection provisions be defined for hESC research? 

This  Q  is  slightly  difficult  to  understand  (syntactic  error?).  Until  now,  the  National 

Medical Ethics Committee has received only one application for approval of a study on 

hESC  derived  from  embryos  and  has  approved  harvesting  hESC  from  nonviable 

embryos from in vitro fertilisation procedures.  

The usual rules of confidentiality and data protection apply.  

11 

Are data deriving from hESC projects necessarily provided, whether positive or 

negative (in form of publications)? 

Yes. This is among the requirements of the NMEC. 

12 

How is patenting of hESC lines regulated? 

Specific regulation does not exist. 

Regulatory frame applying to SPAIN 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
Law 14/2006 about Human Assisted Reproduction Techniques (HARTAct): 
http://www.boe.es/boe/dias/2006/05/27/pdfs/A19947-19956.pdf 
http://www.boe.es/g/es/bases_datos/doc.php?coleccion=iberlex&id=2006/09292&txtlen=1000
Act of 2007, on Biomedical Research (BMRAct) 
(It has not been published in the State Official Journal) 
Other regulations: 
Research with spare frozen embryos after assisted reproduction techniques: 
http://www.isciii.es/htdocs/terapia/legislacion/Terapia_RD_2132_2004.pdf 
Organization of the National Bank of Stem Cell Lines: 
http://www.boe.es/boe/dias/2006/02/18/pdfs/A06637-06641.pdf 

2 

Does the regulation provide a definition of 'embryo', if so which one? 
Yes, it does. 
In the Spanish legislation there are two definitions, on the human pre-embryo and on the 
human embryo:  

a) Pre-embryo: the in vitro embryo as constituted by a group of cells derived of the 
continuous division of the fertilised oocyte until 14 days later (art. 1.2 of HARTAct and art. 3, 
s, BMRAct) 

b) Embryo: A step of embryonic development, which includes the time in what the fertilised 
oocyte is located in the uterus of a woman until the time of the beginning of the step of the 
formation of organs, it is to say, 56 days after fertilisation occurs, regardless the time during 
such development could be stopped (art. 3, l, BMRAct). 

3 

Is hESC research allowed and in what terms and conditions? 
Yes, this type of research is allowed but only under case by case scrutiny. The research 
project has to fulfil, by the research group, the ethical guarantees requested. 
A) From surplus pre-embryos HARTAct): 
Article 15. Using pre-embryos for research purposes. 

Informed consent of the couple or of the single woman. 

a) 
b)  The pre-embryo shall not be developed in vitro more than 14 days, regardless the time it could be 

cryo-preserved 

c)  Research shall be performed in authorised centres 
d)  Research will be done on the basis of a research project authorised by the competent authority, 

previous the perceptive and favourable Commission (see down). 

B) From cloned pre-embryos (BMRAct): 
Article 34 Guarantees and requisites for research 
1. Research or experimentation with surplus oocytes and pre-embryos from the application of assisted 

137

01_2007_5944_txt_EN.indd   137

12-02-2008   13:59:12

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
reproduction techniques, or from their biological structures, with the aim to obtain, develop and use 
embryonic stem cell lines or with other purposes not associated with the development and application 
of assisted reproduction techniques, shall be undertaken in accordance with the conditions established 
in Law 14/2006, of 26 May, and comply with the following requisites: 

a)  That the research abides by the applicable ethical principles and legal regulations, especially 
in  that  provided  in  this  Law  and  its  development  of  rules  and  guidelines  in  law,  and  that  it 
follows  the  principles  of  relevance,  feasibility  and  suitability,  specifically  of  the  main 
researcher,  of  the  research  team  and  of  the  facilities  of  the  centre  that  shall  undertake  the 
research. 

b)  That  it  is  based  on  a  research  project  authorised  by  the  relevant  State  or  autonomous 
authorities,  after  a  favourable  report  by  the  Commission  for  establishing  guarantees  in  the 
donation and use of human cells and tissues, in the event that the project deals with matters 
provided in article 35. 

2. The authorisation of the research projects shall be conditioned on the project including at least the 
following elements: 

a) The authorisation by the management of the centre that shall undertake the research, as 

well as the favourable report of the corresponding Research Ethics Committee. 

b) The notification of the common relations and interests, of any nature or the absence of 
such, between the team and the centre that have undertaken each of the processes of assisted 
reproduction that have generated pre-embryos or have intervened in the obtaining of oocytes. 
c) The written commitment to supply to the corresponding public authority the data that will 
permit to identify and know the storage of the cell lines that could be obtained as a consequence 
of the development of the research. 

d) The commitment of the free conveyance of line cells that could be obtained in the 

development of the research, for its use by other researchers. 

e) When using oocytes or pre-embryos, the indication and justification of its size, origin and the 
document of the informed consent signed by the donors or progenitors respectively. 

4 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

A)  For  researches  related  with  the  application  and  implementation  of  human  assisted 
reproductive techniques: the National Commission on Assisted Human Reproduction 
(art.  15.1,  d,  HARTAct)  ‘Comision  de  Garantías  para  la  Donación  y  Utilización  de 
Células y Tejidos Humanos’ 

B)  For  researches  related  with  the  gain,  implementation  and  use  of  hESC  lines:  the 
Commission for Establishing Guarantees in the donation and use of human cells and 
tissues (art. 35 BMRAct) 

5 

In both cases the previous review by a local Research Ethics Committee is also needed. 
Is the creation of embryos for research purposes, or stem cells procurement, allowed 
in your country, if yes at what conditions? 
The new law explicitly prohibits the creation of pre-embryos and embryos for the exclusive 
use of research, although it permits the use of any other technique, including nuclear 
transfer, aimed to obtaining human embryonic stem cells for research or therapy (BMRAct): 
Article 33 Obtaining of embryonic cells 
1. The creation of human pre-embryos and embryos solely for experimentation purposes shall be 
prohibited. 
2. The use of any technique for obtaining human stem cells for therapeutic or research purposes shall 
be permitted, when it doesn’t entail the creation of a pre-embryo or embryo solely for this purpose, in 
the terms provided in this Law, including the activation of oocytes through nuclear transfer. 
A perceptive and favourable previous opinion by the Commission for Establishing 

138

01_2007_5944_txt_EN.indd   138

12-02-2008   13:59:13

 
 
  
 
 
 
 
 
reproduction techniques, or from their biological structures, with the aim to obtain, develop and use 

embryonic stem cell lines or with other purposes not associated with the development and application 

of assisted reproduction techniques, shall be undertaken in accordance with the conditions established 

in Law 14/2006, of 26 May, and comply with the following requisites: 

a)  That the research abides by the applicable ethical principles and legal regulations, especially 

in  that  provided  in  this  Law  and  its  development  of  rules  and  guidelines  in  law,  and  that  it 

follows  the  principles  of  relevance,  feasibility  and  suitability,  specifically  of  the  main 

researcher,  of  the  research  team  and  of  the  facilities  of  the  centre  that  shall  undertake  the 

research. 

b)  That  it  is  based  on  a  research  project  authorised  by  the  relevant  State  or  autonomous 

authorities,  after  a  favourable  report  by  the  Commission  for  establishing  guarantees  in  the 

donation and use of human cells and tissues, in the event that the project deals with matters 

provided in article 35. 

2. The authorisation of the research projects shall be conditioned on the project including at least the 

following elements: 

a) The authorisation by the management of the centre that shall undertake the research, as 

well as the favourable report of the corresponding Research Ethics Committee. 

b) The notification of the common relations and interests, of any nature or the absence of 

such, between the team and the centre that have undertaken each of the processes of assisted 

reproduction that have generated pre-embryos or have intervened in the obtaining of oocytes. 

c) The written commitment to supply to the corresponding public authority the data that will 

permit to identify and know the storage of the cell lines that could be obtained as a consequence 

of the development of the research. 

d) The commitment of the free conveyance of line cells that could be obtained in the 

development of the research, for its use by other researchers. 

e) When using oocytes or pre-embryos, the indication and justification of its size, origin and the 

document of the informed consent signed by the donors or progenitors respectively. 

4 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

A)  For  researches  related  with  the  application  and  implementation  of  human  assisted 

reproductive techniques: the National Commission on Assisted Human Reproduction 

(art.  15.1,  d,  HARTAct)  ‘Comision  de  Garantías  para  la  Donación  y  Utilización  de 

Células y Tejidos Humanos’ 

B)  For  researches  related  with  the  gain,  implementation  and  use  of  hESC  lines:  the 

Commission for Establishing Guarantees in the donation and use of human cells and 

tissues (art. 35 BMRAct) 

In both cases the previous review by a local Research Ethics Committee is also needed. 

5 

Is the creation of embryos for research purposes, or stem cells procurement, allowed 

in your country, if yes at what conditions? 

The new law explicitly prohibits the creation of pre-embryos and embryos for the exclusive 

use of research, although it permits the use of any other technique, including nuclear 

transfer, aimed to obtaining human embryonic stem cells for research or therapy (BMRAct): 

Article 33 Obtaining of embryonic cells 

1. The creation of human pre-embryos and embryos solely for experimentation purposes shall be 

prohibited. 

2. The use of any technique for obtaining human stem cells for therapeutic or research purposes shall 

be permitted, when it doesn’t entail the creation of a pre-embryo or embryo solely for this purpose, in 

the terms provided in this Law, including the activation of oocytes through nuclear transfer. 

A perceptive and favourable previous opinion by the Commission for Establishing 

6 

7 

8 

Guarantees in the donation and use of human cells and tissues is needed, as well as the 
authorisation of the Autonomous Community Authority. 

Is the source of hESC used in research traceable and well documented? 
Yes, it is (art. 8 BMRAct). 

 What are the formal ethical and legal requirements for hESC research approval? 
1-Informed consents from the parents of all embryos used;  
2-approval by the ethical committee of the institution or the autonomous community and  
3-approval by the ad hoc ‘Comision de Garantías para la Donación y Utilización de Células y 
Tejidos Humanos’ 
(See on this previous answer to question Nr 4). 
 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please describe 
them? 
Yes. If embryos are going to be used for a research project, parents must sign an informed 
consent specific for that project. The informed consent form includes the name of the 
research project, a short summary of the main research objectives, the name of the IP and a 
disclosure of any financial interest (Art. 15.1, a of HARTAct). 

9 

 Is financial inducement allowed? If so, in what terms? 

No, it is not. 
(See art. 7 BMRAct and art. 15.1, a of HARTAct). 
 Are ad hoc data protection provisions be defined for hESC research? 
Yes, they are. (arts. 5 and 53 of BMRAct): 

10 

Article 5 Protection of personal data and Confidentiality (general provisions on the use of 
human biological material). 

Article 53 Genetic analysis on pre-embryos, embryos and foetuses. The results of 
genetic analysis on per-embryonic, embryonic and foetal material shall be submitted to 
the principles of data protection and confidentiality established in this Act. 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
Yes, they are, although it is not required to be provided in form of publications. 

How is patenting of hESC lines regulated? 
In the same conditions as it is at the Directive 98/44/EC, on the legal protection of biological 
inventions. 
See the Act 11/1986 of 26 March, on Patent, as modified by Act 10/2002 of 29 April, 
transposing that Directive. 
Information provided by Prof. C.M. Romeo-Casabona (Universidad de Deusto, Bilbao) and 
Dr. Javier Arias (Institut de salud Carlos III, Madrid) 

11 

12 

139

01_2007_5944_txt_EN.indd   139

12-02-2008   13:59:13

 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory frame applying to SWEDEN 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

2 

3 

4 

5 

6 

7 

8 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
The Act (2006:351) on genetic integrity etc.. 
The Biobanks in Medical Care Act (2002:297) 
The Act (2003:460) on ethics review of research on humans  
http://www.epn.se/eng/start/index.aspx 
The Transplantation Act (1995:831) 
Guidelines issued by the Swedish Research Council 
Does the regulation provide a definition of 'embryo', if so which one? 

The word used in Sweden is ‘fertilised egg’. There is a 14 day limit for its use. 
Is hESC research allowed and under what terms and conditions? 
Yes. Approval by regional research ethics authority. Consent from both donors. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 
see above 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes under what conditions? 
same as 3 

Is the source of hESC used in research traceable and well documented? 
Yes 
 What are the formal ethical and legal requirements for hESC research approval? 
same as 3 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
Consent should be informed. Procedures are reviewed by the Regional Research Ethics 
Authority. 

9 

 Is financial inducement allowed? If so, on what terms? 

No. Normally, only reimbursement of costs allowed 

10 

11 

12 

 Are ad hoc data protection provisions defined for hESC research? 
The Patient Records Act and the Personal Data Act apply 

Are data deriving from hESC projects necessarily (?) provided, whether positive 
or negative (in form of publications)? 
No different from other research 

How is patenting of hESC lines regulated? 
Indirectly in the Transplantation Act 

140

01_2007_5944_txt_EN.indd   140

12-02-2008   13:59:14

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory frame applying to SWEDEN 

Regulatory frame applying to UNITED KINGDOM 

Please the information here provided should concern current regulatory 

requirements and not other reference documents having not a legal personality. 

Please the information here provided should concern current regulatory 
requirements and not other reference documents having not a legal personality. 

1 

Please list existing regulation applying to human embryonic stem cells (hESC) 

research (web address where to get the texts would be welcomed). 

The Act (2006:351) on genetic integrity etc.. 

The Biobanks in Medical Care Act (2002:297) 

The Act (2003:460) on ethics review of research on humans  

http://www.epn.se/eng/start/index.aspx 

The Transplantation Act (1995:831) 

Guidelines issued by the Swedish Research Council 

Does the regulation provide a definition of 'embryo', if so which one? 

The word used in Sweden is ‘fertilised egg’. There is a 14 day limit for its use. 

Is hESC research allowed and under what terms and conditions? 

Yes. Approval by regional research ethics authority. Consent from both donors. 

If yes, which body is in charge of the approval of hESC research (ethics review)? 

see above 

same as 3 

Yes 

same as 3 

Is the creation of embryos for research purposes, or stem cells procurement, 

allowed in your country, if yes under what conditions? 

Is the source of hESC used in research traceable and well documented? 

 What are the formal ethical and legal requirements for hESC research approval? 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

Consent should be informed. Procedures are reviewed by the Regional Research Ethics 

describe them? 

Authority. 

2 

3 

4 

5 

6 

7 

8 

9 

 Is financial inducement allowed? If so, on what terms? 

No. Normally, only reimbursement of costs allowed 

10 

 Are ad hoc data protection provisions defined for hESC research? 

The Patient Records Act and the Personal Data Act apply 

11 

Are data deriving from hESC projects necessarily (?) provided, whether positive 

or negative (in form of publications)? 

No different from other research 

12 

How is patenting of hESC lines regulated? 

Indirectly in the Transplantation Act 

1 

2 

3 

4 

5 

6 

7 

Please list existing regulation applying to human embryonic stem cells (hESC) 
research (web address where to get the texts would be welcomed). 
The use of embryos to derive hES cell lines is regulated by the Human Fertilisation and 
Embryology Authority (HFEA) in the UK (www.hfea.gov.uk).  
The UK Stem Cell Bank Steering Committee also issues guidelines on the use of hES 
cell lines in the UK (www.ukstemcellbank.org.uk) 

Does the regulation provide a definition of 'embryo', if so which one? 
The Human Fertilisation and Embryology Act (HF&E Act) 1990 provides that ‘an embryo 
means a live human embryo where fertilisation is complete, and references to an 
embryo include an egg in the process of fertilisation, and, for this purpose, fertilisation is 
not complete until the appearance of a two cell zygote’. 

Is hESC research allowed and in what terms and conditions? 
The HFEA regulates the use of embryos to derive hES cell lines. The use of hES cell 
lines in research is permitted in the UK but is not within the remit of the HFEA.  

If yes, which body is in charge of the approval of hESC research (ethics review)? 
The HFEA regulates the use of embryos to derive hES cell lines. 

Is the creation of embryos for research purposes, or stem cells procurement, 
allowed in your country, if yes at what conditions? 
Yes the creation of embryos for use in research, including the derivation of hES cell 
lines, is permitted in the UK. An explanation of how the HFEA licences research 
projects can be found on our website at www.hfea.gov.uk. 

Is the source of hESC used in research traceable and well documented? 
Yes 
 What are the formal ethical and legal requirements for hESC research approval? 
The use of embryos to derive hES cell lines requires a licence from the HFEA. 
The HFEA has set up a dedicated Research Licence Committee. Under section 
9(5) of the 1990 Act, a Licence Committee is required to include at least 1 member 
who is not authorised to carry on or participate in any activity under the authority 
of a licence and would not be so authorised if outstanding applications were 
granted. In addition to this requirement, and in accordance with the 
recommendations of the Better Regulation Task Force, the Research Licence 
Committee has a lay chair and a lay majority. 

In considering whether to grant or renew a licence, the Committee will have access to 
the following documentation: 

(cid:120) 

(cid:120) 
(cid:120) 
(cid:120) 
(cid:120) 
(cid:120) 

Application form signed by the Person Responsible and the Nominal 
Licensee 
Curricula vitae of the principal personnel involved in the research 
Approval of a properly constituted local research Ethics Committee, 
Report of the inspection of the research centre 
Comments from 2 peer reviewers 
The centre’s licensing history 

141

01_2007_5944_txt_EN.indd   141

12-02-2008   13:59:15

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(cid:120) 
(cid:120) 

Copies of relevant publications 
Patient Information and Consent Forms 

Before considering whether it is appropriate to grant or renew a licence the Research 
Licence Committee has to be satisfied that activities proposed in the licence application 
are necessary or desirable for one or more of the purposes set out in Schedule 2 to the 
HF&E Act 1990 (as amended by the Research Purposes Regulations 2001). In addition, 
the Research Licence Committee has to be satisfied that any proposed use of embryos 
is necessary for the purposes of the research. 

In addition the Research Licence Committee has to be satisfied that the character, 
qualifications and experience of the Person Responsible are such as are required to 
supervise the activities that s/he will discharge their duties under section 17 of the 
HF&E Act 1990 and that the premises where the research is to be carried out are 
suitable for the activities. 

To aid the Licence Committee in its consideration of research applications a decision 
making tool (the Decision Tree) which was formulated on the basis of legal advice and 
includes the statutory criteria that the Committee is required to consider.  

If the Licence Committee decides to grant or renew a licence, the Licence Committee 
will consider whether any conditions should be specified in the licence. 

Decision Tree for Research 
Applications

Identify activities

Yes -
Reject

Are any activities 
prohibited under 
HFE Act?

No -
Reject

No -
Reject

No

No - Reject

Is each activity 
necessary or 
desirable for one 
of the specified 
purposed purposes

Yes

No -
Reject

Is it 
appropriate 
to grant a 
Licence?

Yes

Satisfied 
with patient 
information 
and consent 
forms?

Yes

Satisfied 
that use of 
embryos is 
necessary?

Yes

Should 
conditions 
be put on 
licence

Decision on 
whether to 
grant licence

8 

 Does the relevant regulatory frame foresee informed consent procedures from 
individuals involved in embryo donation for research, if so could you please 
describe them? 
The HFEA, as part of the licensing procedure, see and must approve the patient 
information and consent forms used in obtaining consent from patient donating gametes 
and/or embryos in licensed research projects. These documents must also be approved 
by a local research ethics committee.  
Furthermore, all research centres are inspected, by the HFEA, annually and as part of 
this process, the HFEA examines the process used by the centre in obtaining the 

142

01_2007_5944_txt_EN.indd   142

12-02-2008   13:59:22

 
 
  
 
 
 
 
 
 
 
 
(cid:120) 

(cid:120) 

Copies of relevant publications 

Patient Information and Consent Forms 

Before considering whether it is appropriate to grant or renew a licence the Research 

Licence Committee has to be satisfied that activities proposed in the licence application 

are necessary or desirable for one or more of the purposes set out in Schedule 2 to the 

HF&E Act 1990 (as amended by the Research Purposes Regulations 2001). In addition, 

the Research Licence Committee has to be satisfied that any proposed use of embryos 

is necessary for the purposes of the research. 

In addition the Research Licence Committee has to be satisfied that the character, 

qualifications and experience of the Person Responsible are such as are required to 

supervise the activities that s/he will discharge their duties under section 17 of the 

HF&E Act 1990 and that the premises where the research is to be carried out are 

suitable for the activities. 

To aid the Licence Committee in its consideration of research applications a decision 

making tool (the Decision Tree) which was formulated on the basis of legal advice and 

includes the statutory criteria that the Committee is required to consider.  

If the Licence Committee decides to grant or renew a licence, the Licence Committee 

will consider whether any conditions should be specified in the licence. 

Decision Tree for Research 

Applications

Identify activities

Is it 

appropriate 

Yes

No -

Reject

No -

Reject

Yes -

Reject

Are any activities 

prohibited under 

HFE Act?

No

No - Reject

Is each activity 

necessary or 

desirable for one 

of the specified 

purposed purposes

Yes

No -

Reject

to grant a 

Licence?

Yes

Satisfied 

with patient 

information 

and consent 

forms?

Yes

Satisfied 

that use of 

embryos is 

necessary?

Should 

conditions 

be put on 

licence

Decision on 

whether to 

grant licence

8 

 Does the relevant regulatory frame foresee informed consent procedures from 

individuals involved in embryo donation for research, if so could you please 

describe them? 

The HFEA, as part of the licensing procedure, see and must approve the patient 

information and consent forms used in obtaining consent from patient donating gametes 

and/or embryos in licensed research projects. These documents must also be approved 

by a local research ethics committee.  

Furthermore, all research centres are inspected, by the HFEA, annually and as part of 

this process, the HFEA examines the process used by the centre in obtaining the 

consent of patients whose gametes and/or embryos are used in licensed research.  

9 

 Is financial inducement allowed? If so, in what terms? 

Women will not be paid for donating their eggs. Researchers will have to follow the 
same system as donation for treatment.  

Non patient donors can only claim back the expenses that they have actually incurred 
i.e. in money or money’s worth, a donor may be given reasonable, demonstrable 
expenses which she has incurred, within the UK, in connection with the donation. 
Donors may be compensated for loss of earnings (but not for other costs or 
inconveniences) up to a daily maximum of £55.19 but with an overall limit of £250 (or 
the equivalent in local currency) for each cycle of egg donation. 

Patient participating in egg sharing schemes will be permitted to receive treatment 
services in exchange for sharing a proportion of the eggs collected. 

10 

11 

12 

 Are ad hoc data protection provisions be defined for hESC research? 
This is not within the remit of the HFEA 

Are data deriving from hESC projects necessarily provided, whether positive or 
negative (in form of publications)? 
This is not within the remit of the HFEA 

How is patenting of hESC lines regulated? 
This is not within the remit of the HFEA 

When clinical experiments are carried out, the Ethics Review Board must 

broaden its review to cover research ethics questions and consider patients’ 

protective rights as laid down in the general medical ethics principles and 

guidelines. It may be necessary at that point to review these guidelines, as they 

are based upon the current status quo in human embryonic stem cell research.  

143

01_2007_5944_txt_EN.indd   143

12-02-2008   13:59:28

 
 
  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
  APPENDIX: 

  SECRETARIAT OF THE EGE 

01_2007_5944_txt_EN.indd   144

12-02-2008   13:59:28

 
 
  
 
 
 
 
 
 
 
  APPENDIX: 

  SECRETARIAT OF THE EGE 

01_2007_5944_txt_EN.indd   145

12-02-2008   13:59:29

 
 
  
 
 
 
 
 
 
 
Secretariat of the European Group on Ethics 

Dr Maurizio Salvi, PhD 

Head of the EGE Secretariat 

Member of the European Bureau of Policy 

Advisors (BEPA) 

Tel. (32-2) 299 11 79 

Fax (32-2) 299 45 65 

E-mail: maurizio.salvi@ec.europa.eu 

Ms Alessandra Ferrari 

Tel. (32-2) 295 43 29 

Fax (32-2) 299 45 65 

E-mail: alessandra.ferrari@ec.europa.eu 

Ms Joëlle Bezzan 

Tel. (32-2) 296 19 48 

Fax (32-2) 299 45 65 

E-mail: joelle.bezzan@ec.europa.eu 

Secretariat of the European Group on Ethics in Science and New Technologies 

Secretariat e-mail address 

bepa-group-ethics@ec.europa.eu 

Postal address 

European Commission 

BERL 8/143 

B–1049 Brussels 

Office 

European Commission 

Berlaymont Building 

Rue de la Loi 200 

B–1049 Brussels 

Website 

http://europa.eu.int/comm/european_group_ethics 

01_2007_5944_txt_EN.indd   146

12-02-2008   13:59:29

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Secretariat of the European Group on Ethics 

Dr Maurizio Salvi, PhD 
Head of the EGE Secretariat 
Member of the European Bureau of Policy 
Advisors (BEPA) 

Tel. (32-2) 299 11 79 
Fax (32-2) 299 45 65 
E-mail: maurizio.salvi@ec.europa.eu 

Ms Alessandra Ferrari 

Tel. (32-2) 295 43 29 
Fax (32-2) 299 45 65 
E-mail: alessandra.ferrari@ec.europa.eu 

Ms Joëlle Bezzan 

Tel. (32-2) 296 19 48 
Fax (32-2) 299 45 65 
E-mail: joelle.bezzan@ec.europa.eu 

Secretariat e-mail address 
bepa-group-ethics@ec.europa.eu 

Postal address 
European Commission 
Secretariat of the European Group on Ethics in Science and New Technologies 
BERL 8/143 
B–1049 Brussels 

Office 
European Commission 
Berlaymont Building 
Rue de la Loi 200 
B–1049 Brussels 

Website 
http://europa.eu.int/comm/european_group_ethics 

147

01_2007_5944_txt_EN.indd   147

12-02-2008   13:59:30

 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
01_2007_5944_txt_EN.indd   148

12-02-2008   13:59:30

European Commission

Recommendations on the ethical review of hESC FP7 research projects —  
Opinion No 22

Luxembourg: Office for Official Publications of the European Communities

2008 — ii, 147 pp. — 21 x 29.7 cm

ISBN 978-92-79-07137-9

01_2007_5944_txt_EN.indd   149

12-02-2008   13:59:30

01_2007_5944_txt_EN.indd   150

12-02-2008   13:59:30

